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Introduction and outline of this thesis
Ever since the Institute of Medicine released its report ‘Crossing the quality chasm: A New 
Health System for the 21st Century’ in March 20011, variation in quality of care between 
providers has been debated by policymakers, purchasers, health care providers, doctors 
and their patients. Not only in the United States, but also in Europe improving the quality 
of Health care is high on the political agenda. In the last 20 years medical science and 
technology is advancing in an unprecedented rate. This has come with a growing complexity 
of the care process requiring a multidisciplinary infrastructure in which the full complement 
of services is provided timely and in a safe, effective, efficient but patient-centered way. 
Simultaneously, the population is aging with an increase in the incidence and prevalence of 
chronic conditions, which make these patients especially vulnerable for the risks of medical 
treatments. Reducing risks, ensuring safety, but also continuous quality improvement are 
needed to face the challenges in our Health care system.  
Measuring quality
A basic way of explaining quality healthcare is that it is the right care, for the right person, in 
the right setting at the right time. An important mechanism to improve quality of care is to 
reduce variation and to learn from practices that prove to have excellent outcomes. Though 
variation in the way care is delivered can be legitimate, there is evidence that differences in 
outcomes between providers are unconscionably large. To gain insight in the mechanisms 
leading to variation in quality of care, comparative measurement of performance is essential: 
clinicians may find out what problems they have, and who else may have solved these 
problems. In the beginning of the century, data to compare the performance of hospitals 
were hardly available. The first reports on variation in quality of care were mostly based on 
information derived from administrative databases. For example, in the Netherlands Caspari 
et al. published on their analysis of production data from medical insurance companies in 
1991. A remarkable variation in amount of ENT procedures per 1000 insured persons were 
found for 11 partnerships of ENT specialists2. Though, in general, these kind of administrative 
data were thought to be less reliable and were often missing essential characteristics of 
patients treated by different providers, possibly explaining practice variation. Therefore, 
in several countries clinical registries were designed to provide detailed and meaningful 
information concerning the quality of care in different hospitals3. This thesis describes the 
use of detailed clinical data to measure and improve quality of care in surgical oncology.
Volume and outcome
The relationship between procedural volume and outcome was one of the first causes of 
variation in outcome between providers, reported in the literature. From 2000 until now a 
plethora of studies has been published evaluating variation in outcome between procedures 
performed in low and high volume hospitals and by low and high volume surgeons4. 
First, an inverse relation between hospital volume and mortality was shown, especially for 
high-risk low-volume surgical procedures, like esophagectomies and pancreatectomies4. 
Later on other outcome parameters were studied, like postoperative morbidity, quality of 
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life and survival5-7. In chapter 2 of this thesis a systematic review and meta-analysis of the 
relationship between hospital and surgeon volume of esophagectomies for cancer on the 
one hand and postoperative mortality and survival on the other, is reported5. 
High-risk procedures
Esophagectomies for cancer are high-risk surgical procedures, with considerable morbidity 
and mortality rates 9,10. Surgery is the primary curative therapy for esophageal cancer 
patients, though after esophagectomy overall 5-year survival hardly reaches 50%, even 
in specialized centers11. Next to the technical skills needed to perform the operation, 
careful patient selection with accurate staging and risk assessment is essential6. Moreover 
experience with the detection and management of complications is needed to prevent the 
patient from dying postoperatively7. These do not only appeal to the competence of the 
individual surgeon, but also to the infrastructure, experience and expertise available in the 
institution.                 
Clinical audit
In 2000, considering the growing evidence for a volume-outcome relationship for 
esophageal cancer surgery, the professional network of surgical oncologists working in 
hospitals affiliated with the Comprehensive Cancer Centre Leiden1 decided to perform a 
region-wide clinical audit. All patients who underwent an esophagectomy for cancer in 
the period 1990-1999 were included. Retrospectively, detailed clinical data were retrieved 
from the original patient files, including information on patient demographics, comorbid 
diseases, diagnostic procedures, tumor and treatment characteristics as well as outcome. 
None of the eleven hospitals performed more than 7 esophagectomies a year, consequently 
all had to be considered low-volume hospitals. To put the data in the right perspective, 
outcomes were compared with the results of the nearest high volume referral center for 
esophagectomies. Due to the extensive set of clinical data collected in the audit, important 
casemix-adjustments could be made in the comparison of outcome in high and low volume 
hospitals. The results of this study are reported in Chapter 38.
Centralization
In the audit important variation in outcome between patients operated in different hospitals 
were revealed. Therefore, the professional network of surgical oncologists decided to 
concentrate esophageal cancer surgery in three to four hospitals in the region. As none of 
the hospitals performed more than 7 esophagectomies a year it was agreed on that not 
differences in procedural volume, but the actual outcome of patients treated in different 
1   The Comprehensive Cancer Centre Leiden was a network organization of 11 hospitals in the south-
west region of the Netherlands, stimulating collaborations between hospitals and health care providers 
in oncological and palliative care and collecting data for the Netherlands Cancer Registry. In 2010 seven 
regionally organized comprehensive cancer centres merged into one organization, the comprehensive 
cancer centre the Netherlands (IKNL). 
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hospitals in the region, would be leading in the centralization process. From 2000 the audit 
was continued with prospective data-collection and feedback was given to the professional 
network every half year. After 5 years of auditing esophagectomies for cancer, these 
procedures were concentrated in only 4 of 11 hospitals in the region. The effects on patient 
outcome of this regional centralization project are reported in Chapter 49. 
Volume standards
In 2006 the Netherlands Health Care Inspectorate (IGZ) decided to ban esophageal 
resections from hospitals with a mean annual volume less than 10. At that time, the number 
of studies showing a relationship between procedural volume and outcome of high-risk 
surgical procedures was already extensive. Nevertheless, few changes were seen in referral 
patterns for esophageal and pancreatic cancer in the other regions in the Netherlands10. 
Therefore we decided to compare the outcome of esophageal resections for cancer before 
and after the centralization project in the region of the Comprehensive Cancer Centre Leiden, 
with the outcome in other regions in the Netherlands. For this purpose, the independently 
collected data of the Dutch National Medical Registry (LMR) were analyzed. In addition, we 
compared the historic outcome of hospitals which were selected and those that were not 
selected as future referral center for esophagectomies by the volume cut-off of the Dutch 
Health Care Inspectorate. The results are reported in Chapter 511. 
Volume or outcome-based referral
The Leapfrog group, a large coalition of private and public purchasers of health insurance 
in the United States, established minimal volume standards for the contracting of hospitals 
performing esophagectomies, in the year 2000. In contrast to the results in the region 
of the Comprehensive Cancer Centre Leiden, no actual improvement in outcome for the 
Leapfrog patients where reported in the international literature. Therefore, the dramatic 
improvements in outcome shown in our regional centralization project could not only be 
based on rising hospital volumes, though also on the feedback given to the surgeons, urging 
them to improve their performance. The question if concentration of esophageal cancer 
surgery should be based on a hospitals procedural volume (volume-based referral) or the 
actual outcome of patients treated (outcome-based referral), was addressed in an editorial 
published in the Journal of Surgical Oncology (Chapter 6)12. 
Quality indicators
The question, which method is more effective in reducing morbidity and mortality after 
high-risk surgical procedures, like esophagectomies, is still under debate. Many authors 
state that procedural volume is only a proxy for differences in expertise, processes of care 
and the subsequent outcome between hospitals and could be a poor predictor of quality of 
care in individual hospitals. To gain more insight in the variation in quality of care delivered 
by different institutions, quality indicators are developed in many countries19,20. Quality 
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indicators are measurable aspects of care that discriminate between high and low quality 
care processes. Adopting the Donebedian paradigm quality indicators are discerned into 
structure, process and outcome indicators21,22. Unfortunately, few quality indicators are 
supported by solid scientific evidence proving their ability to discriminate high from low 
quality of care in different institutions. In Chapter 7 a review of the evidence supporting 
quality indicators for esophagectomies for cancer available in the literature is reported23.
Composite measures
In the attempts made to measure the quality of clinical practice, there has been a focus on 
readily available and easily understandable outcome measures, such as hospital mortality or 
duration of hospital admission. Another approach has been to use procedural volume as a 
readily available quality-proxy. However, neither of these simplifying approaches does justice 
to the multi-dimensional concept of quality. High quality care is safe, effective, patient-
centered and cost-efficient, and is the result of high quality (infra)structure, care processes 
and outcome. Thus, not only at the conceptual but also at a clinical-practical level, quality 
is a more-dimensional concept and should ideally be measured as such. In Chapter 8 we 
present the Exemplary Care and Outcome (ECO) score, that integrates various attributes 
of quality of care into one overall (composite) measure.  Moreover, to obtain a high level 
of reliability this ECO score is adjusted for differences in case-mix between hospitals and 
represented graphically in a comprehensive and understandable way, without the loss of 
information about the quality of different aspects of surgical cancer care. 
Variation in quality of care
In cancer care future developments force us to re-evaluate the way care is provided for 
our patients. The number of cancer patients is increasing and the relative part of elderly 
cancer patients, with an increased risk of treatment related morbidity and mortality will 
raise. Moreover, care processes, including diagnostic procedures, multidisciplinary decision 
making and combined modality treatments, are becoming more and more complex, 
demanding more specific knowledge, expertise and infrastructure in institutions providing 
cancer care. This does not only apply to tumors with a low incidence and high treatment-
related risk, like esophageal cancer, but also for higher incidence tumors like Non Small Cell 
Lung Cancer (NSCLC) and Colon cancer care processes become more demanding. In the 
Netherlands, under the supervision of the Signaling Committee of the Dutch Cancer Society 
a ‘Quality of Cancer Care’ taskforce was formed in 2007, which was charged with the 
evaluation of quality of cancer care in the Netherlands and the development of strategies 
for improvement. Using the hospital specific data from the Netherlands Cancer Registry, 
the taskforce investigated variation in quality of care between hospitals in the Netherlands 
for bladder, non-small cell lung, colorectal and breast cancer and its relationship with a 
hospitals volume, infrastructure and academic or training status. The results for NSCLC and 
Colon cancer are reported in Chapter 9 and 10 respectively24,25
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Improving quality of care
The ‘Quality of Cancer Care report’ became available in the summer of 2010 13. The taskforce 
concluded that on a population level, there was significant potential for improvement of 
outcome for cancer patients in the Netherlands. Especially the concentration of complex 
high-risk cancer procedures in specialized centres, with the right infrastructure, sufficient 
volume and adequate expertise, could lead to substantial improvement in outcome. These 
conclusions are supported by our study in which outcome was compared of patients who 
underwent esophagectomy or gastrectomy for cancer in the Netherlands, from 1989 tot 
2009 (Chapter 11) 14.  In this time period, due to regionalisation projects and actions taken 
by the Dutch Healthcare Inspectorate, esophagectomies were increasingly concentrated 
in higher volume hospitals. In contrast, the percentage of gastrectomy patients treated 
in high-volume hospitals decreased. As a result outcome for esophagectomy patients 
improved to a much greater extent than for gastrectomy patients, indicating an urgent 
need for improvement in quality of surgery and perioperative care for gastric cancer patients 
in the Netherlands. Recently, these findings have urged the Dutch Association of Surgical 
Oncologists to establish quality standards, not only for esophageal but also for gastric 
cancer surgery, including a minimal hospital volume standard of 20 resections a year. In 
addition, a nation-wide clinical audit program has been initiated to measure and improve 
quality of care for gastric and esophageal cancer patients continuously, the Dutch UpperGI 
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To conduct a systematic review and meta-analysis of the literature on the relationship 
between procedural volume and outcome of esophagectomies.
Methods:
A systematic search to identify articles investigating effects of hospital (HV) or surgeon 
volume (SV) on short- and long-term outcomes, published between 1995 and 2010. Articles 
were scrutinized on methodological quality and after inclusion of only high-quality studies a 
meta-analysis assuming a random effects model was done to estimate the effect of higher 
volume on patient outcome. Heterogeneity in study results was evaluated with an I2-test 
and risk of publication bias with an Egger’s regression intercept.
Results:
Forty-three studies were found. Sixteen studies met the strict inclusion criteria for the 
meta-analysis on HV and postoperative mortality and 4 studies on HV and survival. The 
pooled estimated effect size was significant for high-volume providers in the analysis of 
postoperative mortality (OR 2.30; CI 1.89-2.80) and in the survival analysis (OR 1.17; CI 
1.05-1.30). The meta-analysis on SV and outcome showed no significant results.
Studies in which the results were adjusted not only for patient characteristics, but also for 
tumor characteristics and urgency of the operation, showed a stronger correlation between 
HV and mortality. Also, studies performed on data from the United States showed higher 
effect sizes.
Conclusions:
The evidence for HV as an important determinant of outcome in esophageal cancer surgery 
is strong. Concentration of procedures in high volume hospitals with a dedicated setting 
for the treatment of esophageal cancer, might lead to an overall improvement in patient 
outcome.
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INTRODUCTION
Improving quality and effectiveness of health care is one of the priorities of health policies. 
In surgical oncology there has been a continuous debate about how to assure that every 
patient gets the optimal treatment for his or her cancer. Despite improvements in targeted 
therapies and adjuvant treatments, surgery is still the key to cure cancer patients with solid 
malignancies. In the past, surgical outcomes and causes of variation were largely unknown, 
but since the beginning of this century there are an increasing number of population-based 
studies evaluating differences in practice patterns and outcomes between providers. 
Many studies suggest that procedural volume is an important determinant of outcome in 
cancer surgery1. Especially for high-risk, low-volume surgical procedures, like esophagectomies 
and pancreatectomies, differences in outcomes between high- and low-volume providers 
have been reported2,3. Though the number of volume-outcome studies in the literature is 
high and continues to increase, there is solid criticism on the methodological quality of these 
studies. The vast majority of volume-outcome studies in cancer surgery is observational 
and based on administrative data collected for other purposes. Moreover, potential 
differences in case mix between high- and low-volume hospitals are not always accounted 
for and postoperative mortality is often presented as the sole outcome measure. Inadequate 
reporting of volume-outcome studies restricts the generalizability and credibility of study 
results, feeds a fruitless debate and hampers the introduction of minimal volume standards 
for cancer surgery in several countries, for example in the Netherlands4. 
Esophagectomy for cancer is a high-risk, low-volume surgical procedure for which the 
volume-outcome relationship could be important. In many countries esophagectomies are 
performed in a low-volume setting. For example, until 2007 approximately 350 of these 
operations were performed annually in the Netherlands, shared by more than 50 different 
hospitals5. It is believed that concentration of these procedures with high-volume providers 
could improve overall patient outcome. 
The aim of this study was to inform the debate on the volume-outcome relationship in 
esophageal cancer surgery, by conducting a systematic review of the literature on this 
subject. The methodological quality of the studies in this review was scrutinized and only 
high-quality volume-outcome studies were included in a meta-analysis. 
METHODS
Systematic Search Strategy
We performed a systematic search to identify all articles describing the association between 
hospital or surgeon volume of esophagectomies and clinical outcomes (morbidity, mortality, 
survival, quality of life), published after January 1st 1995. The search was conducted in the 
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electronic Medline database (Pub med) with a combination of MESH terms and text words 
(Table 1). Because volume is not well indexed in the electronic databases, we formulated the 
search terms as sensitive as possible to ensure no publications were missed. The last search 
was done on July 1st 2010. 
Study selection 
Two reviewers (MW, GG) independently screened titles and abstracts of all retrieved articles. 
Studies were selected using the following inclusion criteria:
l	 The article was in the English language
l	 The study used primary data (i.e., letters, editorials, and reviews were excluded)
l	 The subject of the study was the surgical treatment of esophageal cancer.
l	 The study did not describe the results of a single hospital or surgeon. 
After this first selection on titles and abstracts, the remaining articles were obtained in full 
text and were further selected by the same two reviewers using the following exclusion 
criteria:
l	 Lack of comparisons between providers (hospitals or surgeons). 
l	 No definition for procedural volume as a distinct number or cut-off value (i.e., studies 
that defined volume as ‘specialization’ were excluded)
l	 No postoperative morbidity, mortality, survival or quality of life among outcome 
parameters.
 
Any discrepancies regarding inclusion or exclusion of a study were solved by consulting a 
third investigator (RT). In addition, reference lists of relevant articles and recent reviews 
were hand-searched to identify additional articles, which could have been missed in the 
initial search6,7. We also used the “related articles” function in Pub med.
Assessment of study quality
Two authors (MW, GG) critically appraised each study in the review on methodological quality 
and risk of bias. Data of the included studies were gathered in a data-extraction form, which 
was based on the Strengthening the Reporting of Observational studies in Epidemiology 
(STROBE) criteria (www.strobe-statement.org). From each study, characteristics were 
collected regarding the unit of analysis (hospital or surgeon), the data source (administrative 
Table 1. Search terms used in the search in the Medline database
Medline (Pubmed)
(“Esophagectomy”[MAJR] OR “Esophageal Neoplasms/surgery”[MAJR] OR (“Surgical Procedures, 
Operative”[MAJR:NoExp] AND “Neoplasms”[MAJR:NoExp])) AND (“hospital volume” OR “surgeon 
volume” OR “provider volume” OR “Outcome Assessment (Health Care)”[MAJR] OR regionalization[ti] OR 
regionalization[ti] OR “Health Facility Size”[majr] OR “Workload”[majr] OR (outcome*[ti] AND volume*[ti]) 
OR (outcome*[ti] AND complication*[ti]) OR (outcome*[ti] AND mortality*[ti]) OR (outcome*[ti] AND 
morbidity*[ti]) OR (outcome*[ti] AND survival*[ti]) OR (outcome*[ti] AND quality of life*[ti]))
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or clinical data), study period, the study design (prospective or retrospective), the country 
of origin, the number of analyzed patients, hospitals and surgeons, volume categories for 
hospitals and surgeons, outcome parameters (morbidity, mortality, survival, quality of life) 
and results regarding these outcome parameters (statistically significant or not significant) 
and the degree of risk adjustment. We noted the case mix factors for which statistical 
adjustment was done. Case mix factors were categorized as demographic parameters (age, 
gender, race and income); co morbidities; tumor characteristics (stage, grade, location); 
treatment characteristics (neo-adjuvant treatments) and urgency of the operation. In 
addition, some studies adjusted for in-hospital mortality in the survival analyses. 
Study inclusion criteria were checked to verify if there was a probability of selection bias. 
Cut-off values for high- and low-volume were noted per volume group, along with how 
these cut-off points were determined. The study results were recorded separately for 
each unit (surgeon or hospital) and for each outcome parameter (postoperative morbidity, 
postoperative mortality, 2- or 5-year survival and quality of life). The crude outcomes for 
each volume group were noted (if reported). Subsequently, we noted for each volume 
group and outcome parameter the estimated effect size after adjustment, expressed as 
odds ratio’s (OR), hazard ratio’s (HR) or risk rates (RR) with confidence intervals (CI) and 
measures of significance. 
Synthesis of the data for meta-analysis
A meta-analysis was performed for the relationship between hospital volume and surgeon 
volume on the one hand and postoperative mortality and survival on the other. No 
meta-analysis was performed for postoperative morbidity because this outcome parameter 
was defined too heterogeneous among the included studies. For quality of life, only one 
study was available. 
Only high quality studies were included in the meta-analyses. A high quality study was defined 
as a multicenter study in which a multivariate analysis was performed including casemix 
factors, such as demographic parameters (age, gender, race and income); comorbidities; 
tumor characteristics (stage, grade, location); treatment characteristics (neo-adjuvant 
treatments) and urgency of the operation. Studies without a multivariate analysis and/or no 
reporting of OR, HR or RR were excluded from the meta-analysis. The reference category 
varied between studies. Therefore, we had to convert the effect sizes so that the highest 
volume group was the reference in all studies. As a result, the OR of mortality or the HR of 
survival reflected the odds of mortality in the lowest volume group compared to the odds of 
mortality in the highest volume group. 
To determine a pooled estimated effect, we used the random effect model for meta-analyses. 
The random effects model accounts for expected heterogeneity, which is more appropriate 
with pooling of observational studies.
Heterogeneity was quantified by the I2 test. An I2 < 40 was considered homogeneous, 
between 40 and 60 moderately heterogeneous and > 60 very heterogeneous8. We 
conducted a sensitivity analysis to further explore heterogeneity and to assess the impact 
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of subgroups. A subgroup analysis was done by data source (administrative versus clinical), 
adjustments for urgency of the operation (adjusted versus not adjusted), adjustments for 
tumor characteristics (adjusted versus not adjusted) and by study country (United States 
versus non-United States). No subgroup analysis by patient characteristics was performed, 
because all studies were adjusted for age, gender and co morbidities.  
Publication bias was assessed with an Egger’s regression intercept and shown in a 
funnelplot9. 
The meta-analysis was conducted with Comprehensive Meta Analysis, professional version 
2.2 (©2006, Biostat inc. Englewood, USA).
RESULTS
Search results
Our initial search identified 97 potentially relevant articles regarding the volume-outcome 
relationship in the surgical treatment of esophageal cancer (figure 1). After the first 
screening on titles and abstracts we excluded 37 studies. The other 60 articles were 
retrieved for more detailed evaluation. Among these 35 articles were excluded: in 27 
studies, comparisons were made between treatment techniques or patient groups, instead 
of comparing the outcome between providers (hospitals or surgeons). In 3 studies, degree 
of specialization (board-certified vs. non-certified surgeons, academic vs. non-academic 
hospitals) or nurse-to-patient ratio was evaluated, instead of procedural volume10-12. And 
in 5 studies, other outcome parameters than morbidity, mortality, survival or quality of life 
were evaluated13-17. The remaining 25 papers were selected. After this first selection, the 
related articles feature in Pub med was used and the reference lists of retrieved articles were 
hand-searched. We identified 18 additional articles which met the predefined criteria for our 
systematic review. 
Figure 1. Selection of reviewed studies
Potentially relevant 
studies identified in 
Pubmed (table 1)
N=97
Studies retrieved for 
more detailed evaluation 
N=60
First study selection 
N=25
37 studies excluded: 
2   not in the english language
6   studied no esophageal resections 
25 contained no primary data
4   single center studies    
35 studies excluded:
27 studies made no comparisons 
between providers
2 no volume categories





through related articles feature 
Pubmed 
Final study selection 
N=43
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Systematic review
Table 2 shows the characteristics of the 43 studies included in the review. Most studies 
are from the United States and Canada, though the number of European studies has been 
growing. Study data have been obtained frequently from insurance companies’ databases 
(Medicare, National Inpatient Sample). The number of patients, hospitals and surgeons 
varied widely between the included studies. In most studies, results were adjusted for 
differences in case mix between high- and low-volume providers, but the parameters used 
for adjustments differed largely among studies. In some studies, data were corrected for 
differences in age and gender only. In other studies, adjustments were made for race, 
income, co morbidities, ASA-classification, tumor characteristics (stage, grade and location), 
urgency of the operation, (neo-adjuvant) treatments and (other) hospital characteristics. 
There was a considerable variation in the cut-off values for the volume groups in the included 
studies. For hospital volume, cut-off values of the highest volume strata varied between 3 
and 87 procedures annually. The cut-off values of the lowest hospital volume strata varied 
between 1 and 20 procedures per year. The rationale for the cut-off values used was seldom 
explained in the methodological paragraph of the articles. 
Hospital volume
In 36 studies, the relationship between hospital volume and outcome was evaluated. 
Postoperative mortality was used as an outcome parameter in 32 studies, and in 24 of 
these studies, a significant inverse relationship between hospital volume and postoperative 
mortality was found. In 9 studies, hospital volume and postoperative morbidity were 
investigated; in 4 studies, a statistically significant association was found, favoring high 
volume. Differences in survival between high- and low-volume hospitals were evaluated in 
7 studies of which 4 were positive. Quality of life was evaluated in only one study; in this 
study, there was no correlation between hospital volume and quality of life18. 
Meta-analysis: hospital volume & postoperative mortality
Of the 32 studies evaluating the relationship between hospital volume and postoperative 
mortality, 16 met the inclusion criteria for the meta-analysis. All of these studies had an 
observational design and only three studies were based on clinical data, often collected in 
regional or national cancer registries. The other 13 studies were based on administrative 
data. In all but one study, the results of the multivariate analysis were adjusted for age, 
gender and co morbidities and in 9 studies the results were adjusted for urgency of the 
operation. A few studies adjusted for other confounding factors like stage of the disease, 
type of resection and neo-adjuvant treatments. 
Figure 2a shows the forest plot of the included studies regarding hospital volume and 
postoperative mortality. The pooled estimated effect size was significant in favor of 
high-volume providers (OR 2.30; CI 1.89-2.80). There was moderate heterogeneity between 
the studies (I2=60). 
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Table 2. Studies included in the systematic review of the literature on the relationship between volume and 
outcome of esophagectomies for cancer (adjusted from Gruen et al.6).
Study Country Data Patients Hospitals Surgeons Casemix
adjustment
Hospital volume Surgeon volume
Volume
categories
Morbidity Mortality Survival QoL Volume
categories
Morbidity Mortality Survival QoL
Leigh 2009 27 UK Adm 9034 n.r. n.r. D <20> - S - - - - - - -
Meguid 2009 28 US Adm 4080 1506 n.a. D, C, V <15> - S - - - - - - -
Rutegard 2009 29 Swe Clin 615 n.a. n.a. D, C, S, T - - - - - <2-7> NS - - -
Gasper 2009 30 US Adm 1210 183 n.a. D, C <1-2-4-6> - S - - - - - - -
Yasunaga 2009 31 Jap Adm 642 n.a. 183 n.r. - - - - - <50-100> S - - -
Sundelöf 2008 32 Swe Clin 232 33 n.r. D, C, S, T <10> NS NS S - <10> NS NS S -
Reavis 2008 33 US Adm 5236 107 n.a. n.r. <6-13> S S - - - - - - -
Wouters 2008 34 Neth Clin 903 12 n.a. D, C, U, S, T, M <7> - S S - - - - - -
Ra 2008 35 US Adm 1172 361 n.a. D, C, S <.68-2.33> - S - - - - - - -
Rutegard 2008 18 Swe Clin 355 n.a. n.a. D, C, S, T <10> - - - NS <7> - - - NS
Hollenbeck 2007 36 USA Adm 421 151 n.a. D, C, U, S n.r. - NS - - - - - - -
Thompson 2007 37 UK Clin 1079 53 n.a. D, C, U, S <13-20-35> - - NS - - - - - -
Jensen 2007 38 Den Adm 1152 26 n.a. none <5-21> - NS - - - - - - -
Allareddy 2007 20 US Adm 2437 717 n.a. D, C, U, V <13> - S - - - - - - -
Rodgers 2007 21 US Adm 8075 995 1651 D, C, V <5-10> - NS - - <2-7> - S - -
Rouvelas 2007 39 Swe Clin 1199 53 n.a. D, C, S, T <10> - NS NS - - - - - -
Birkmeyer 2007 19 US Adm 822 206 n.a. D, C, U, S, T, M <4-14> - - S - - - - - -
Rouvelas 2007 39 Swe Clin 328 n.a. n.r. D, C, S, T - - - - - <2-7> - NS - -
Simunovic 2006 40 Can Clin 629 n.r. n.a. D, C <8-20-44> - NS NS - - - NS NS -
Lin 2006 41 Tai Adm 6674 111 n.a. D, C <20-34-59-87> - S - - - - - - -
Urbach 2005 42 Can Adm 613 58 93 D, C <2.2-7.1-12.1> - NS - - <2.4-4.6-6.9> - NS - -
Wenner 2005 43 Swe Clin 1429 74 n.a. D <5-16> - S S - - - - - -
Birkmeyer 2004 44 US Adm 4350 n.r. n.a. none <13> - S - - - - - - -
Ward 2004 45 US Adm 44 14 n.a. D, C <13> - NS - - - - - - -
Goodney 2003 46 US Adm n.r. n.r. n.a. D, C, U <2-5-8-20> NS - - - - - - - -
Elixhauser 2003 47 US Adm 1623 710 n.a. none <7> - S - - - - - - -
Dimick 2003 48 US Adm 3023 192 n.a. D, C, U, T <3-6-17> - S - - - - - - -
McCulloch 2003 49 UK Clin 955 32 n.a. D, C, S, T <11-21> NS S - - - - - -
Dimick 2003 50 US Adm 1226 n.r. n.a. D, C, U <median> S S - - - - - -
Birkmeyer 2003 3 US Adm n.r. n.a. n.r. D, C, U - - - - - <2-6> - S - -
Dimick 2003 51 US Adm 366 52 n.a. D, C, U, T <8.5> S S - - - - - -
Urbach 2003 52 Can Adm 613 47 n.a. D, C quartiles - S - - - - - -
Finlayson 2003 53 US Adm 5282 603 n.a. D, C, U <4-10> - S - - - - - -
Gillison 2002 54 UK Clin 1125 n.a. 64 D, U, S - - - - - <4-12> - S NS -
Bachmann 2002 55 UK Clin 322 n.a. 23 D, C, U, S - - - - - continuous - S S -
Birkmeyer 2002 2 US Adm 6337 1575 n.a. D, C, U <2-5-8-20> - S - - - - - - -
Kuo 2001 56 US Adm 1193 64 n.a. D, C, U <6> - S - - - - - - -
Dimick 2001 57 US Adm 1136 62 n.a. D, C, U <4-16> S S - - - - - - -
vLanschot 2001 58 Neth Adm 1792 100 n.a. D, S <11-20> - S - - - - - - -
Swisher 2000 59 US Adm 340 25 n.a. D,C, U <5> NS S - - - - - - -
Begg 1998 60 US Adm 503 190 n.a. D, C, S <6-11> - S - - - - - - -
Patti 1998 61 US Adm 1561 273 n.a. D, C <1-2-4-6> NS S - - S
Miller 1997 62 Can Clin 74 n.a. 20 none - - - - - <6> NS S - -
QoL = Quality of life; Adm = based on administrative data ; Clin = based on clinical data; n.r. = not reported; n.a. 
=not applicable; D = adjusted for demographic data (e.g. patient age, gender, race, income); C = adjusted for 
comorbidities (including ASA-classification); U = adjusted for urgency of the operation; S = adjusted for tumor 
characteristics (e.g. stage, grade, location); T = adjusted for treatment differences (e.g. surgical approach; 
(neo)adjuvant treatments); M = survival analysis adjusted for postoperative mortality; V = adjusted for other 
hospital characteristics (e.g., teaching or academic status); <10-20> = low-volume group less than 10, medium-
volume group 10-19 and high-volume 20 or more esophageal resections a year; S = statistically significant; NS 
= statistically not significant.
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Table 2. Studies included in the systematic review of the literature on the relationship between volume and 
outcome of esophagectomies for cancer (adjusted from Gruen et al.6).
Study Country Data Patients Hospitals Surgeons Casemix
adjustment
Hospital volume Surgeon volume
Volume
categories
Morbidity Mortality Survival QoL Volume
categories
Morbidity Mortality Survival QoL
Leigh 2009 27 UK Adm 9034 n.r. n.r. D <20> - S - - - - - - -
Meguid 2009 28 US Adm 4080 1506 n.a. D, C, V <15> - S - - - - - - -
Rutegard 2009 29 Swe Clin 615 n.a. n.a. D, C, S, T - - - - - <2-7> NS - - -
Gasper 2009 30 US Adm 1210 183 n.a. D, C <1-2-4-6> - S - - - - - - -
Yasunaga 2009 31 Jap Adm 642 n.a. 183 n.r. - - - - - <50-100> S - - -
Sundelöf 2008 32 Swe Clin 232 33 n.r. D, C, S, T <10> NS NS S - <10> NS NS S -
Reavis 2008 33 US Adm 5236 107 n.a. n.r. <6-13> S S - - - - - - -
Wouters 2008 34 Neth Clin 903 12 n.a. D, C, U, S, T, M <7> - S S - - - - - -
Ra 2008 35 US Adm 1172 361 n.a. D, C, S <.68-2.33> - S - - - - - - -
Rutegard 2008 18 Swe Clin 355 n.a. n.a. D, C, S, T <10> - - - NS <7> - - - NS
Hollenbeck 2007 36 USA Adm 421 151 n.a. D, C, U, S n.r. - NS - - - - - - -
Thompson 2007 37 UK Clin 1079 53 n.a. D, C, U, S <13-20-35> - - NS - - - - - -
Jensen 2007 38 Den Adm 1152 26 n.a. none <5-21> - NS - - - - - - -
Allareddy 2007 20 US Adm 2437 717 n.a. D, C, U, V <13> - S - - - - - - -
Rodgers 2007 21 US Adm 8075 995 1651 D, C, V <5-10> - NS - - <2-7> - S - -
Rouvelas 2007 39 Swe Clin 1199 53 n.a. D, C, S, T <10> - NS NS - - - - - -
Birkmeyer 2007 19 US Adm 822 206 n.a. D, C, U, S, T, M <4-14> - - S - - - - - -
Rouvelas 2007 39 Swe Clin 328 n.a. n.r. D, C, S, T - - - - - <2-7> - NS - -
Simunovic 2006 40 Can Clin 629 n.r. n.a. D, C <8-20-44> - NS NS - - - NS NS -
Lin 2006 41 Tai Adm 6674 111 n.a. D, C <20-34-59-87> - S - - - - - - -
Urbach 2005 42 Can Adm 613 58 93 D, C <2.2-7.1-12.1> - NS - - <2.4-4.6-6.9> - NS - -
Wenner 2005 43 Swe Clin 1429 74 n.a. D <5-16> - S S - - - - - -
Birkmeyer 2004 44 US Adm 4350 n.r. n.a. none <13> - S - - - - - - -
Ward 2004 45 US Adm 44 14 n.a. D, C <13> - NS - - - - - - -
Goodney 2003 46 US Adm n.r. n.r. n.a. D, C, U <2-5-8-20> NS - - - - - - - -
Elixhauser 2003 47 US Adm 1623 710 n.a. none <7> - S - - - - - - -
Dimick 2003 48 US Adm 3023 192 n.a. D, C, U, T <3-6-17> - S - - - - - - -
McCulloch 2003 49 UK Clin 955 32 n.a. D, C, S, T <11-21> NS S - - - - - -
Dimick 2003 50 US Adm 1226 n.r. n.a. D, C, U <median> S S - - - - - -
Birkmeyer 2003 3 US Adm n.r. n.a. n.r. D, C, U - - - - - <2-6> - S - -
Dimick 2003 51 US Adm 366 52 n.a. D, C, U, T <8.5> S S - - - - - -
Urbach 2003 52 Can Adm 613 47 n.a. D, C quartiles - S - - - - - -
Finlayson 2003 53 US Adm 5282 603 n.a. D, C, U <4-10> - S - - - - - -
Gillison 2002 54 UK Clin 1125 n.a. 64 D, U, S - - - - - <4-12> - S NS -
Bachmann 2002 55 UK Clin 322 n.a. 23 D, C, U, S - - - - - continuous - S S -
Birkmeyer 2002 2 US Adm 6337 1575 n.a. D, C, U <2-5-8-20> - S - - - - - - -
Kuo 2001 56 US Adm 1193 64 n.a. D, C, U <6> - S - - - - - - -
Dimick 2001 57 US Adm 1136 62 n.a. D, C, U <4-16> S S - - - - - - -
vLanschot 2001 58 Neth Adm 1792 100 n.a. D, S <11-20> - S - - - - - - -
Swisher 2000 59 US Adm 340 25 n.a. D,C, U <5> NS S - - - - - - -
Begg 1998 60 US Adm 503 190 n.a. D, C, S <6-11> - S - - - - - - -
Patti 1998 61 US Adm 1561 273 n.a. D, C <1-2-4-6> NS S - - S
Miller 1997 62 Can Clin 74 n.a. 20 none - - - - - <6> NS S - -
QoL = Quality of life; Adm = based on administrative data ; Clin = based on clinical data; n.r. = not reported; n.a. 
=not applicable; D = adjusted for demographic data (e.g. patient age, gender, race, income); C = adjusted for 
comorbidities (including ASA-classification); U = adjusted for urgency of the operation; S = adjusted for tumor 
characteristics (e.g. stage, grade, location); T = adjusted for treatment differences (e.g. surgical approach; 
(neo)adjuvant treatments); M = survival analysis adjusted for postoperative mortality; V = adjusted for other 
hospital characteristics (e.g., teaching or academic status); <10-20> = low-volume group less than 10, medium-
volume group 10-19 and high-volume 20 or more esophageal resections a year; S = statistically significant; NS 
= statistically not significant.
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In table 3 the results of the sensitivity analysis of the 16 included studies are depicted. 
A larger effect size was noted in studies from the United States (OR 2.56; P<0.001), in 
studies based on clinical data (OR 2.29; P<0.001), in studies with data that were adjusted for 
urgency of the operation (OR 2.84; P<0.001) and in studies with data that were adjusted for 
tumor characteristics (OR 2.20; P<0.001). 
Figure 4 shows the qualitative analysis of publication bias of all studies regarding hospital 
volume and postoperative mortality using OR’s. The results were suggestive for publication 
Figure 2a. Forest plot of the included studies in the meta-analysis on hospital volume and postoperative 
mortality for esophageal resections for cancer. Year = year of publication; Low = highest annual volume of low 
volume category; High = lowest annual volume of high volume category; CI = confidence interval
Figure 2b. Forest plot of the included studies in the meta-analysis on hospital volume and survival of esophageal 
resections for cancer. Year = year of publication; Low = highest annual volume of low volume category; High = 
lowest annual volume of high volume category; CI = confidence interval
Study name Year Low High Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Allareddy 2007 12 13 1.980 1.279 3.066 3.061 0.002
Birkmeyer 2002 2 20 2.778 2.003 3.852 6.124 0.000
Dimick, Cataneo 2001 4 16 4.762 2.324 9.759 4.263 0.000
Dimick, Cowan 2003 16 2.900 1.708 4.923 3.943 0.000
Dimick, Pronovost 2003 2 7 5.700 2.015 16.122 3.281 0.001
Finlayson 2003 4 10 2.632 1.637 4.230 3.996 0.000
Gasper 2009 1 6 1.650 1.011 2.693 2.004 0.045
Kuo 2001 5 6 4.300 2.350 7.868 4.732 0.000
Leigh 2009 20 1.620 1.377 1.906 5.818 0.000
Lin 2006 20 87 1.538 1.024 2.311 2.076 0.038
McCulloch 2003 20 2.041 1.015 4.103 2.002 0.045
Ra 2008 1 2 1.810 1.179 2.778 2.714 0.007
Simunovic 2006 44 0.900 0.312 2.598 -0.195 0.846
Swisher 2000 4 5 3.970 1.141 13.813 2.167 0.030
Urbach 2003 3 19 1.900 0.988 3.655 1.923 0.054
Wouters 2008 6 7 3.050 1.820 5.111 4.234 0.000
2.300 1.890 2.799 8.308 0.000
0.1 0.2 0.5 1 2 5 10
Favors Low Volume    Favors High Volume
Hospital mortality
Study name Year Low High Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Rouvelas 2007 1 7 1.110 0.968 1.273 1.490 0.136
Sundelöf 2008 9 10 1.300 0.943 1.792 1.602 0.109
Simunovic 2006 7 44 1.200 0.849 1.697 1.031 0.303
Birkmeyer 2007 3 14 1.320 1.000 1.742 1.962 0.050
1.170 1.049 1.305 2.824 0.005
0.5 1 2
Favors low volume Favors high volume
Hospital Survival
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bias, which indicates that smaller negative studies are missing, which to some degree could 
have influenced the results of this meta-analysis. 
Meta-analysis: hospital volume & survival
Of the seven studies evaluating the relationship between hospital volume and survival, four 
met the criteria for the meta-analysis. All four studies were observational, though three 
studies used clinical instead of administrative data. Adjustments for age, gender and co 
morbidities were made in all four studies; three of them adjusted for tumor characteristics 
(e.g. stage and grade) and two studies corrected also for (neo)adjuvant treatments in their 
survival analysis. Figure 2b shows the forest plot of the included studies on hospital volume 
and survival. Again, the meta-analysis showed a significant pooled estimated effect size in 
favor of high-volume hospitals (HR 1.17; CI 1.05-1.31). This result was very homogeneous 
(I2=0.0). 
Surgeon volume
In 12 studies, the relationship between surgeon volume and outcome was investigated. 
Nine of these studies used postoperative mortality as an outcome parameter and 5 of them 
showed a significant result favoring high volume. In 4 studies, postoperative morbidity was 
an outcome parameter; only one study was positive. The relationship between surgeon 
volume and survival was investigated in 4 studies; in two of them, a significant relationship 
was found. Quality of life was evaluated in one study; again the result was negative. 
Meta-analysis: surgeon volume & postoperative mortality
Of the nine studies evaluating surgeon volume and postoperative mortality, only three 
met the inclusion criteria for the meta-analysis. In all three studies age, gender and co 
morbidities were included in the multivariate analysis. Figure 3a shows the forest plot of 
the included studies regarding the effect of surgeon volume on postoperative mortality. 
In the meta-analysis a pooled estimated effect size was detected in favor of high-volume 
Table 3. Sensitivity analysis of the 16 included studies on hospital volume and postoperative mortality with 
Odds ratios as effect size. 
Factor Subgroup N OR CI P-value
Country US 10 2.56 2.17-3.00 <0.001
other countries 6 1.70 1.48-1.94 <0.001
Datasource Administrative 13 1.99 1.79-2.22 <0.001
Clinical 3 2.29 1.56-3.37 <0.001
Urgency Not adjusted 7 1.69 1.49-1.92 <0.001
Adjusted 9 2.84 2.37-3.40 <0.001
Tumor stage Not adjusted 13 1.99 1.78-2.22 <0.001
Adjusted 3 2.20 1.63-2.97 <0.001
N = number of studies; OR = Odds ratio; CI = confidence interval; I2 = result of I square test on heterogeneity 
of study results8. US = United States 
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surgeons, but this effect did not reach statistical significance (OR 1.55; 0.88-2.75) and was 
very heterogeneous ( I2=75). 
Meta-analysis: surgeon volume & survival
Two out of four studies evaluating surgeon volume and survival were included in the 
meta-analysis and both adjusted for tumor characteristics in their survival analyses. Figure 
3b shows the forest plot of the two included studies regarding the effect of surgeon 
volume on survival. In the meta-analysis there was a pooled estimated effect size in favor 
of high-volume surgeons (HR 1.16; 0.94-1.45), which was not significant. The result was 
moderately heterogeneous (I2=48).
DISCUSSION
The present study contains the first meta-analysis on the relationship between procedural 
volume and outcome of esophageal resections for cancer, with strict criteria for 
Study name Year Low High Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Bachmann 2002 . . 7.690 1.104 53.579 2.060 0.039
Birkmeyer 2003 1 6 1.800 1.129 2.869 2.472 0.013
Rodgers 2007 1 7 1.110 1.062 1.160 4.598 0.000
1.551 0.876 2.745 1.506 0.132
0.1 0.2 0.5 1 2 5 10
Favors low volume Favors high volume
Surgeon Mortality
Study name Year Low High Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Bachmann 2002 . . 1.090 1.008 1.178 2.168 0.030
Sundelöf 2008 9 10 1.400 0.990 1.980 1.903 0.057
1.164 0.938 1.445 1.379 0.168
0.5 1 2
Favors low volume Favors high volume
Surgeon Survival
Figure 3a. Forest plot of the included studies in the meta-analysis on surgeon volume and postoperative 
mortality of esophageal resections for cancer. Year = year of publication; Low = highest annual volume of low 
volume category; High = lowest annual volume of high volume category; CI = confidence interval
Figure 3b. Forest plot of the included studies in the meta-analysis on surgeon volume and survival of esophageal 
resections for cancer. Year = year of publication; Low = highest annual volume of low volume category; High = 
lowest annual volume of high volume category; CI = confidence interval
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methodological quality. Our systematic review shows that there is an increasing number of 
studies on this subject originating from different parts of the world and evaluating hospitals’ 
as well as surgeons’ procedural volume. Not only short-term outcomes like postoperative 
morbidity and mortality have been evaluated, but also long-term outcomes like survival and 
quality of life. Only a minority of these studies met the methodological inclusion criteria for 
our meta-analysis. We found that hospital volume has a strong inverse relationship with 
postoperative mortality and that patients operated in high-volume centers have a better 
survival. This relationship is much stronger than that between surgeon volume and outcome 
of esophageal cancer resections. 
There is solid criticism on the level of evidence for a volume-outcome relationship regarding 
low-volume, high-risk surgical procedures, like esophagectomies for cancer10. Our review 
confirms that most studies are observational, retrospective and based on administrative data 
collected for other purposes, instead of carefully designed comparative studies (Table 2). 
Moreover, studies originate from different health care systems all over the world introducing 
a large variety in demographical, geographical and epidemiological factors as well as 
standards of care. For example, our analyses showed larger differences in postoperative 
mortality between high- and low-volume hospitals identified in the United States than in 
other countries. In the evaluation of the methodological quality of the available studies 
substantial heterogeneity was identified. Especially, the choice of volume categories 
was extremely diverse among all studies. The rationale for specific volume cut-offs was 
Figure 4. Analysis of risk of publication bias: funnel plot of studies included in the meta-analysis on hospital 
volume and postoperative mortality using odds ratio’s. The funnel plot is asymmetric, missing smaller negative 
studies, suggesting publication bias. Quantitative analysis with the Egger’s regression intercept showed an 
intercept of 1.7 with a two-sided P value of 0.03, confirming the suggestion of publication bias.














Funnel Plot of Standard Error by Log odds ratio
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seldom explained in the methodological paragraphs suggesting a potential selection bias. 
In addition, the risk of publication bias was calculated for the studies on hospital volume 
and postoperative mortality, missing the smaller negative studies, which obviously had little 
chance for publication in peer-reviewed medical journals.
Only high-quality comparative studies were included in our meta-analyses. All but one 
study included at least age, gender and co morbidity in the multivariate analysis on the 
relationship between hospital volume and postoperative mortality. Several studies used 
additional parameters as potential confounders (e.g., neo-adjuvant treatments, urgency of 
the operation, tumor characteristics). This led to higher effect sizes and less heterogeneity 
in results between properly adjusted studies, as was shown in our sensitivity analyses (Table 
3). Because of these robust effect sizes, the risk of publication bias detected in our analyses 
(Figure 4), is expected to have influenced the results of this meta-analysis insignificantly.   
Adjustments for tumor characteristics not only gave higher effect sizes in studies on hospital 
volume and postoperative mortality. Also, in three out of four studies on hospital volume 
and survival in which results were adjusted for tumor stage, a significantly better outcome 
was found in high-volume hospitals (Table 2). 
In the meta-analysis on surgeon volume and outcome, the correlations between volume and 
postoperative mortality and volume and survival were not significant. This suggests that 
outcome of esophageal cancer surgery is not only dependent on the experience and skills 
of individual surgeons. The hospital setting in which they perform their operations seems 
more important. The above results indicate that - for high-quality of care - experience with 
esophageal cancer surgery is important on a hospital’s level rather than on an individual 
surgeon’s level. 
Apart from the methodological shortcomings mentioned above, volume-outcome studies 
have other important limitations. First, surgery is not the only treatment used in esophageal 
cancer patients. Differences in treatment patterns, like the use of (neo)adjuvant chemo- 
and/or radiotherapy may also influence long-term survival. In our meta-analysis on the 
relationship between hospital volume and survival, data in three out of four studies have 
been adjusted for differences in the use of (neo)adjuvant therapies. Especially in the study 
of Birkmeyer, based on the SEER-Medicare database, it is shown that the percentage 
of patients that receives chemo- and / or radiotherapy besides surgical treatment is not 
different between low-, medium- and high-volume hospitals19. 
In addition, in only few studies, data have been corrected for (other) provider 
characteristics20,21, such as the available infrastructure, teaching or academic status, 
inner city or private hospital status, experience with other high-risk operations, expertise 
in multimodality cancer treatments, a hospital’s budget, focus and/or referral bias. These 
factors are often related to, but not identical with procedural volume. In a recent study, 
Courrech-Staal et al. have reported the results of esophageal cancer surgery in a tertiary 
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referral center, with a mean annual hospital volume of more than 100 esophageal cancer 
patients a year22. Due to selective referral of patients with higher tumor stages only 20% 
of them had potentially curable disease, an unfavorable tumor mix when compared to the 
50% reported in most series. Nevertheless, the authors have shown excellent results of 
esophageal cancer surgery despite a low procedural volume (<10 resections/year). The use 
of procedural volume as the sole measure of quality of care might fall short in identifying 
high-leverage processes of care in individual institutions. In our opinion policy makers should 
bare this in mind when efforts are made to centralize complex high-risk surgical procedures. 
In the Netherlands, the Quality of Cancer Care taskforce of the Dutch Cancer Society has 
recently proposed to concentrate specific cancer treatments in those hospitals that meet 
a set of criteria. These criteria do not only focus on procedural volume, but also on the 
available infrastructure, specialization of medical professionals and outcome measures, 
that should be reported by individual institutions23. From a patients’ perspective outcome 
information might be more interesting and informative than volume alone. However, also 
from a professional perspective too much focus on proxy variables like ‘volume’ is not 
preferable. Volume standards do have little ability to move the medical field forward24. 
Identifying ‘best practices’ in patient selection, treatment strategies, technical procedures 
and peri-operative care is much more important and the central issue in outcomes research 
and surgical audits25,26. Careful analysis of data retrieved from different hospitals, that 
vary in patterns of care and outcomes, might identify ways to improve the whole field of 
esophageal cancer treatment. 
In conclusion, this meta-analysis has shown that procedural volume is associated with less 
postoperative mortality and better survival in esophageal cancer surgery. A hospital’s annual 
volume seems more important than the experience of individual surgeons. Although there is 
no evidence for a specific volume cut-off in the literature, centralization of esophageal cancer 
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Most studies addressing the volume-outcome relationship in complex surgical procedures 
use hospital mortality as the sole outcome measure and are rarely based on detailed clinical 
data. The lack of reliable information about comorbidities and tumor stages makes the 
conclusions of these studies debatable.  
The purpose of this study was to compare outcome for esophageal resections for cancer in 
low- versus high-volume hospitals, using an extensive set of variables concerning case-mix 
and outcome measures, including long-term survival.
Methods: 
Clinical data, from nine hundred and three esophageal resections performed between 
January 1990 and December 1999, were retrieved from the original patients’ files.  Three 
hundred and forty-two patients were operated on in eleven low-volume hospitals (< 7 
resections/year) and five hundred and sixty-one in a single high volume center. 
Results:
Mortality and morbidity rates were significantly lower in the high-volume center; an 
in-hospital mortality of 5 versus 13% (p<0.001).  On multivariate analysis, hospital volume, 
but also the presence of co-morbidity proved to be strong prognostic factors predicting 
in-hospital mortality (ORs 3.05 and 2.34). For stage I and II  disease, there was a significant 
better 5-year survival in the high-volume center. (p = 0.04) .
Conclusions:
Hospital volume and comorbidity patterns are important determinants of outcome in 
esophageal cancer surgery. Strong clinical endpoints like in-hospital mortality and survival can 
be used as performance indicators, only if they are joined by reliable case-mix information.
36
Case-mix: an important determinant of outcome
INTRODUCTION
Since Luft published his study on the inverse relationship between surgical volume and 
hospital mortality in 1979, a plethora of studies has demonstrated an improvement of 
clinical outcome with increased hospital volume 1. Most of these studies use hospital 
mortality as the sole outcome measure. Often, data are obtained from insurance company’s 
databases and few studies use clinical data for risk-adjustment 2. 
The surgical treatment of esophageal cancer is often mentioned as one of the procedures 
for which concentration in high-volume centers might improve outcome 3,4. Nevertheless, 
a clear volume cut-off point at which a cancer center is justified to perform esophageal 
resections can hardly be defined 5,6. Also, the volume-outcome literature for esophageal 
resections is limited to post-operative mortality as the sole determinant of outcome. 
Considering the growing evidence for this volume-outcome relationship for esophageal 
cancer surgery, we decided to investigate the outcome of these procedures in our region 
from 1990 until 1999. During this study period none of the eleven hospitals, affiliated with 
the Comprehensive Cancer Center Leiden (CCCL) in the Netherlands, performed more than 
seven esophageal resections a year, all to be considered as low volume hospitals (LVH).
In contrast to most volume-outcome studies, we decided to use clinical data, obtained 
from the original patients’ files. We retrieved information about comorbid diseases, tumor 
characteristics, treatment and outcome. Next to hospital mortality, several determinants of 
outcome were examined, like the number of tumor-free margins and complication rates. 
Assuming that survival is an essential  indicator for quality in cancer surgery, we included a 
5 years follow-up. To put our data in the right perspective, we compared these outcomes 
to the results of the topographically nearest high volume referral center (HVH).
METHODS
All surgically treated esophageal carcinomas in the period 1990-1999 were retrospectively 
identified through the Leiden Cancer Registry (LCR) of the Comprehensive Cancer 
Center Leiden (CCCL), in which all cancer patients treated in the mid-western part of the 
Netherlands are registered (1.7 million inhabitants). All of the eleven hospitals gave consent 
to participate in this audit and were visited by two investigators to retrieve the original 
patient files. Patient demographics, pathological notes,  data on the surgical and (neo)
adjuvant treatments, co-morbidity as well as postoperative morbidity, mortality, length 
of stay, radicality of the resection, and long-term survival could all be retrieved from the 
patient’s files.
All tumors were staged according to the UICC  TNM classification of 1997. This was done 
by two independent researchers. The obtained pTNM stages were checked with the pTNM 
stages registered in the LCR.  Any discrepancies were discussed between the researchers 
and a trained data manager from the CCCL. If consensus could not be reached, the pTNM 
stage was registered as ‘unknown’. 
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In order to make a comparison with the outcomes of the nearest high-volume center, data 
were categorized according to the database of this center. In this hospital data of patients 
operated on for an esophageal carcinoma are prospectively collected by a trained data 
manager. 
Differences in patient, tumor and treatment characteristics as well as outcome measurements 
were assessed using the Kruskal-Wallis test for continuous variables and the chi-square test 
for categorical variables. Logistic regression was used to determine prognostic factors of 
in-hospital mortality. Variables were entered in the multivariate model as a prognostic factor 
when P values < 0.10. 
Survival was calculated as the difference between date of surgery and either the date of 
death or the date of last patient follow up. For both groups follow up of the patients was 
completed until December 31st, 2005.  Observed survival rates were estimated by using the 
Kaplan–Meier method. The log-rank test was used to assess differences in survival between 
patients who were operated in LVHs and the HVH. All analyses were conducted using SPSS 
software (version 12.0; SPSS Inc., Chicago. IL).
RESULTS
Hospital volume
In the period 1990-1999 the evaluation and treatment of patients with an esophageal 
carcinoma was performed in eleven hospitals in the region of the CCCL (one university 
hospital, five teaching hospitals and five general hospitals). In 342 patients the tumor 
was resected with curative intent. Figures 1a and 1b illustrate the distribution of surgical 
procedures within the studied time period and between the different hospitals. None of the 
CCCL  hospitals performed more than seven esophageal resections a year, what makes them 
low volume hospitals (LVHs)7. In the same period 561 esophageal resections were performed 





















 = high volume hospital  (HVH)
 = low volume hospitals (LVHs)
Figure 1a. number of esophageal resections per year in HVH versus LVH group (1990-1999)
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Patient, tumor and treatment characteristics
Table 1 shows the patient, tumor and treatment characteristics of both groups. More 























































Figure 1b. total number of esophageal resections per hospital for HVH and LVHs (1990-1999)
Table 1. Patient, Tumor and Treatment Characteristics of Esophageal Resections in LVH* and HVH**  
LVH HVH
Characteristics No. of patients % No. of patients % P value
Age (years) 65 64 0.240
    range (years)    33-87 31-83
Gender 0.072
    male 249 73 438 78
    female 93 27 123 22
Comorbidity 0.078
    no 142 42 273 49
    1  organ system 111 32 179 32
    2  organ systems 51 15 80 14
    ≥3 organ systems 11 3 27 5
    Unknown 27 8 2 0
Histology 0.039
    adenocarc 238 69 347 62
    squamous 96 28 193 34
    barrets dysplasia 4 1 6 1
    other 2 1 14 3
    unknown 2 1 1 0
Tumour localisation 0.740
    cervical esoph. 7 2 14 3
    mid esoph. 53 15 86 15
    distal esoph. 114 33 204 36
    ge-junction 166 49 251 45
    unknown 2 1 6 1
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Table 2a. Outcome after resection of esophagus for cancer in LVH* and HVH** 
LVH HVH
P valueOutcome No. of patients % No. of patients %
Margins 0.93
    R0 248 72 377 67
    R1 55 16 161 28
    R2 35 11 21 4
    Unknown 4 1 2 1
Complications
    surgical compl. 144 42 207 37   0.010
    general compl. 191 56 207 37 <0.001
    no compl. 89 26 247 44 <0.001
Hospital stay 
    median (days) 21 14 <0.001
In-hospital
Mortality 45 13 28 5 <0.001
Survival
    median (months) 21 22 0.90
    range (months) (1-171) (1-158)
Total no. of patients 342 561
*   LVH = low volume hospitals. ** HVH = high volume hospital
Table 1. Patient, Tumor and Treatment Characteristics of Esophageal Resections in LVH* and HVH** (Cont).
LVH HVH
Characteristics No. of patients % No. of patients % P value
Stage (pTNM) < 0.001
    0 and I 43 12 61 11
    II 162 47 214 38
    III 107 31 186 33
    IV 21 6 94 17
    Unknown 9 3 6 1
(Neo)-adj.Treatment < 0.001
    none 316 92 464 83
    chemotherapy 17 5 93 17
    radiotherapy 0 0 2 0
    chemoradiation 4 1 0 0
    unknown 5 2 1 0
Surgical approach < 0.001
    abdomino-cervical 150 44 466 83
    thoraco-abdominal 97 28 60 11
    abd-thor-cervical   43 13 17 3
    abdominal 52 15 18 3
Anastomoses < 0.001
    cervical 195 57 541 96
    thoracic 91 27 8 2
    abdominal 56 16 8 2
    unknown 0 0 4 0
Total no. of patients 342 561
*   LVH = low volume hospitals. ** HVH = high volume hospital
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disease. Operative strategy as well as adjuvant or neoadjuvant treatment varied widely 
between the groups. The vast majority of resections in the HVH was performed according 
to the transhiatal technique, with a gastric tube reconstruction and anastomosis to the 
cervical remnant esophagus. In the LVH-group a substantial number of anastomoses were 
located in the thoracic cavity, after a (partial) gastro-esophagectomy with either a gastric 
tube reconstruction or esophago-jejunostomy. In the pathology clear surgical margins (R0) 
were reported in 72 % and 67 %, respectively for the LVHs and the HVH group.
Morbidity and mortality
A significant higher postoperative morbidity rate was found in the LVH-group, which probably 
also is reflected by the longer hospital stay (Table 2a). The clinical anastomotic leakage rate 
differed between both groups: LVHs 17 % versus  HVH 5 %. The mortality rate was almost 
three times higher for patients treated in the LVHs than those who had their operation in 
the HVH: 13 versus 5 percent respectively (p < 0.001). None of the LVHs had a mortality rate 
lower than the 5 percent of the HVH (Table 2b). Univariate analysis showed that hospital 
volume, age and co-morbidity are prognostic factors for mortality (table 3a). The mortality 
risk increased with higher age and the number of organ systems affected. Especially cardiac 
(OR 3.22, CI 1.91 – 5.44), vascular (OR 2.49, CI 1.45 – 4.27) and respiratory (OR 1.90 CI 
1.09 – 3.33) co morbidity were risk factors for postoperative mortality.  
Multivariate analysis showed that both hospital volume and co morbidity were independent 
prognostic factors for hospital mortality (Table 3b).
Table 2b. Mortality after resection of oesophagus for cancer in LVH* and HVH**  
Hospitals In-hospital mortality
No. of patients No. of deaths %
HVH 561 28 5.0
LVH 1 16 2 12.5
LVH 2 19 2 10.5
LVH 3 28 2 7.1
LVH 4 25 3 12.0
LVH 5 14 1 7.1
LVH 6 28 2 7.1
LVH 7 34 2 5.9
LVH 8 64 12 18.7
LVH 9 44 10 22.7
LVH 10 6 2 33.3
LVH 11 64 7 10.9
Total no. of patients 903 73 8
*   LVH = low volume hospitals




Figure 2a shows the crude 10-year overall survival rate of all patients, in who an esophageal 
resection for cancer was performed. Survival rates for patients treated in the HVH are 
significantly better (p=0.01). This survival benefit loses its statistical significance, after 
exclusion of patients who died postoperatively of complications of the surgical procedure 
(Figure 2b).  Only, when we select patients with stage I and II disease we see a better 
Table 3a. Univariate Analysis of In-Hospital Mortality
Univariate analysis
 OR 95% CI P value
Region <0.001
   HVH 1.00 Ref*
   LVH 2.88 1.76 – 4.72
Age (years) 0.01
    < 50 0.19 0.04 – 0.79
    50-59 0.51 0.25 – 1.04
    60-69 1.00 Ref*
    > 70 1.20 0.70 – 2.04
Gender 0.20
    Male 1.00 Ref*
    Female 0.67 0.36 – 1.24
Co-morbidity <0.001
    No 1.00 Ref*
    1 organ system 2.02 1.06 – 3.86
    2 organ systems 4.51 2.30 – 8.85
    ≥ 3 organ systems 4.97 1.92 – 12.83
Histology 0.97
    Adenocarc 1.00 Ref*
    Squamous 0.99 0.60 – 1.65
Stage 0.24
    I 1.00 Ref*
    II 0.50 0.24 – 1.04
    III 0.80 0.39 – 1.63
    IV 0.65 0.26 – 1.61
Tumor localisation 0.33
    cervical / mid esoph 1.00 Ref*
    distal esoph / GE junction 1.41 0.71 – 2.80
Neo-adj treatment 0.14
    No 1.00 Ref*
    Yes 0.49 0.20 – 1.25
Surgical approach 0.31
    Transhiatal 1.00 Ref*
    Transthoracic 1.51 0.90 – 2.54
Anastomosis 0.46
    Cervical 1.00 Ref*
    Thoracic 1.52 0.77 – 3.01
    Abdominal 1.26 0.52 – 3.04
* Ref = Reference category
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Figure 2a. Overall survival after esophagus 
resection for cancer: LVHs versus HVH 
(in-hospital mortality included)
Figure 2b. Overall survival after esophagus 
resection for cancer: LVHs versus HVH. 
(in-hospital mortality excluded)
Figure 2c. Overall survival after esophagus 
resection for stage I and II carcinoma: LVHs 









survival in the HVH (Figure 2c), meaning that its overall results are worsened by the poor 
survival in the higher stages of the disease, stage III and IV. This can be explained by the 
unfavorable tumor mix, with significantly more stage IV disease treated in the HVH, than in 
the LVHs (16.7 versus 6.1%).
DISCUSSION
Currently there is extensive interest in comparing outcome of complex surgical procedures 
between high- and low-volume providers. Most of the studies are registry-based or relatively 
small. Our series offers additional proof to the volume-outcome relationship, because it is 
based on clinical data, retrieved from the original patient files. This allows us to make reliable 
comparisons for comorbidities and tumor-stage, which proved to be important prognostic 
factors for in-hospital mortality and survival.  
A review of the evidence for a volume-outcome relationship was published by Dudley in 
2000 en Halm in 2002 8 2. In the latter publication 135 studies were reviewed, of which 
only 5 were not from the USA or Canada. The majority of reports were based on state- 
or national hospital-discharge databases, where only a few studies used clinical data for 
risk-adjustment. The outcome-measure was ‘death’ in 79 percent of the studies, without 
analyzing other dimensions of ‘outcome’, like morbidity, length of hospital stay, re-operations 
et cetera. For cancer-related procedures long-term survival was not mentioned. Higher-level 
methodological issues were rarely addressed. Only five studies concerning cancer treatment 
adjusted for (neo)-adjuvant therapies or the type of surgical resection, but without any 
adjustment for tumor stage.
Since 2002 more extensive studies on hospital or surgeon volume appeared in the 
international literature. Birkmeyer reported a total number of 2.5 million operations 
concerning 14 different surgical procedures derived from the MEDICARE database 9. 
Table 3b. Multivariate Analysis of In-Hospital Mortality
Multivariate analysis
 OR 95% CI P value
Region <0.001
    HVH 1.00 Ref*
    LVHs 3.05 1.82 – 5.11
Age (years)   0.10
    < 50 0.22 0.05 – 0.96
    50-59 0.60 0.29 – 1.25
    60-69 1.00 Ref*
    > 70 1.07 0.61 – 1.88
Co-morbidity   0.004
    No 1.00 Ref*
    Yes 2.34 1.30 – 4.19
Ref = Reference category
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Table 4. Volume-outcome articles for in-hospital mortality after esophagectomy 1998-2006  
  Author Journal / Year Data Volume ‘cut-off’ Conclusion
Dimick 32 Ann.Thorac.Surg. 2005 Adm <6> S
Urbach 33 BMJ 2004 Adm <9> NS
McCulloch 12 BMJ 2003 Clin <10-20> S
Christian 34 Ann. Surg. 2003 Adm <22> S
Finlayson 35 Arch Surg. 2003 Adm <4-9> S
Urbach 36 CMAJ 2003 Adm * S
Dimick 37 Ann.Thorac.Surg. 2003 Adm <7> S
Birkmeyer 9 N.Engl.J.Med. 2002 Adm <2-4-7-19> S
Gillison 11 Br.J.Surg 2002 Clin <19> NS
Bachmann 10 Br.J.Surg 2002 Clin * NS
Dimick 38 Ann.Thorac.Surg. 2001 Adm <4-15> S
vLanschot 7 Cancer 2001 Adm <10-20> S
Kuo 39 Ann.Thorac.Surg. 2001 Adm <6> S
Swisher 40 J.Thorac.Cardiovasc.Surg.2000 Adm <5> S
Gordon 41 J.Am.Coll.Surg. 1999 Adm <10-20-50> S
Begg 42 JAMA 1998 Mixed <5-10> S
Patti 43 J.Gastrointest.Surg.1998 Adm <1-2-4-6> S
* Urbach and Bachmann used equally sized groups and reported only median volumes of these groups. Adm = 
administrative data; Clin = clinical data; S = significant; NS = not significant
Mortality was the only outcome-measure. Even after risk-adjustment, which decreased 
the outcome-differences between high- and low-volume hospitals, the differences in 
results for esophageal and pancreatic resections were highly significant, favoring surgery 
in a high-volume center. Two more recently published reviews of the volume-outcome 
relationship for esophagectomies came up with 12 papers addressing this subject 5 4.  Only 
two of these studies were based on clinical data. Although both showed a decrease in 
mortality, they failed to show a statistically significant relationship of operative mortality 
with hospital volume 10,11. In our own  review of the literature we identified another study 
from the UK using clinical data, in which hospital case volume independently predicted 
operative mortality 12 (table 4).
In the present study independent data managers collected data retrospectively from the 
patient files. Not only the (in-hospital) mortality rate was obtained, but also a range of other 
outcome data, like complication rates,  resection margins, length of stay and long-term 
survival. In our opinion the latter is an important performance indicator in surgical oncology, 
surprisingly sporadically mentioned in the volume-outcome literature. 
The results of patients treated in eleven low-volume hospitals were compared with the results 
of  patients treated in the nearest high-volume referral center. Significant differences in 
outcome could be revealed. In-hospital mortality was significantly higher in the low-volume 
hospitals. The retrieved information about co- morbidity and stage of the disease made 
an extensive preoperative risk- and tumor load comparison possible. Risk-adjustment is an 
important issue in outcome research, because patients with severe co-morbidity may be 
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unequally distributed between (groups of) hospitals. Especially, when only administrative 
data are used to assess hospital performances, a selection-bias could lead to inadvertently 
penalizing those surgeons who provide excellent care to patients with more severe co 
morbid disease 7,13. Administrative data-sets were never designed to predict risk and should 
probably not be used as such14. Therefore, the validity of studies which fail to make case-mix 
adjustments based on clinical data, has to be questioned.
Nevertheless, a multivariate analysis of our data shows hospital volume to be an independent 
prognostic factor for in-hospital mortality. Although differences in surgical technique could 
be detected, with more transthoracic esophagectomies and intrathoracic anastomoses in 
the low-volume group, these factors are not significantly related to mortality. These findings 
are confirmed by earlier reports 15-18. Also, there is little evidence for a beneficial role of 
neo-adjuvant therapies 19-22. But, above all, choices made concerning diagnostic strategy, 
neo-adjuvant treatments and surgical technique are related to the knowledge, experience 
and judgment of the (team of) specialists.
    
After exclusion of in-hospital mortality, the survival of patients in the HVH was equal to 
those treated in the LVHs. But, the results of the HVH were negatively influenced by its 
case-mix. More patients with stage IV disease were treated in the HVH, corresponding 
with its status as a tertiary referral center. The very poor survival in this group of patients 
influences the overall results significantly. Only when we are informed about differences in 
tumor stage, we are able to detect real differences in survival, between patients treated 
in different hospitals. Although in this study all pathology reports were reviewed, and the 
number of lymph nodes resected was equal for both groups, we still have to be cautious 
suggesting a survival benefit for high-volume surgery. Only when a uniform pathologic 
evaluation is guaranteed, we can be sure that observed differences in tumor stages are truly 
characteristic for patient groups. This could be the reason that few studies have attempted 
to examine the influence of hospital volume on long-term survival in cancer surgery, only 
one of them concerning esophagectomies 23-27. A recent study from the Netherlands failed 
to show a survival benefit in high volume hospitals (>20 resections a year), but did show an 
improved survival for esophagectomies performed in University compared to non-University 
hospitals28. On the other hand, for pancreatectomies and hepatectomies registered in the 
MEDICARE-database, Fong showed a significant better survival for procedures performed 
in high volume centers 25. In his study administrative data about age, gender, co morbidity, 
and extent of the resection were included in a uni- and multivariate analysis, but stages of 
the disease, radicality and intent of the resection (palliative or curative) were not reported. 
In conclusion, our study shows that hospital volume is an important determinant of 
peri-operative morbidity and mortality in esophageal cancer surgery.  Nevertheless, volume 
in itself is no guarantee for high quality of surgical care in a specific institution.  Selecting 
(only) favorable patients can be the basis of superior results. Therefore case-mix adjustments 
are essential in the assessment of surgical performance of different institutions. 
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The volume-outcome relationship for complex surgical procedures has been extensively 
studied. Most studies are based on administrative data and use in-hospital mortality as 
the sole outcome measure. It is still unknown if concentration of these procedures leads to 
improvement of clinical outcome. The aim of our study was to audit the process and effect 
of centralizing esophageal resections for cancer by using detailed clinical data.
Methods: 
From January 1990 till December 2004, five-hundred fifty-five esophagectomies for cancer 
were performed in eleven hospitals in the region of the Comprehensive Cancer Center 
Leiden, 342 patients were operated on before and 213 patients after the introduction of a 
centralization project. In this project patients were referred to the hospitals which showed 
superior outcomes in a regional audit. In this audit patient-, tumor- and operative details as 
well as clinical outcome were compared between hospitals. The outcome of both cohorts, 
patients operated on before and after the start of the project, were evaluated.
Results:
Despite the more severe comorbidity of the patient group, outcome improved after 
centralizing esophageal resections. Next to a reduction in postoperative morbidity and 
length of stay, mortality fell from 12 to 4% and survival improved significantly (p = 0.001). 
The hospitals with the highest procedural volume, showed the biggest improvement in 
outcome. 
Conclusion:
Volume is an important determinant of quality of care in esophageal cancer surgery. Referral 
of patients with esophageal cancer to surgical units with adequate experience and superior 
outcomes (outcome-based referral), improves quality of care.
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INTRODUCTION
The number of publications that report on the relationship between the volume of high-risk 
surgical procedures and patient outcome continues to grow1. Most studies show better 
outcome with increasing number of operations performed by a specialized center or 
surgeon. However, there is still a debate about the level of evidence of these studies and 
the appropriateness of minimum volume thresholds for high-risk surgical procedures2 3 4. 
For example, there are no randomized controlled trials that have compared outcome for 
complex surgical procedures between high and low volume hospitals. Despite this “lack 
of evidence”, authors claim that many surgical deaths could be saved by centralizing these 
high-risk procedures5. However, studies that have analyzed the actual effect of centralization 
(or regionalization) on hospital volumes and outcomes are rare6.
It has been widely acknowledged that esophagectomy for cancer is a complex surgical 
procedure and that concentration in high-volume centers could lead to improved outcome 
7 8. However, translation of the conclusions of observational series to clinical practice is 
difficult. Cut-off values between high- and low volume esophageal surgery vary greatly 
between studies (Table I). In the Netherlands, van Lanschot et al. investigated the volume-
mortality relationship for esophageal resections, analyzing data from the Dutch National 
Medical Registry 9. They also showed an inverse relationship between hospital volume and 
mortality. The purpose of our study was to analyze whether centralization of esophageal 
cancer surgery truly improves clinical outcome. Besides mortality, we were also interested in 
a more extensive set of outcome measures, including overall survival. As case-mix has also 
been shown to be an important predictor for treatment outcomes, we included detailed 
clinical data of individual patient and tumor characteristics10. 
METHODS
Comprehensive Cancer Center Leiden
Eleven hospitals in the mid-western part of the Netherlands are affiliated with the 
Comprehensive Cancer Center Leiden (CCCL). In this urbanized area travelling distances 
between hospitals are not more than 45 kilometres (30 miles). In 1997, a Professional 
Network of Surgical Oncologists (PNSO) involving all affiliated hospitals was established, 
with the objective to improve the effectiveness and efficiency of surgical care for patients 
with cancer. Within the light of the increasing number of reports on a volume-outcome 
relationship for esophagectomies, the Network decided to evaluate the surgical care for 




All surgically treated esophageal carcinomas from 1990 till 1999, were identified through 
the ‘Cancer Registry’ of the CCCL, in which all cancer patients diagnosed and treated in 
the mid-western part of the Netherlands (1.7 million inhabitants) are registered. All eleven 
hospitals formally gave their consent to participate in this audit and were subsequently 
visited by two investigators who retrieved the original patient files. Patient demographics, 
pathological notes, data on surgical and (neo)adjuvant treatments, co-morbidity as well as 
post-operative morbidity, mortality, length of stay and survival were extracted from the 
patients’ files. Pathological notes were reviewed in detail by two independent researchers 
and all cancers were staged according to the TNM-staging system of the UICC 1997. The 
obtained pTNM stages were then cross-checked with the tumor stages in the ‘Cancer 
Registry’. Discrepancies in tumor stage were discussed between the researchers and a 
trained data manager from the CCCL/Cancer Registry database. If consensus could not be 
reached, the tumor stage was classified as ‘unknown’. 
Intervention
In January 2000 the results of this retrospective analysis were presented at the PNSO 
meeting10. Differences in volume and outcome between hospitals were discussed and all 
surgeons agreed to participate in a prospective registration. Also all surgeons agreed upon 
the scenario of having to refer esophageal cancer patients to centers with a better outcome 
if their own results proved to be unfavorable (outcome-based referral). These referrals were 
on a voluntary basis, however, both for the patient and the surgeon. 
Prospective registration
From January 2000 until December 2004 the same data were prospectively collected 
from the original patient files, and again all affiliated hospitals took part in this exercise. 
Completeness of the data was cross-checked with the independently collected information 
from the ‘Cancer Registry’. Each year, the interim results were presented and discussed 
within the group of surgeons at the meeting of the PNSO. 
Control group 
To put the data of the CCCL in national perspective, we compared the outcome of the CCCL 
region with the results of the nearest referral center for esophagectomy outside the CCCL 
region. In this high volume university hospital, information of patients operated on for an 
esophageal carcinoma is prospectively collected from the original patient files by a data 
manager.
Statistics
Differences in patient, tumor and treatment characteristics, as well as in outcome 
measurements were assessed using the Kruskal-Wallis test for continuous variables and 
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the chi-square test for categorical variables. Patients with an ‘unknown’ status for a given 
variable were excluded for the analyses. Duration of survival was calculated as the difference 
between date of surgery and either the date of death or the date of last patient contact. 
To prevent the problem of differential follow up, for all groups follow-up was cut-off at 
two years after surgery. Observed survival rates were estimated by using the Kaplan-Meier 
method. The log-rank test was used to assess differences in survival between patients who 
were operated in different time-periods and in low-volume versus high-volume hospitals. The 
Cox proportional hazard model was used to calculate hazard ratios, adjusting for possible 




Between 1990 and 2004, the evaluation and treatment of patients with esophageal cancer 
was performed in eleven hospitals in the region of the CCCL (one university hospital, five 
teaching hospitals and five general hospitals). In 555 consecutive patients, an esophageal 
tumor was resected with curative intent. Figure 1a illustrates the distribution of surgical 
procedures within the studied time period for the 11 hospitals and Figure 1b shows the 
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Period 1990- '94 Period 1995-'99 Period 2000-'04
Figure 1a number of esophageal resections in hospitals in region of CCCLeiden per 5-years period (1990-1994, 
1995-1999, 2000-2004) * Hospitals that abandoned esophageal resections during 2000-2004 period: 4 
Hospital that abandoned esophageal resections after January 1st 2005 
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From 1990 till 1999, none of the hospitals performed more than seven esophageal resections 
per year (low volume hospitals; LVH). From the year 2000 onwards, a gradual concentration 
of esophageal resections has occurred, and in two hospitals (I and II) procedural volumes 
increased to more than 10 resections per year (high volume hospitals; HVH). In the same 
period of time, a mean annual number of 56 esophageal resections were performed in the 
nearest high volume center.
Patient, tumor and treatment characteristics
Table 1 shows the patient, tumor and procedural characteristics of esophageal resections 
performed in three consecutive time periods. There was no significant difference in age, 
gender, histological type or location of the tumors. However, the number of patients with 
co-morbidities increased during the study period. Stage I tumors were more frequently seen 
in the later time periods and an increasing number of transhiatal resections were performed. 
The number of nodes evaluated by the pathologist changed in time, with a mean number 































Figure 1b resection rates of newly 
diagnosed patients with esophagus 
carcinoma in hospitals in region of CCCL 
per 5-years period (1990-1994, 1995-1999, 
2000-2004)
Table 1. Characteristics of patients who underwent esophageal resection by period of surgery
Characteristics
1990-1994 1995-1999 2000-2004
No. of patients % No. of patients % No. of patients % P value
Age (years) 0.19
  Median 66 65 64
  Range 37-87 33-85 33-86
Gender 0.70
  Male 109 70.8 139 74.3 159 74.3
  Female 45 29.2 48 25.7 55 25.7
Co-morbidity 0.25#,*
  No 68 44.2 74 39.6 83 38.8
  1 organ system 51 33.1 61 32.6 85 39.7
  2 organ systems 19 12.3 30 16.0 41 19.2
  ≥ 3 organ systems 4 2.6 7 3.7 4 1.9
  Unknown 12 7.8 15 8.0 1 0.5
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time-period more neo-adjuvant chemotherapy was used, especially in patients with a 
tumor in the lower esophagus, included in a trial on peri-operative epirubicin, cisplatin and 
fluorouracil (ECF)11.
Outcome
The outcome of esophagectomies in the CCCL region improved with time (Table 2). The 




No. of patients % No. of patients % No. of patients % P value
Histology 0.93#,**
  Adenocarc 107 69.5 130 69.5 144 67.3
  Squamous carc 45 29.2 51 27.3 52 24.5
  Barrets dysplasia 1 0.6 3 1.6 6 2.8
  Others - - 2 1.1 5 2.3
  Unknown 1 0.6 1 0.5 7 3.3
Tumor localisation 0.97#,***
  Cervical esoph. 4 2.6 3 1.6 4 1.9
  Mid esoph. 23 14.9 30 16.0 32 15.0
  Distal esoph./ge-junction 127 82.5 152 81.3 177 82.7
  Unknown - - 2 1.1 1 0.5
Stage (pTNM) 0.65#
  0 2 1.3 5 2.7 6 2.8
  I 10 6.5 26 13.9 31 14.5
  II 80 51.9 80 42.8 82 38.3
  III 52 33.8 60 32.1 74 34.6
  IV 9 5.8 12 6.4 15 7.0
  Unknown 1 0.6 4 2.1 6 2.8
Neo-adj. treatment <0.001#,****
  No 150 97.4 165 88.2 160 74.8
  Chemo +/- radiother. 2 1.3 19 10.1 54 25.2
  Unknown 2 1.3 3 1.6 - -
Surgical approach <0.001#,*****
  Abdomino-cervical 53 34.4 97 51.9 156 72.9
  Thoraco-abdominal 62 40.3 34 18.2 11 5.9
  Abd-thor-cervical 16 10.4 27 14.4 27 12.6
  Abdominal 23 14.9 29 15.5 15 7.0
  Unknown - - - - 5 2.3
Anastomoses <0.001******
  Cervical 69 44.8 126 67.4 187 87.4
  Thoracic 60 39.0 30 16.0 12 5.6
  Abdominal 25 16.2 31 16.6 15 7.0
Total no. Of patients 154 187 214
# unknown category was excluded, *  linear trend analysis, ** squamous versus adenocarcinoma plus barrets 
dysplasia, *** distal esophagus / GE-junction versus others, **** no neo-adjuvant therapy versus others, 
***** abdomino-cervical versus others, ******cervical versus thoracic plus abdominal
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73%. The number of patients who left the hospital without adverse events was highest in 
the 2000 - 2004 period. Hospital stay was shortened significantly and in-hospital mortality 
was reduced almost three-fold. As shown in figure 2, a significantly better 2-yrs survival 
Table 2. Outcome after esophageal resections in region of CCCLeiden (1990-1994, 1995-1999, 2000-2004)
1990-1994 1995-1999 2000-2004
Outcome No. of patients % No. of patients % No. of patients % P value
Margins 0.57#,*
  R0 107 69.5 140 74.9 156 72.9
  R1 34 22.1 21 11.2 39 18.2
  R2 10 6.5 25 13.4 12 5.6
  Unknown 3 1.9 1 0.5 7 3.3
Complications 0.20#
  No 43 27.9 46 24.6 70 32.7
  Yes 106 68.8 140 74.9 143 66.8
  Unknown 5 3.2 1 0.5 1 0.5
Re-intervention 0.27#,**
  None 115 74.4 155 82.9 163 76.2
  1 27 17.5 21 11.2 32 15.0
  2 5 3.2 7 3.7 12 5.6
  ≥ 3 2 1.3 3 1.6 3 1.4
  Unknown 5 3.2 1 0.5 4 1.9
Hospital stay (days)+ 0.002
  Median 20 21 17
  Range (9-92) (9-125) (8-273)
In-hospital mortality 0.003#
    No 131 85.1 160 85.6 204 95.3
    Yes 22 14.3 23 12.3 10 4.7
    Unknown 1 0.6 4 2.1 - -
Total no. of patients 154 187 214
+ patients who died during hospital stay were not included, # unknown category was excluded, * R0 versus R1 
plus R2, ** no re-intervention versus others
Figure 2. Two year survival after resection for 
all stages of esophageal carcinoma in 3 time 
periods (p1:1990-1994, p2: 1995-1999, p3: 
2000-2004), incl. hospital mortality   
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Table 3b. Cox multivariate model adjusted for the impact of covariates on the risk of dying (HR) for patients 
who underwent esophageal resection by period of  surgery (patients who died in-hospital excluded).
HR 95% CI
Univariate
  1990-1994 1.00
  1995-1999 0.87 0.64–1.20
  2000-2004 0.66 0.48–0.91
Adjusted for stage#
  1990-1994 1.00
  1995-1999 0.90 0.65–1.24
  2000-2004 0.67 0.48–0.93
Adjusted for stage#, age and gender
  1990-1994 1.00
  1995-1999 0.88 0.64–1.22
  2000-2004 0.67 0.48–0.93
Adjusted for stage#, age, gender and co-morbidity#
  1990-1994 1.00
  1995-1999 0.88 0.64–1.22
  2000-2004 0.67 0.48–0.93
Adjusted for stage#, age, gender, co-morbidity# and surgical approach
  1990-1994 1.00
  1995-1999 0.92 0.66–1.29
  2000-2004 0.75 0.52–1.07
HR: hazards ratio, 95% CI: 95% confidence interval, #  unknown categories were excluded 
Table 3a. Cox multivariate model adjusted for the impact of covariates on the risk of dying (HR) for patients 
who underwent esophageal resection for cancer by period of surgery.
HR 95% CI
Univariate
  1990-1994 1.00
  1995-1999 0.89 0.69–1.14
  2000-2004 0.66 0.50–0.86
Adjusted for stage# and co-morbidity#
  1990-1994 1.00
  1995-1999 0.82 0.61–1.11
  2000-2004 0.57 0.42–0.77
Adjusted for stage#, co-morbidity# and surgical approach#
  1990-1994 1.00
  1995-1999 0.85 0.62–1.15
  2000-2004 0.60 0.43–0.84
Adjusted for stage#, co-morbidity#, surgical approach# and neo-adjuvant treatment#
  1990-1994 1.00
  1995-1999 0.85 0.63–1.16
  2000-2004 0.61 0.44–0.86
HR: hazards ratio, 95% CI: 95% confidence interval, #  unknown categories were excluded 
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is seen for the last time-period (p = 0.001). After exclusion of in-hospital mortality, this 
difference is still significant ( p = 0.045).
Table 3a shows the results of a multivariate analysis for the risk of dying after surgery 
in the three time periods with adjustments for the impact of the covariates: stage, 
comorbidity, surgical approach and neo-adjuvant treatments. Somewhat higher stages 
of the disease and more patients with multiple comorbidities were operated in the last 
time-period. Although there are significant differences in surgical approach and the use of 
neo-adjuvant chemotherapy between time-periods, the survival benefit in the 2000-2004 
period remains significant in multivariate analysis (HR 0.61). An analysis of the data after 
exclusion of patients who received (neo-)adjuvant treatment showed similar improvements 
in mortality rates and survival after 2000. Also, a multivariate analysis was performed after 
exclusion of the patients who died during hospital stay (Table 3b). Improvements in survival 
stayed (borderline) significant after adjustments for differences in stage, age, gender and 
comorbidities (p = 0.05), but after introducing surgical approach in the model, significance 
was lost (p = 0.25).
In table 4 patient, tumor and treatment characteristics of patients operated on in hospitals 
with less than 10 resections a year (low volume hospitals LVH) and with more than 9 
Table 4. Characteristics of patients who underwent esophageal resection by hospital volume in the 2000-2004 
time-period
LVHs HVHs
Characteristics No. of patients % No. of patients % P value
Age 0.24
  Median (years) 64 63
  Range (years) (33-86) (43-80)
Gender 0.53
  Male 80 72.1 79 76.7
  Female 31 27.9 24 23.3
Co-morbidity 0.001#,*
  No 56 50.5 27 26.2
  1 organ system 35 31.5 50 48.5
  2 organ systems 18 16.2 23 22.3
  ≥ 3 organ systems 1 0.9 3 2.9
  unknown 1 0.9 - -
Histology 0.98#,**
  Adenocarc 73 65.8 71 68.9
  Squamous 27 24.3 25 24.3
  Barrets dysplasia 3 2.7 3 2.9
  Other 2 1.8 3 2.9
  Unknown 6 5.4 1 1.0
Tumor localisation 0.61#,***
  Cervical esoph. 2 1.8 2 1.9
  Mid esoph. 18 16.2 14 13.6
  Distal esoph./ge-junction 90 81.1 87 84.5
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resections a year (high volume hospitals HVH) are shown. Only patients operated in a 
year in which the procedural volume of the hospital concerned, exceeded 9 resections, 
were included in the HVH group. In this group more patients with more comorbidity 
were operated and the transhiatal approach was used more often, than the transthoracic 
approach. Significantly more adverse events occurred in the LVH group, with a mortality 
rate of 6.3% in the LVH group and 2.9% in the HVH group (table 5). After exclusion of 
the patients who died in-hospital, the median hospital stay was 8 days shorter in the HVH 
group. Survival analysis did not show a difference in 2-year survival between the LVH and 
HVH group (p = 0.63).   
DISCUSSION
In the last decade, many studies have been published that have addressed the volume-
outcome relationship for complex surgical procedures1,12. The results of these studies focus 
Table 4. Characteristics of patients who underwent esophageal resection by hospital volume in the 2000-2004 
time-period  (Cont).
LVHs HVHs
Characteristics No. of patients % No. of patients % P value
  Unknown 1 0.9 - -
Stage (pTNM) 0.90#
  0 3 2.7 3 2.9
  I 15 13.5 16 15.5
  II 43 38.7 39 37.9
  III 39 35.1 35 34.0
  IV 6 5.4 9 8.7
  Unknown 5 4.5 1 1.0
Neo-adj. treatment 0.27#,****
  No 90 81.1 70 68.0
  Chemo +/- radioth. 21 18.9 33 32.0
Surgical approach <0.001#,***** 
  Abdomino-cervical 66 59.5 90 87.4
  Thoraco-abdominal 10 9.0 1 1.0
  Abd-thor-cervical 17 15.3 10 9.7
  Abdominal 14 12.6 1 1.0
  Unknown 4 3.6 1 1.0
Anastomoses <0.001******
  Cervical 86 77.5 101 98.1
  Thoracic 12 10.8 - -
  Tbdominal 13 11.7 2 1.9
Total no. of patients 111 103
LVHs: Low Volume Hospitals (< 10 resections/yr) HVHs: High Volume Hospitals (≥ 10 resections/yr), # unknown 
category was excluded, ** adenocarcinoma / barrets dysplasia versus squamous and others, *** distal 
esophagus / GE-junction versus cervical / mid esophagus, **** no neo-adjuvant therapy versus others, ***** 
abdomino-cervical versus others, ****** cervical anastomoses versus others
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Table 5. Outcome after esophageal resections by hospital volume in the 2000-2004 time-period
Characteristics
LVHs HVHs
P valueNo. of patients % No. of patients %
Margins 0.35#,*
  R0 77 69.4 79 76.7
  R1 19 17.1 20 19.4
  R2 10 9.0 2 1.9
  Unknown 5 4.5 2 1.9
Complications
  No 24 21.6 46 44.7 0.001#
  Yes 86 77.5 57 55.3
  Unknown 1 0.9 - -
Surgical complications 0.05#
    No 54 48.6 64 62.1
    Yes 56 50.5 39 37.9
    Unknown 1 0.9 - -
General complications 0.001#
    No 44 39.6 65 63.1
    Yes 66 59.5 38 36.9
    Unknown 1 0.9 - -
Re-intervention 0.39#,**
  None 82 73.9 81 78.6
  1 19 17.1 13 12.6
  2 7 6.3 5 4.9
  ≥ 3 1 0.9 2 1.9
  Unknown 2 1.8 2 1.9
Hospital stay (days)+ <0.001
  Median 22 14
  Range (10-273) (8-104)
In-hospital mortality 0.24
    No 104 93.7 100 97.1
    Yes 7 6.3 3 2.9
Total no. of patients 111 103
LVHs: Low Volume Hospitals (< 10 resections/yr)  HVHs: High Volume Hospitals (≥ 10 resections/yr), + 
patients who died during hospital stay were not included, # unknown category was excluded, * R0 versus R1 
plus R2, ** no re-intervention versus others
on the rather high difference in mortality rates between high- and low-volume providers 
for esophageal resections for cancer7. As a consequence, these authors speculate that 
concentration of these high-risk surgical procedures in centres with adequate experience 
could avoid thousands of preventable deaths5,13. However, the present study is the first that 
shows an actual improvement in outcome after the process of centralization of esophageal 
resections for cancer.   
Chowdhury et al. reviewed 163 studies that looked at the volume-outcome relationship for 
complex surgical procedures1. Seventy-three percent of these studies showed significant 
better outcomes in high volume hospitals and for high-volume surgeons. However, most 
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studies are registry-based and omit important case-mix adjustments from clinical data. 
Moreover, hospital mortality is often presented as the sole outcome measure, without 
presenting other dimensions of quality of care. Therefore, there is solid criticism on the 
methodological issues, which hampers centralization initiatives for complex surgical 
procedures, especially in the Netherlands. Despite the expected benefits of centralizing 
complex surgical procedures at high-volume providers, there are few studies that show an 
actual improvement in clinical outcome after centralization of a specific procedure14. As 
a part of a broader initiative, The Leapfrog group, a large coalition of private and public 
purchasers of health insurance in the United States, is referring their patients to high volume 
providers of esophagectomies since 2000. Although expectations about the beneficial 
effects of this intervention were high, no results have been published yet5,13. 
Our study adds clinical proof to the effectiveness of concentrating complex surgical 
procedures: not only hospital mortality was reduced to a third of the original value, but 
also other outcome indicators, like the number and severeness of adverse events, showed a 
significant improvement after centralization of esophagectomies in the CCCL region in the 
Netherlands. This was also reflected in a lower number of reinterventions and a lower length 
of stay. Remarkable is the significant improvement in survival that is already demonstrated 
after a limited concentration of esophageal resections (Figure 2). To our opinion overall 
survival, adjusted for differences in tumor stages, should be the most important performance 
indicator in surgical oncology, being even more valuable than operative mortality.
In an earlier article from our group we showed that case-mix is an important determinant 
of outcome and should be part of every study comparing outcome between providers10. 
Therefore, we tried to study the effect of differences in case-mix between the hospitals. 
The identification of more patients with multiple comorbid diseases and more patients with 
stage IV disease in the last time period (Table 1), supports our conclusion that outcome 
improved with centralization of esophageal resections. 
 
However, our study has several limitations. First, the accuracy of the registry database should 
be confirmed. This was done by comparing the results with the data of the independently 
retrieved information in the Cancer Registry of the CCCL. Only 3% of the patients operated 
on for esophageal cancer in our region were missing from our prospective database. 
The treatment and outcome characteristics of this small group of patients did not differ 
significantly from the original group. An earlier report on a detailed medical audit confirms 
the accuracy of clinical outcomes databases on major fields like operative mortality, major 
complications, and significant factors in risk stratification15.
Secondly, our dataset is still limited, though more (co)variables were included than in 
most volume-outcome studies. In contrast to the available data on case-mix variations, no 
information on structural changes in perioperative care was available. To our knowledge 
no important improvements in the treatment of esophageal cancer are known from the 
61
Chapter 4
literature nor within the region of the CCCL. Nevertheless, progress in anesthesiologic 
techniques and postoperative care within the study period, could have interfered with our 
findings. In addition, limited data were available on the survival of patients in the later 
time-period (2-year survival). This could be insufficient to evaluate differences in disease 
control obtained by transthoracic and transhiatal procedures. Recently, the 5-year survival 
data of the Dutch randomized controlled trial comparing these surgical approaches were 
published16. No survival benefit was shown for either approach. Nevertheless, after 
introducing surgical approach in our multivariate analyses (Table 3b), the statistical difference 
in survival between the time-periods was lost, suggesting an important role for the choice of 
operative approach. To our opinion, the choice for a transhiatal or transthoracic procedure 
is made in a decision making process in which careful interpretation of diagnostic images 
and surgical experience is combined. The increase in hospital volumes, as a result of the 
concentration of esophagectomies in our study, might have lead to better surgical decision 
making, especially in the choice of operative approaches. 
The beneficial effects of the centralization-process conducted in the last time-period is 
further supported by the comparison of outcome between LVHs and the hospitals that 
acquired the status of HVH (> 10 resections/ year) in the last time-period (Table 5). Although 
differences in operative mortality are not significant, they strongly suggest that the most 
important improvement in outcome is made in the HVHs, which now parallel the outcome in 
the nearest high-volume referral center (data not shown). Differences in case-mix, especially 
comorbidities, are also in favour of the HVHs (Table 4). A continuation of the centralization 
process and the outcome registration in our region will elucidate the mechanisms behind 
these improvements in patient outcome. From January 1st 2005 esophagus resections in the 
region of the CCCL are concentrated in three hospitals with a mean annual volume of more 
than 15 esophagus resections. 
Finally, the feedback we gave to individual surgeons and hospital organizations on their 
performance (mirror-information) could in itself have influenced practice patterns and 
dedication of the professionals. When outcomes data are used for internal peer review 
within institutions, changes in the process of care can be initiated by surgeons or hospitals 
themselves. A good example is the Veterans Affairs National Surgical Quality Improvement 
Program (NSQIP) in which feedback to providers and managers lead to a decrease in 
the relative risk for postoperative mortality of 27% and a 45% decrease in postoperative 
morbidity17. However, this program was more detailed consisting of outcome-based 
annual reports, periodic assessment of performance, self-assessment tools, structured site 
visits and dissemination of best practices. Nevertheless, the observed improvements in 
outcome in our study could not only be a result of the concentration of services, but also 
of the introduced feedback on surgical performance. This could be the explanation for the 
improved outcome that was also demonstrated in the LVHs, though of a lesser magnitude 
than the improvements in HVHs (Table 5). 
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Some authors believe that procedural volume, as a proxy for quality, is preferable above 
direct outcomes measurement 18,19. The availability and easy access of these data and 
the avoidance of the statistical ‘problem of small sample size’ are mentioned as important 
advantages 20. However, in a study from our own country, van Heek et al. showed that, 
despite a 10-year lasting ‘evidence-based’ plea for centralization of pancreatic surgery, no 
reduction of mortality or change in referral pattern was seen in the Netherlands 21. The 
problem is that provider volume as a quality measure only holds true on average, and is a 
poor predictor of quality in individual hospitals or surgeons 22 23 . 
In our opinion, a continuous monitoring of clinical outcomes has not only the ability to assess 
quality of care, but can actually improve surgical performance. A number of methods for 
surgical monitoring, that take into account different levels of prior risk, have been described 
in the literature 24,25. A routinely conducted clinical audit, providing hospitals and surgeons 
with individualized and pooled outcome-information, can be a stimulus to the introduction 
of a range of improvements in hospital and surgical care 26-28. In addition, a national or 
regional approach, like the example for esophageal cancer surgery in our study, clarifies 
important differences in quality of care. In a peer review environment or when reliable, 
hospital specific outcome information is made available to the public, actual changes in 
referral patterns can be made (outcome-based referral).
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Recently, in the Netherlands esophageal resections for cancer are banned from hospitals 
with an annual volume less than ten. In this study we evaluate the validity of this specific 
volume cut-off, based on a review of the literature and an analysis of the available data on 
esophagectomies in our country. In addition, we compare the expected benefits of volume-
based referral to the results of a regional centralization process based on differences in 
outcome (outcome-based referral). 
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INTRODUCTION
For high-risk surgical procedures, variation in outcome between hospitals and surgeons, has 
been the subject of a large number of studies performed in different countries1. Most studies 
are from the United States, but also in European countries outcomes research has become 
a subject of major interest. In the Netherlands differences in outcome for esophagectomies 
and pancreatectomies between high- and low volume hospitals have been the subject of 
a continuing debate in the last decade2. In 2001 van Lanschot et al. reported the effect 
of hospital volume on hospital mortality after esophagectomy in the Netherlands on data 
from the Dutch National Medical Registry3. In the 1993-1998 study period mortality rates 
varied from 5 to 12 percent between high- and low volume providers. Despite extensive 
discussions within the Association of Surgeons in the Netherlands about the consequences 
this volume-based variation should have, there were few changes in referral patterns. In 
2006 this lead to a decision of the Netherlands Health Care Inspectorate to ban esophageal 
resections from hospitals with a mean annual volume less than ten. 
In the mid-western part of the Netherlands eleven hospitals are affiliated with the 
Comprehensive Cancer Center West (CCCL), one of the nine regional comprehensive cancer 
centers in the country. Based on the volume-outcome literature the Professional Network of 
Surgical Oncologists (PNSO) in this region decided to start a surgical outcome registration 
(clinical audit) for esophageal cancer surgery in 2000. Detailed clinical data were retrieved 
retrospectively from the 1990 -1999 time-period. In this period no hospital performed more 
than six esophagectomies a year and the overall in-hospital mortality rate was 13 percent, 
much higher than the national average and the results of high-volume referral centers in 
our country4. 
Based on these results the PNSO decided that esophageal resections had to be concentrated 
in 2 to 3 hospitals in the region. Because concentration of services could not be based 
on historical differences in procedural volume, all surgeons agreed upon a prospective 
outcome-registration, with a scenario of having to refer patients to hospitals with better 
outcome if their own results proved to be unfavorable (outcome-based referral). 
The primary purpose of our study is to evaluate variations in outcome for esophageal 
cancer surgery in a nation-wide cohort of hospitals, in a larger time-period. By reviewing 
the volume-outcome literature and analyzing hospital specific data on esophagectomies 
performed in the Netherlands, we investigate the proportion of hospital variation that can 
be attributed to differences in volume and the validity of a specific cut-off value of 10 
resections a year.
In addition, we evaluate outcome-based referral as an instrument to concentrate 
esophageal cancer surgery in a situation where historical hospital volumes are insufficient 




Review of the Volume-outcome Literature 
A search of the medical literature was performed in Medline for the period 1998-2008. 
The search was limited to publications in the English language and original articles. The 
medical subject headings (MeSH) ‘esophagectomy’ and ‘hospitals’ were combined with the 
key words ‘volume’ or ‘mortality’. Also the related articles feature of PubMed was used. A 
manual search was performed for references mentioned in the first selection of articles, to 
identify all publications considerable for inclusion. 
All original articles comparing mortality rates after esophagectomy between hospitals with 
a lower and higher procedural volume, were selected. Reports on data from less than 10 
hospitals or less than 500 patients were excluded. Two authors (MW and GG) performed the 
search independently. Disagreements were resolved by discussion with a third author (RT). 
From the selected articles ‘study period’, ‘country of origin’, ‘number of patients’, ‘number of 
hospitals’, ‘volume categories’ and ‘outcome measures’ being ‘hospital mortality’ or ‘30-day 
mortality’ were retrieved. The relation between the different hospital volume categories 
and the corresponding mortality rates was graphically displayed.
A meta-analysis of the data provided by these studies was not considered feasible because 
of the heterogeneity in study populations and volume categories. In addition, several sources 
of bias, like selection- and publication bias can not be controlled for without the availability 
of the primary data.
Esophagectomies in the Netherlands
Patients
Data of all esophageal resections for cancer that were performed in Dutch hospitals from 
January 1991 to January 2005 were retrieved from the Dutch National Medical Registry 
(DNMR) administered by Prismant, the Dutch Center for Health Care Information, Utrecht, 
the Netherlands. This register is a (near) complete database of hospital discharge data for all 
in-hospital and day-care treatments in Dutch hospitals (general and academic). The DNMR 
collects data on diagnosis and treatments performed during hospital admission. In addition, 
demographic (age and gender) and outcome data (length of stay, mortality) are available. 
Only esophageal resections that were followed by reconstruction with a gastric tube or 
colon interposition were included in our study. Though individual patients and hospitals 
could not be identified, the number of resections performed per calendar year could be 
calculated for each hospital code. Hospital volume was defined as the average number of 
resections performed in that hospital in the three preceding calendar years. Hospitals were 
divided in three volume categories according to an earlier publication of vLanschot et al 3: 
low volume, less than 10 resections a year, medium volume, 10 to 20 resections a year, and 
high volume, more than 20 resections a year.
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CCCLeiden: hospital identification
To identify the data from the hospitals affiliated with the CCCL we asked the representing 
surgeons for a written consent to break their hospital code. The region of the CCCL has 1.7 
million inhabitants and is served by eleven hospitals (one university hospital, five teaching 
hospitals and five general hospitals). The results of these hospitals were analyzed separately 
to be able to compare their results historically and in relation to the national averages.
Statistics
Differences in patient and hospital characteristics as well as in outcome were assessed 
using the chi-square test for categorical variables and ANOVA and Kruskall-Wallis test for 
continuous variables. 
To study the difference in performance between hospitals and the relation between volume 
and mortality, logistic regression models with a random hospital effect were used. To study 
the difference in performance in the CCCL region before and after 2000, a logistic regression 
model with the independent variables age, sex, region, time-period and a random hospital 
effect was used.
To visualise the relation between hospital volume and mortality and show the variation 
in outcome among hospitals, funnel plots were made5. Therefore the observed mortality 
rates were compared to expected numbers, based on gender, age and operation year of 
the patients within the hospital. The expected numbers were obtained by fitting a logistic 
regression model with mortality as dependent and sex, age and year of operation as 
independent variables. Then standardized mortality rates (SMR) were computed (SMR = 
observed/expected).The SMRs and the control limits were then multiplied by the average 
mortality rate in the population in the study period to obtain adjusted mortality rates. As 
target the average mortality in the high volume hospitals was used, with the 95 and 99 % 
limits from the Possoin distribution.
Analyses were conducted using SPSS software (version 14.0; SPSS inc., Chicago.IL), SAS 
PROC NLMIXED (SAS Institute Inc., Carey, North Carolina) for the random effect logistic 
regression or R for Funnelplots (www.r-project.org). 
RESULTS
Review of the Volume-outcome Literature
The initial two search strategies yielded 96 articles, of which 75 did not meet the inclusion 
criteria: 58 had a different subject, 6 where not original studies (reviews or comments), 9 
studies reported the results of less than ten hospitals, 1 study was published twice and 1 
article was not in the English language. The other 21 articles where included in our review. 
On these articles the related articles feature of PubMed was used and a manual reference 
search was performed. Four additional articles were found that met the inclusion criteria. The 
assessment of the 25 candidate articles led to exclusion of one article, which reported only 
the results of the lowest volume decile and the top volume decile of hospitals performing 
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Table 1. Studies evaluating the volume-outcome relationship for esophagectomies 1998-2008.





1998 Begg 7 USA 1984-1993 503 190 <6-11> Mortality S
1998 Patti 8 USA 1990-1994 1561 273 <30> Mortality S
1999 Gordon 9 USA 1989-1997 518 51 <11-21-51> Mortality S
2000 Swisher 10 USA 1994-1996 n.k. 101 <5> Mortality S
2001 Kuo 11 USA 1992-2000 1193 64 <6> Mortality S
2001 Lanschot 3 Netherlands 1993-1998 1792 n.k. <10-20> Mortality S
2001 Dimick 12 USA 1984-1999 1136 52 <4-16> Mortality S
2002 Birkmeyer 13 USA 1994-1999 6337 1575 <2-5-8-19> Mortality S
2003 Finlayson 14 USA 1995-1997 5282 603 <4-10> Mortality S
2003 Urbach 15 Canada 1994-1999 613 47 <3-9-17-19> Mortality S
2003 McCulloch 16 UK 1999-2002 955 23 <10-21> Mortality S
2003 Dimick 17,18 USA 1995-1999 3023 200 <3-6-16> Mortality S
2004 Urbach 19 Canada 1994-1999 613 47 <9> Mortality NS
2005 Wenner 20 Sweden 1987-1996 1429 74 <5-16> Mortality S
2005 Dimick 21 USA 1997-2000 3031 n.k. <6> Mortality S
2006 Simunovic 22 Canada 1990-2000 629 68 <8-20-44> Mortality NS
2006 Lin 23 Taiwan 2000-2003 6674 111 <20-34-59-86> Mortality S
2007 Rodgers 24 USA 1988-2000 8075 n.k. <5-10> Mortality NS




2007 Al-Sarira 26 UK 2002-2003 3229 111 <10-20-30-40> Mortality S
2007 Allareddy 27 USA 2000-2003 2473 717 <13> Mortality S
2008 Ra 28 USA 1997-2003 1172 361 <1-2> Mortality S




2008 Pal 29 UK 1999-2005 8874 144 <11-21-39> Mortality S
S = Significant. NS = Not significant. n.k. = not known. * = Volume categories are represented by ‘<x-y>’ 
meaning: lowest volume category with hospitals performing less than x resections a year, medium volume 
category with x to less than y resections a year, high volume category with y or more resections a year.
esophagectomies6. The remaining 24 articles are listed in Table 1 3 4 7 8 9 10 11 12 13 14 15 16 
17,18 19 20 21 22 23 24 25 26 27 28 29 .
A total number of 61,214 esophagectomies performed between 1984 and 2005 were 
studied. Most studies are from the USA and Canada, but more recently several European 
studies have been published. The median number of patients per study was 1429 and the 
median number of hospitals 106. Volume cut-offs between (very) low volume, median and 
(very) high volume differed widely. Twenty-one studies reported a statistically significant 
difference in hospital mortality between low- and high volume providers, with a median 
difference in mortality between the lowest and highest volume category of 7.2 percent. 
Two studies also report a difference in long-term survival. 
Figure 1 shows the mortality rate found for each volume category in these studies. Mortality 
rates are high and vary widely, especially for hospital volume categories beneath 20 
resections a year.
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Esophagectomies in the Netherlands
In the period 1991-2004, a total of 4939 esophageal resections for cancer were performed 
in 104 Dutch hospitals. Patient, hospital and procedural characteristics of the resections 
are described in Table 2. Over time, no relevant differences were found in the distribution 
of age and gender. The hospital volume of esophageal resections increased since the mid 
1990’s and the length of hospital stay decreased during the study period (p<0.0001). In the 
most recent time-period (2000-2004) forty-seven percent of esophageal resections were 
performed in low volume hospitals, with a mean annual volume less than 10. 
Nation-wide, the in-hospital mortality decreased from 9.7% in the period 1991-1994 to 7.3% 





















Figure 1. Mortality after 
esophageal resections for 
different hospital volume 
categories as reported in the 
literature
Table 2. Patient, hospital and procedural characteristics of esophageal resections for cancer between 1991-2004 









  mean ±SD 62.1 ±10.3 63.1 ±10.1 62.6 ±9.8 0.02
Gender
  male 1035 (75) 1290 (76) 1436 (77) 0.37
  female 342 (25) 412 (24) 424 (23)
Hospital volume *
  low (<10 /yr) 200 (54) ** 802 (47) 884 (48) <0.0001
  medium (10-20 /yr) 0  ( 0) 150 (9) 265 (14)
  high (>20 /yr) 168 (46) 750 (44) 711 (38)
Hospital stay (days)
  median (range) 18.4 (0.4-206) 17.6 (0-215) 16.4 (0.1-212) <0.0001
In-hospital mortality 133 (9.7) 130 (7.6) 136 (7.3) 0.04
* Hospital volume was calculated as the average number of resections in a specific hospital in the three 
preceding calendar years. ** Available for calendar year 1994 (n=368). Hospital volume could not be calculated 
for 1991-1993, because the resection volume in the 3 preceding years was not (completely) known.
71
Chapter 5
hospitals as well as in low-volume hospitals. A growing number of patients were treated 
in medium volume hospitals (10-20 resections / year) during the study period, from none 
during 1991-1994 period to 265 during the 2000-2004 time period. Mortality was high in 
these medium-volume hospitals; 11% during the most recent time period. 
Figure 3 shows the mortality after esophageal resections for all hospitals performing 





















Figure 2. Mortality after esophageal resections in the Netherlands for low, medium and high volume hospitals 
in three time-periods: 1991-1994, 1995-1999, 2000-2004. 
Risk-adjusted (gender, age, operation year) mortality rates
Target is 4.6 % (observed in high volume hospitals)
Figure 3.  In-hospital mortality in relation to the average annual volume of esophageal resections, for each 
hospital in the Netherlands. (Mortality is adjusted for age, sex and year of operation. The straight line indicates 
the average mortality in the high volume hospitals, the dotted lines the 95 and 99 percent limits) 
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esophagus resections in the 14 years study period. Targeting the outcome as was identified 
in the three high volume hospitals (>20 resections / year) mortality proved to be significantly 
worse in four out of five of the hospitals in the medium volume category (10-20 resections 
a year). Several low volume hospitals with a mean annual volume between five and ten, 
showed an in-hospital mortality similar to the mortality rate identified in the high volume 
hospitals. Logistic regression with mortality as dependent variable and a random hospital 
effect showed that after adjusting for age, gender and year of operation, there was a 
highly significant difference in performance between hospitals (hospital variation was 
Table 3. Results of logistic regression for in-hospital mortality with random hospital effect 
Multivariate Analysis
  for age, gender and 
operation year
for age, gender, 
operation year and volume
for age, gender, operation 
year, volume and region
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age (years) 1.05 1.04-1.07 <0.0001 1.05 1.04-1.07 <0.0001 1.05 1.04-1.07 0.0001
Gender 0.78 0.58-1.04 0.09 0.78 0.58-1.04 0.09 0.78 0.58-1.04 0.09
Operation year 0.96 0.92-0.99 0.02 0.96 0.92-1.00 0.03 0.97 0.93-1.01 0.10
Hospital volume
  medium vs low 1.01 0.66-1.55 0.95 1.00 0.66-1.54 0.98
  high vs low 0.49 0.30-0.79 0.004 0.48 0.30-0.77 0.003
CCCLeiden
  before 2000 1.35 0.75-2.43 0.31
  after 2000 0.31 0.09-1.08 0.07
Hospital variation 
(on logit scale) 0.27 0.14 0.13
OR = Odds ratio. 95% CI = 95 percent confidence interval. CCCL = region of Comprehensive Cancer Center 
West. Bold values indicate that p-values are statistically signìficant.
0.27). The hospital volume accounted for 50% of this variation; after adjusting for hospital 
volume, hospital variation reduced to 0.14 (Table 3). There was no difference in mortality 
risk between median volume and low volume hospitals (odds ratio median volume versus 
low volume was 1.01, 95%CI (0.66;1.55). The high volume hospitals performed significantly 
better (OR compared to low volume 0.49, 95%CI (0.30;.079). 
Esophagectomies in the CCCL region
Of the 4939 esophageal resections, 312 (6.3%) were performed in the hospitals of the CCCL 
region. In this region, a centralization process for esophageal cancer surgery was started in 
the year 2000. The in-hospital mortality rates decreased from 11.6% before 2000 to 3.1% in 
the period afterwards (Figure 3). In a logistic model, adjusting for age, gender and between 
hospital variation, with a separate effect for the period before and after 2000 the odds of 
dying in the CCCL decreased 4.68 times (95% CI (1.26;17.3), p=0.02). In the other regions 
of the Netherlands, the in-hospital mortality rate was stable: 8.3% in the period 1991-1999 
and 7.5% in 2000-2004, with a decrease in OR of 1.09 (95% CI (0.84; 1.41), p=0.50). This 
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considerable decrease in the odds of dying in the CCCL region is not caused by an increase 
in hospital volumes; after adjustments for volume, the improvements in the CCCL region are 
still statistically significant: OR 4.76 (1.30;17.48).
DISCUSSION 
In the last decade, esophagectomies for cancer have been the subject of many volume-
outcome studies, addressing differences in mortality between high- and low volume providers. 
In the Netherlands, only recently esophagus resections were banned from hospitals with a 
mean annual volume below ten resections a year. In the literature there is little evidence 
for this specific volume-cut-off. In addition, our study based on the best available data on 
esophagectomies in our country, shows that hospitals with an annual volume between 10 
and 20 resections a year, on average do not perform better than lower volume hospitals 
(less than 10 resections a year). Therefore, expectations about quality improvements as 
a result of this volume standard of 10 resections a year, have to be moderate. Procedural 
volume is not the only factor determining the variation in outcome between institutions. 
A strategy that directs patients to hospitals showing superior outcomes (outcome-based 
referral) could be more effective in improving quality of care than the current strategy of 
volume-based referral. 
Volume standards for Esophageal Cancer Surgery
In 2004 a review by Metzger et al. showed 13 papers on the volume-outcome relationship 
for esophagectomies, showing a clear reduction in postoperative mortality with increasing 
case volumes30. The majority of these series originate from the United States, with several 



















Figure 4. In-hospital mortality rates following esophageal resections in the CCCL region and in the other 
regions of the Netherlands by calendar period.
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the authors concluded: “only with the experience of more than 20 procedures a year a 
significant reduction of mortality can be achieved”.
In the present, more recent review of the literature we found 24 original articles concerning 
the inverse volume-mortality relationship for esophageal resections for cancer, on an 
institutional level. Some series describe procedures in more than 2000 hospitals (Table 1). 
Between studies, the choice of volume categories differs widely, with the lowest volume 
categories varying from less than 1 to less than 30 resections a year. In our study, we 
didn’t perform a meta-analysis, because of heterogeneity in methodology and the choice of 
volume categories, with possible publication- and selection biases that can not be controlled 
for. Instead, a graphical representation of mortality rates found for the different volume 
categories in the literature is given in Figure 1. This figure also suggests that a volume cut-off 
for esophagectomies should at least be 20 resections a year. However, mortality rates found 
in several of these high volume categories exceed 10 percent, which in our opinion is still 
unacceptably high for non-emergency surgical procedures.
Our population-based study on patients that underwent an esophagus resection in the 
Netherlands in the period 1991-2004, shows an overall improvement in mortality rates over 
time. The introduction of relatively new anesthesiologic techniques, like the increasingly 
widespread use of thoracic epidurals, and better staffed ICU departments can be the cause of 
decreasing mortality rates. Some authors suggest that differences in quality of care between 
high and low volume hospitals could be based on the earlier adoption of new diagnostic 
tools and surgical or anesthesiologic techniques in high volume hospitals31. Nevertheless, 
differences in hospital mortality between high- and low volume providers proved to be 
persistent in the three consecutive time periods investigated in our study (Figure 2). 
Since 2000, the evidence for these differences in mortality rates is available to the Dutch 
surgical community3. Despite, the remarkable variation in outcome, no changes in referral 
patterns were made in the most recent time-period. Only 38 percent of esophagectomies 
were performed in high volume hospitals, between 2000 and 2004 (Table 2). This information 
supports the decision of the Netherlands Health Care Inspectorate to ban esophageal 
resections from hospitals with low procedural volumes: the safety of patients surgically 
treated for esophageal cancer is at stake and quality improvements are certainly needed. 
However, the present study does not support the cut-off value of ten resections a year that 
was chosen to concentrate esophagectomies in hospitals with historically higher procedural 
volumes. Our data show that only 3 centers have procedural volumes of more than 20 
resections a year, with an in-hospital mortality of approximately 5%. On the other hand, the 
group of hospitals performing 10 to 20 resections a year, has significantly worse results than 
the outcome shown by these three high volume centers. On average they do not perform 
better than the low-volume group, but are selected as future referral centers for esophageal 
cancer surgery, under the current provision. Besides, there are several low volume hospitals, 
performing 5 to10 resections a year which do perform better, with similar results to those 
of the high volume centers (Figure 3). To our opinion, the effectivity of the current volume 
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standard (10 resections a year) as an instrument to improve quality of care for esophageal 
resections in the Netherlands is questionable, considering the presented data. 
In addition, we found that volume accounted for only 50 percent of the variation in 
mortality between hospitals performing esophagectomies (Table 3). Probably, differences in 
infrastructure, patient selection, (surgical) expertise and dedication of multidisciplinary teams 
taking care of esophageal cancer patients are at least as important. Volume standards do 
not take these differences into account, bearing the risk of selecting the ‘wrong’ hospitals to 
become future referral centers for esophageal cancer surgery.
For example, recently the Netherlands Cancer Institute, a tertiary referral center for 
esophageal cancer patients with advanced stages of the disease, evaluated the outcome of 
patients treated in their hospital in the last thirteen years (1995-2007). The annual number 
of esophageal cancer patients referred to and treated in this hospital is high, more than 70 
patients a year. However, the number of patients with an indication for surgical resection is 
below the volume standard of ten resections a year. Although most of these patients were 
downstaged with neoadjuvant therapies before surgery (65%), outcome in this patient group 
was remarkably good, with an in-hospital mortality of 1% and a five-year survival of 42% 
[unpublished data. Volume standards for operative procedures do not take in to account the 
experience with advanced tumor stages and multimodality treatments accumulated in the 
multidisciplinary setting of specialized cancer centres32.  
Moreover, few studies have been published that show an actual improvement in outcome 
after the introduction of minimal volume standards29. The leapfrog group, a large coalition 
of private and public purchasers of health insurance in the United States, is referring their 
patients to high volume providers of high-risk surgical procedures (esophagectomies, 
pancreatectomies etc.) since 200033. Although expectations were high, no beneficial 
effects of this ‘volume-based referral’ initiative have been published yet34.   
Outcome-based Referral
In the region of the CCCL concentration of esophageal cancer surgery has started in 2000, 
with a scenario in which region-wide outcome registration was linked to a commitment 
to refer patients to hospitals with superior outcomes (outcome-based referral). In a recent 
article from our group we describe the results of this regional centralization project, in which 
detailed clinical data of the patients operated in the region were reported regularly to the 
participating surgeons. In a five years time period esophagus resections were concentrated in 
three of the original eleven hospitals. The data analyzed in the present study were retrieved 
from an independent data-source and validate the conclusions about quality improvements 
in the CCCL region. The dramatic fall in mortality after the intervention in this region differs 
significantly from the national trend (Figure 4). Moreover, this considerable decrease in the 
odds of dying in the CCCL region is not only caused by an increase in hospital volumes. After 
adjustments for differences in hospital volume between time-periods, the mortality rate in 
the CCCL region was still statistically significant (Table 3).
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In the literature we find several examples of multi-institutional outcome registration 
programs, in which case-mix adjusted data are fed back to those personally involved in the 
clinical process of diagnosis, treatment planning, surgical intervention and peri-operative 
care35 36. In Europe, the Nordic countries like Norway and Sweden started a ‘national 
audit’ for the surgical treatment of rectal cancer more than 10 years ago. They focussed on 
the optimalization of the surgical technique for rectal cancer resections (Total Mesorectal 
Excisions).  A nation-wide rectal cancer registry was established and results of rectal cancer 
resections were fed back to individual institutions and surgeons. In both countries the rate of 
local recurrence and overall survival improved within a few years37. Simultaneously, referral 
patterns changed with more patients treated in specialized surgical units which continued to 
show excellent results. Recently, national audit programs for colorectal cancer surgery have 
been started in the United Kingdom, the Netherlands and Belgium, to improve 
quality of care on a national level.
Transforming Outcomes into Health Care Policy
The present study is based on the best available data on esophageal cancer resections in 
the Netherlands. Unfortunately, these data have several limitations. First, few data were 
available on patient and tumor characteristics like co morbid diseases and stages of the 
disease. Adjustments for differences in case-mix can lead to considerable changes in results. 
Detailed clinical data of patients who underwent esophagectomy in the region of the CCCL 
were analyzed in a recently published study by Wouters et al4. Only minor differences in co 
morbid diseases and stages of the disease were identified between patients operated on in 
low and high volume hospitals in our country.
Second, in this study only in-hospital mortality and length of stay could be evaluated. In 
our opinion, more dimensions of outcome should be assessed to evaluate and compare the 
quality of care in different institutions. Unfortunately, few data collection systems that deliver 
comprehensive and reliable (case-mix adjusted) outcome data are available, at this moment. 
Moreover, our analysis of differences in outcome between institutions is based on data 
from a 14 years time period. Presuming that concentration of esophageal cancer surgery 
in the Netherlands should ideally be based on differences in outcomes between providers 
(outcome-based referral), volumes of the hospitals performing esophageal resections should 
be sufficient to find statistical differences in quality of care in a more limited time-period 38. 
Apparantly, outcome-based referral as an instrument to improve quality of care for esophageal 
resections for cancer is only feasible in a combination with minimal volume standards. 
In conclusion, our study could not provide the evidence for a specific volume cut-off of ten 
resections a year as was established for esophageal cancer surgery by The Netherlands Health 
Care Inspectorate. Our data suggest that the use of ‘volume’ as a proxy for quality of care 
bears the risk of selecting hospitals with unfavorable outcomes as future referral centers for 
esophagectomies. Outcome-based referral could be a safer and more effective instrument 
for procedure-specific quality improvement, but the data needed to transform outcomes 
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in to policy are not available in most countries. In our opinion, (minimal) volume-standards 
should at least be accompanied by some sort of outcome registration (clinical audit), not 
only assessing hospital mortality, but a more extensive set of outcome parameters. 
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“……..adequate hospital caseloads are important for achieving safe pancreatic resection, 
but not necessarily sufficient. To ensure acceptable operative mortality rates, high-volume 
surgeons and hospitals should actively monitor their outcomes and benchmark their 
performance against their peers. They should also look for opportunities to learn from each 
other and improve.”
Sonnenday C.J. and Birkmeyer J.D., Annals of Surgical Oncology 2010
Outcome-based referral to improve quality of care in upper gi surgery
In most western countries quality of care is high on the political agenda. In different 
health care systems various methods are used to improve patient safety and outcome in 
surgical oncology. The potential benefits of concentrating high-risk surgical procedures in 
high volume hospitals or with high volume surgeons are often mentioned in this context. 
Nevertheless, studies that show an actual improvement in outcome after centralization of 
complex surgical procedures are still rare. In the United States the Leapfrog group, a large 
coalition of private and public purchasers of health insurance, is referring their patients to 
high volume providers of high-risk surgical procedures (esophagectomies, pancreatectomies 
etc.) since 2000. Although expectations were high, no beneficial effects of this ‘evidence 
based referral’ initiative have been published yet. Also in the Netherlands, van Heek et al. 
showed no reduction in mortality or change in referral patterns, despite a 10-year lasting 
plea for centralization of pancreatic resections 1. 
A plethora of articles has been published about the inverse relationship between hospital 
volume and mortality in high-risk surgical procedures. Chowdhury et al. reviewed 163 
studies that looked at the volume-outcome relationship for complex surgical procedures. 
Seventy-three percent of these studies showed significant better outcomes in high volume 
hospitals and for high-volume surgeons2. However, most studies are registry-based and 
omit important case-mix adjustments from clinical data3. Moreover, hospital mortality is 
often presented as the sole outcome measure, without presenting other dimensions of 
quality of care. 
Nevertheless, the differences in operative mortality between high- and lowvolume providers 
are remarkably high for upper GI procedures, like pancreatectomies and esophagectomies. 
Reviewing the volume-outcome literature for these procedures we find more recent studies 
that not only provide evidence for reduced operative mortality, but also for a survival-
benefit in patients operated on in specialized or high-volume centers. 
Despite the overwhelming number of publications, in many countries the level of evidence 
of these studies and the appropriateness of minimum volume thresholds is under debate. 
Not only the lack of unambiguous cut-off values between high- and low volume hampers 
the introduction of volume-standards. Many doubt if ‘volume’ is an appropriate proxy for 
quality of care. In one of his many publications on the subject John D. Birkmeyer considers 
the relative merits of different approaches to measuring and ultimately improving the quality 
of surgical care, adopting the Donabedian paradigm of structure, process and outcome. He 
concludes that focusing on proxy variables like ‘volume’ does not move the medical field 
forward in improving the quality of care4. A better understanding of the complex clinical 
processes that lead to success or failure has much more potential to improve outcomes of 
medical treatments. 
Identifying highleverage processes of care is the central issue in outcomes research that 
includes not only volume, but carefully analyzes individual patients, their comorbidities, 
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tumor and treatment characteristics. The way the surgeon and his/her team select their 
patients, make use of neo-adjuvant treatments, provide pre-, peri- and postoperative care 
and manage complications, determines the quality of the clinical process and its outcome. 
The ultimate challenge for outcomes researchers is to transfer the ‘excellence’ achieved in 
‘best practices’ to all hospitals performing these procedures5. 
To date, more large-scale data collections are needed to perform solid outcomes research6. 
There are several reports from countries in which a nation-wide registry of cancer treatment 
lead to a significant improvement in outcome. In Norway, for example, surgeons are obliged 
to include all surgical cases of rectal cancer in the Rectal Cancer Registry. Each department 
regularly receives its own results together with the national average for comparison and 
quality control. In 2006, Wibe et al. described a nation-wide improvement in the risk of local 
recurrence and overall survival for rectal cancer treatment as a result of this registry and 
monitoring treatment standards throughout the country7. 
In 2001 the American College of Surgeons (ACS) adopted the National Surgical Quality 
Improvement Program (NSQIP) that was founded twenty years before in the Veterans Affairs 
hospitals in the United States. The ACS NSQIP facilitates surgeons and medical centers 
to reliably collect and analyze risk-adjusted outcome-data, and act on them by making 
improvements in quality of care. Recently, an impressive number of multi-institutional 
outcome studies from the NSQIP was published in one issue of the Journal of the American 
College of Surgeons. One of these articles showed that the clinically rich NSQIP database 
is an effective instrument for local quality improvement programs to significantly reduce 
postoperative adverse event rates 8.
Outcome-based referral
The question which method is most effective in reducing morbidity and mortality rates 
of high-risk surgical procedures, like esophagectomies and pancreatectomies, is still under 
debate. On one hand concentration of services seems to improve outcome significantly, 
but on the other hand the introduction of volume-standards doesn’t empower surgeons 
to improve quality of care. In the Netherlands a regional intervention to concentrate 
esophagectomies for cancer was accompanied by a routine data collection system, to 
monitor performances of the different hospitals in the region. Risk-adjusted outcome data 
were fed back to the participating surgeons and hospitals. Important differences in quality 
of care were revealed and lead to actual changes in practice, but also in referral patterns 
in this ‘peer review environment’. Directing patients to hospitals with superior outcomes 
(outcome-based referral) showed to have a dramatic improvement in overall morbidity, 
mortality and survival for esophagectomy patients. This composite model, in which good 
performers (best practices) are empowered with higher case-loads, could be an effective 
instrument to improve quality of care in high-risk surgical procedures, like esophagectomies 
and pancreatectomies and deserves further exploration.   
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Quality-of-care indicators are measurable elements of practice performance that can 
assess the (change in) quality of the care provided. To date, the literature on quality-of-care 
indicators for esophageal cancer surgery has not been reviewed.
Methods:
We performed a review of the literature on quality-of-care indicators for esophageal cancer 
surgery. The indicators were classified by their nature of care provision (structural, process, 
or outcome). 
Results:
One hundred thirty articles were included. For structural measures, most evidence was 
found for the inverse relationship between hospital or surgeon volume and postoperative 
mortality. Few articles described the required infrastructural and organisational elements for 
esophageal cancer surgery. Regarding process measures, the most common indicators were 
determinants of patient selection for surgery. Other process indicators with considerable 
evidence were found (e.g., multidisciplinary team management), though the number of 
studies was small. For outcome indicators, the level of evidence for pathological outcome 
measures was strong. Data on postoperative complications as outcome indicators varied 
widely.
Conclusion:
Since there is considerable variation in the evaluation of quality of care, the uniform use of 
well-defined quality-of-care indicators to measure and document practice performance holds 
the promise of improving outcome in patients who undergo esophageal cancer surgery.
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INTRODUCTION
Quality assurance in the treatment of cancer is gaining importance since many studies 
have shown variation in outcome between different providers. In Europe, quality assurance 
programmes have been introduced in the field of radiotherapy as well as for medical 
oncology, however, surgical quality control has received less attention1;2. Only recently, the 
European Society for Surgical Oncology (ESSO) has started an international audit program 
for rectal cancer treatment3;4. Few attempts have been made to spread the merits of 
quality assurance programmes to other tumor types. 
Evidence-based guidelines that have been developed for a large variety of cancer treatments 
worldwide are seldom accompanied by well-defined standards for the evaluation of the 
quality of surgical care. Donabedian has conceptualized the evaluation of patient care in 
terms of structure, process, and outcome measures5. 
Esophageal cancer ranks sixth on the list of cancer mortality worldwide6. In 2008, 
the incidence in the Netherlands was around 1850 new patients per year7. It has been 
recommended to concentrate the surgical treatment of esophageal cancer in high-volume 
centers. The effectiveness of such measures in raising the whole level of care has been 
questioned8. Preferably, the concentration of esophageal cancer treatment is accompanied 
by a national quality assurance program, evaluating the different dimensions of quality of 
care in all hospitals taking care of these patients9. A practical definition of quality of care 
would be the degree to which health services achieve a level of care deemed adequate by 
evidence-based quality measures10.
We have performed a review of the literature to identify evidence-based standards for 
high-level quality of care for esophageal cancer patients who are candidates for surgical 
therapy. We used the Donabedian quality-of-care model to categorize the identified 
standards. Furthermore, we aimed to construct a minimum dataset of evidence-based 
quality-of-care indicators for future registration and benchmarking.
METHODS
Search strategy
A search of the literature on PubMed was performed to find articles published between 
January 1990 and October 2009 on quality of care in the surgical treatment of esophageal 
cancer. Three Medical Subject Heading (MeSH) terms were used: ‘esophageal neoplasms’, 
‘surgery’ and ‘esophagectomy’. Studies describing aspects of quality of care were searched 
by combining these three MeSH terms with the following keywords: ‘benchmarking’, ‘health 
care’, ‘hospital mortality’, ‘hospitals’, ‘medical audit’, ‘outcome and process assessment 
(health care)’, ‘postoperative complications’, ‘quality assurance’, ‘quality indicators’, ‘referral 
and consultation’. Articles were selected on the basis of their relevance using pre-defined 
in- and exclusion criteria (Figure 1). Many studies were excluded because they were 
non-comparative studies. Only original articles were considered for inclusion. Selection was 
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performed independently by two investigators (ECS and MW). A third reviewer (JvS) was 
consulted in case of disagreement. One hundred thirty articles were included. 
Classification of studies
Articles were categorized according to the primary subject of the study: structural, process 
or outcome measures. Structural components of care are characteristics of the provider, 
reflecting the setting in which care is delivered. These may be related to the physical or 
organizational characteristics of a hospital, but also include staff expertise and experience. 
Process components of care refer to the interactions between the provider (i.e., physician) 
and the patient. An example is the delivery of adequate staging investigations to detect 
distant metastases in patients who are considered to be candidates for esophagectomy. 
Outcome characteristics are measurable short-term outcomes affecting the final outcome of 
patients (e.g., radicality of resection).
Level of evidence
Of 130 included articles 13 studies were randomised controlled trials, 26 were prospective 
(cohort) studies and 91 were retrospective studies. Because of the comparable level of 
evidence for most of these included studies, we classified results of evidence according 
to a scoring system used in a previous article by Lagarde et al: none (no evidence), minor 
(only evidence from univariate analysis), considerable (evidence from uni- and multivariate 
analysis), strong (evidence from several multivariate analyses or evidence from univariate 
analysis in at least ten articles)11. 
Figure 1. Flow chart of included articles on quality of care in the surgical treatment of esophageal cancer.
* For MeSH terms and keywords: see Methods
Excluded after reading of the article because of:
• Language (non-english publication)
• Study design (non-comparitive study)
• Patient population (non-esophageal cancer patients)
• Study subject (no quality of care indicator)
                             213 articles
Extra articles from ‘Related articles’ feature in 
Pubmed and reference lists:






Included articles in review:
130 articles
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Only characteristics with strong evidence or those with considerable evidence based on at 
least three articles were entered into a minimum dataset of ‘evidence-based’ quality-of-care 
indicators for esophageal cancer surgery.
RESULTS
Structural measures
Structural variables with corresponding articles are listed in Table 1.
Volume
A wide variation in the definitions of hospital volume was found in the various studies on 
hospital volume and mortality rates (e.g., the definition of high-volume ranged from 6 to 40 
resections per year). Besides the clear association between high hospital volume and low 
mortality rates, also lower complication rates and shorter admission times have been found 
in high-volume hospitals as compared to low-volume hospitals. Consequently, treatment in 
high-volume hospitals has been associated with a decrease in hospital charges. Other clinical 
endpoints, such as long-term survival and quality of life, have been studied less often. Two 
out of three studies could not demonstrate a survival benefit in high-volume hospitals and 
one other study did not find an improved quality of life.
As in studies on the influence of hospital volume, higher annual case volume per surgeon 
has been associated with lower postoperative mortality rates.
Specialization
Volume is related to, but does not equal specialization. Three studies have reported on the 
influence of subspecialty training of the surgeon on outcome (Table 1). In two studies, a 
lower postoperative mortality rate has been found in patients operated on by cardiothoracic 
surgeons as compared to that in patients operated on by a general surgeon. The third study 
reported no significant differences in outcome between general and thoracic surgeons 
with regard to postoperative mortality, morbidity, ICU stay and hospital stay. To date, no 
comparisons between dedicated upper gastrointestinal and general surgical oncologists 
have been made.
Organization
Few studies specifically addressed the impact of organization of care on the outcome of 
surgically treated esophageal cancer patients. In one study, daily rounds by an ICU physician 
were associated with shorter lengths of stay, lower hospital cost, and less postoperative 
complications after esophageal resection, but not with a lower in-hospital mortality rate. 
In an other large study, a comparison between 225 patients with a night-time nurse-to-
patient ratio of 1:1 or 1:2 and 128 patients with a night-time nurse-to-patient ratio of 1:3 or 
more (one nurse caring for three or more patients) was made. Patients in the second group 
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Table 1. Structural measures for quality of care in esophageal cancer surgery
Structural 
measure









High-volume hospital 22 out of 25 strong 1-25
Postoperative 
morbidity
High-volume hospital 5 out of 8 considerable 1;2;7;8;13;17;26;27
Postoperative 
ICU-stay
High-volume hospital  1 out of 1 minor 10
Postoperative 
hospital stay
High-volume hospital  6 out of 8 considerable 1;2;7;10;12;17;24;26
Survival High-volume hospital 1 out of 3 minor 18;28;29
Quality of life -- 0 out of 1 none 30





High-volume surgeon 9 out of 10 strong 6;15;18;31-37
Postoperative 
morbidity
High-volume surgeon  1 out of 1 considerable 26
Postoperative 
hospital stay
High-volume surgeon  1 out of 1 considerable 26
Anastomotic 
leakage
High-volume surgeon  1 out of 2 considerable 32;34
Survival High-volume surgeon 2 out of 4 considerable 15;18;35;36






Thoracic surgeon 2 out of 3 considerable 9;38;39
Postoperative 
morbidity
-- 0 out of 1 none 38
Postoperative 
ICU-stay
-- 0 out of 1 none 38
Postoperative 
hospital stay
-- 0 out of 1 none 38
ICU  physician 
staffing 




-- 0 out of 1 none 40
Postoperative 
morbidity
Daily ICU rounds 1 out of 1 considerable 40
Postoperative 
hospital stay
Daily ICU rounds 1 out of 1 considerable 40
Costs Daily ICU rounds 1 out of 1 considerable 40
ICU  nurse-to-
patient ratio




-- 0 out of 1 none 41
Postoperative 
morbidity
1 or 2 patients /nurse 1 out of 1 minor 41
Postoperative 
hospital stay
1 or 2 patients /nurse 1 out of 1 minor 41






Referral centre 3 out of 3 considerable 1;42;43
Postoperative 
morbidity
Referral centre 1 out of 2 minor 42;43
Survival -- 0 out of 1 none 42
Abbreviations: ICU: Intensive Care Unit  None: no evidence; minor: only evidence from univariate analysis; 
considerable: evidence from uni- and multivariate analysis; strong: evidence from several multivariate analyses 
or evidence from univariate analysis in 10 or more articles.
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had an increased risk of postoperative complications after esophageal resection which was 
associated with an increased use of resources. 
Centralization
Following the relationship between volume/specialization and outcome, one may expect 
that centralization of esophagectomies at high-volume providers improves outcome. Few 
studies have actually demonstrated this. Recently, we have shown a dramatic improvement 
in mortality and survival after centralization of esophageal cancer surgery in a region of the 
Netherlands9. This centralization process was accompanied by feedback of detailed clinical 
data to individual hospitals and surgeons (surgical audit).
Process measures
Process variables with corresponding articles are listed in Table 2.
Table 2. Process measures: patient selection, staging and treatment choices for quality of care in esophageal 
cancer surgery










No age limit 11 out of 11 strong 44-54
Postoperative 
morbidity
< 70 years 4 out of 11 minor 44-54
Survival No age limit 11 out of 11 strong 44-54




< 80 years 1 out of 4 minor 44;53;55;56
Postoperative 
morbidity
< 80 years 2 out of 4 considerable 44;53;55;56
Survival < 80 years 1 out of 4 minor 44;53;55;56
Use of risk score 
(yes versus no) Postoperative 
mortality






Normal weight 1 out of 2 minor 58;59
Postoperative 
morbidity





-- 0 out of 2 none 58;59
Postoperative 
morbidity




White race 3 out of 3 considerable 62-64
Income Surgical 
resection




In several studies, the influence of old age was investigated. In a minority of studies, older 
age was associated with an unfavorable postoperative outcome.
The use of a risk score may be a quality indicator. Bartels et al evaluated a risk scoring model 
in a prospective setting and found a marked reduction in post-operative deaths due to 
better patient selection16. 
The relationship between the preoperative nutritional status and the outcome of surgery 
in patients with esophageal carcinoma has shown conflicting results. In one study, 
Table 2. Process measures: patient selection, staging and treatment choices for quality of care in esophageal 
cancer surgery. (Cont).













1  out of 1 minor 66
Postoperative 
morbidity
-- 0 out of 1 none 66
Survival Good  preoperative 
QoL score
4 out of 5 considerable 66-70
Staging




1 out of 1 considerable 71




8 out of 8 strong 72-79










No effect 12 out of 13 strong 81-93
Postoperative 
morbidity
No effect 9 out of 10 strong 81-90
Overall Survival Neoadjuvant 
chemoradiation





2 out of 6 minor 88;93-97
MDT management
(yes versus no)






Transhiatal 1 out of 4 minor 99-102
Postoperative 
morbidity
Transhiatal 3 out of 4 considerable 99-102





Thoracic epidural 1 out of 2 minor 104;105
Postoperative 
morbidity
Thoracic epidural 2 out of 2 considerable 104;105
Hospital stay Thoracic epidural 1 out of 1 minor 106
Pathology reporting Accurateness of 
reporting
Proforma reporting 2 out of 2 minor 107;108
Abbreviations: QoL: quality of life; CT: computed tomography; FDG-PET: fluorodeoxyglucose positron emission 
tomography; EUS: endoscopic ultrasonography; MDT: multidisciplinary team. None: no evidence; minor: only 
evidence from univariate analysis; considerable: evidence from uni- and multivariate analysis; strong: evidence 
from several multivariate analyses or evidence from univariate analysis in 10 or more articles.
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underweight patients who underwent major intra-abdominal surgery, e.g., esophagectomy, 
had a five-fold increased risk of postoperative mortality. Though, other studies including 
exclusively esophageal cancer patients have not confirmed this. In four studies, complication 
rates for obese patients equalled those for non-obese patients.
The role of race and socio-economic status on patient selection has received some attention. 
In the United States, African-American patients with esophageal cancer were less likely 
to undergo surgical resection compared to Caucasian patients. In the Netherlands, low 
socio-economic status proved to be associated with a lower chance of resection. These 
disparities are not fully explainable by differences in medical factors. It has been suggested 
that patients’ but possibly also physicians’ preferences might differ among different 
socio-economic groups of patients. 
In one study, there was a relationship between better pretreatment quality of life and lower 
postoperative mortality. Especially reduced physical function as an aspect of pretreatment 
quality of life was predictive of lower survival in several studies.
Staging
For high-risk surgical procedures, it is important to select only those patients who can be 
cured. For computed tomography (CT) examination, the level of experience of the radiologist 
appeared to influence the detection of metastases in patients with esophageal cancer. 
Fluorodeoxyglucose positron emission tomography (FDG-PET) has shown its incremental 
value with the identification of 5 to 17% additional patients with metastases. Van Vliet 
et al studied the results of endoscopic ultrasonography (EUS) performed in low-volume 
EUS-centers and found unfavorable results in comparison with those in high-volume 
EUS-centers12. 
Treatment choices
-  Multimodality treatment
 Several studies have compared the use of neoadjuvant chemoradiation with surgery alone 
for patients with esophageal cancer. Although a negative effect of neoadjuvant treatment 
on postoperative morbidity and mortality was found in two separate studies, most studies 
could not demonstrate these differences. Regarding overall survival, there was a benefit of 
neoadjuvant chemoradiation in two out of 11 studies.
-  Multidisciplinary team
 It is generally believed that a multidisciplinary approach in cancer treatment results in 
the best achievable outcomes. The added value is hardly measurable. Nevertheless, in 
a study by Stephens et al, the selection, staging and treatment of patients eligible for 
esophagectomy by a multidisciplinary team resulted in a better survival as compared to the 
survival of patients treated by surgeons alone.
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-  Surgical approach
 Four randomized trials have compared the outcome of a limited transhiatal approach 
versus an extended transthoracic approach. Differences in postoperative morbidity were 
in favor of a limited transhiatal approach. Differences in post-operative morbidity were 
in favor of a limited transhiatal approach, and one trial showed a trend towards better 
survival in patients operated via an extended transthoracic approach. Complete 5-year 
survival data suggested that patients with a tumor in the distal esophagus had benefitted 
from an extended transthoracic resection. 
-  Peri-operative care
 Watson et al showed that respiratory complications decreased from 30 to 13% and death 
due to these complications from 5 to 0%, after introducing the routine use of thoracic 
epidural analgesia (TEA)13. In an other series, TEA lowered the anastomotic leakage 
rate14. The authors suggested a causal relationship between hypoxemia and hypotension 
due to respiratory hypofunction in patients undergoing esophagectomy without the use of 
TEA. It has also been shown that the use of TEA enables early discharge of patients after 
esophagectomy. 
-  Pathology reporting
 Histopathological assessment of the resection specimen plays an important role in patient 
management, in confirming whether complete excision has been achieved and in providing 
essential information on pathological tumor-node-metastasis (TNM) staging. The need to 
improve the quality of pathology reporting in esophageal cancer management has been 
recognised.
Outcome measures
Outcome variables with corresponding articles are listed in Table 3.
ICU stay
Length of ICU stay did not influence patients’ survival and long-term quality of life. 
Postoperative complications
The occurrence of postoperative complications after esophageal cancer surgery has not only 
been associated with higher postoperative mortality rates and increase use of resources, but 
also with worse long-term survival.
Radicality of resection
Multiple studies have shown the independent prognostic value of a microscopically radical 
(R0) resection. 
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Number of resected lymph nodes
The number of identified lymph nodes is an independent predictor of survival after 
esophagectomy for cancer. According to Peyre et al, a minimum of 23 lymph nodes should 
be resected15.
‘Evidence-based’ quality indicators for esophageal cancer surgery
A minimum dataset of ‘evidence-based’ quality-of-care indicators for the surgical treatment 
of esophageal cancer was created based on the identified standards with strong evidence 
or those with considerable evidence in at least three articles. This dataset is presented in 
Table 4.
Table 3. Outcome measures for quality of care in esophageal cancer surgery






(≤ 5 days versus ≥6 days)
Survival -- 0 out of 1 none 109






No complication 2 out of 2 considerable 27;110
Postoperative 
ICU stay
No complication 1 out of 1 minor 110
Postoperative 
hospital stay
No complication 1 out of 1 minor 110
Costs No complication 1 out of 1 considerable 110
Survival No complication 2 out of 2 considerable 111;112




No complication 3 out of 4 minor 113-116
Medical 
complications
No complication 3 out of 3 minor 113;114;116
Postoperative 
hospital stay
No complication 2 out of 2 minor 113;116
Survival No complication 1 out of 2 considerable 113;114




No pneumonia 3 out of 3 considerable 117-119
Survival No pneumonia 1 out of 1 considerable 117
Radicality of resection
(R0 versus R1 and R2)
Survival R0 resection 7 out of 8 strong 120-127
Number of resected 
lymph nodes
(high versus low)
Survival Higher nodal count
(ranging from >23 to >40)
3 out of 3 strong 128-130
Abbreviations: ICU: Intensive Care Unit; R0: microscopically radical resection, R1: microscopically irradical 
resection; R2: macroscopically irradical resection. None: no evidence; minor: only evidence from univariate 
analysis; considerable: evidence from uni- and multivariate analysis; strong: evidence from several multivariate 




This has been the first review of the literature to identify evidence-based standards for 
high-level quality of care for esophageal cancer patients who are candidates for surgery. 
Results show that (1) there is strong evidence that both hospital and surgeon volume are 
important determinants for postoperative mortality, (2) other structural measures, e.g., 
infrastructure and organization of esophageal cancer surgery, have been less frequently 
investigated, (3) the most commonly reported process measures were determinants 
of patient selection for surgery (e.g., patients’ age), (4) other process indicators with 
considerable evidence were found (e.g., multidisciplinary team management), though 
the number of studies was small, and (5) the level of evidence for pathological outcome 
measures was high.
Table 4.‘Evidence-based’ quality-of-care indicators for esophageal cancer surgery 




Postoperative mortality High-volume hospital Strong
Postoperative morbidity High-volume hospital Considerable
Postoperative hospital stay High-volume hospital Considerable
Costs High-volume hospital Considerable
Surgeon volume
(high- versus low-volume)
Postoperative mortality High-volume surgeon Strong
Centralization
(referral versus regional center)
Postoperative mortality Referral center Considerable
Process measures
Age Postoperative mortality No age limit Strong
(< 70 years versus > 70 years) Survival No age limit Strong
Preoperative quality of life Survival Good preoperative score Considerable
(good versus bad score)
Staging Detection of metastases Additional value of PET Strong
(FDG-PET versus no FDG-PET)
Neoadjuvant chemoradiation Postoperative mortality No effect Strong
(yes versus no) Postoperative morbidity No effect Strong




(yes versus no) Survival No complication Considerable
(pneumonia versus no pneumonia) Postoperative mortality No pneumonia Considerable
Radicality of resection Survival R0 resection Strong
(R0 versus R1 and R2)
Number of resected lymph nodes Survival Higher nodal count Strong
(high versus low) (ranging from >23 to >40)
Abbreviations: FDG-PET: fluorodeoxyglucose positron emission tomography ; R0: microscopically radical 
resection; R1: microscopically irradical resection; R2: macroscopically irradical resection. Considerable: evidence 
from uni- and multivariate analysis in 3 or more articles; strong: evidence from several multivariate analyses or 
evidence from univariate analysis in 10 or more articles.
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Structural measures
A plethora of studies concerning the volume-outcome relationship for esophageal 
cancer surgery was found. High-volume and specialized care were mostly related to 
a decreased postoperative mortality, and, in a lesser extent, to lower postoperative 
morbidity, shorter hospital stay, better survival and lower costs. Volume is only a surrogate 
for high-level processes of care and does not reveal the mechanisms behind the better 
outcomes. There is evidence that centralization of esophageal cancer resections leads to 
substantial improvements in outcome. Such efforts have been accompanied by continuous 
measurement and feedback of process and outcome indicators to individual surgeons and 
their referring colleagues. Only then, improvements in outcome are to be expected9. Data 
on infrastructural or organizational characteristics that lead to success or failure, were very 
limited (e.g., ICU staffing) or absent (e.g., ICU level).
Process measures
Evidence was found that teams using a risk score for the selection of surgical patients 
can decrease their postoperative mortality rates16. Several risk-prediction models have 
been proposed for this purpose, such as the Physiologic and Operative Severity Score 
for the enumeration of Mortality and morbidity (O-POSSUM)17. The O-POSSUM has only 
been studied retrospectively showing a two- or three-fold overprediction of in-hospital 
mortality18-20. Steyerberg et al. developed a more simple risk score, that also included the 
excess risk on postoperative mortality introduced by operations performed in low-volume 
hospitals21. Again, this risk score could not be validated by others22;23.
Age, nutritional or socio-economic status should not be used as selection criteria for 
esophageal cancer surgery. On the other hand, in assessing resection rates or surgical 
outcome as indicators for quality of care, these factors are to be included as case-mix 
variables. Preoperative feeding to prevent further deterioration of the nutritional state of 
patients presenting with obstructive symptoms and weight loss could be a valid quality 
indicator, but the level of evidence for a better outcome is low24. 
We found evidence –although limited- that volume and experience play a role in the staging 
process of patients with esophageal cancer25;12. It would be better to assess the whole 
staging process by calculating the percentage of patients in whom a futile operation has 
been performed due to inadequate staging. 
Neoadjuvant chemoradiation followed by surgery was associated with similar postoperative 
mortality rates as surgery alone in all studies, and survival rates improved in two studies26;27. 
If neoadjuvant chemoradiation becomes standard of care, there is a need to formulate 
quality indicators for its use (e.g., toxicity criteria).
Diagnosis and treatment of esophageal cancer patients by a dedicated multidisciplinary 
team could be an important quality indicator, but this is supported by only one paper28. 
Not only the expertise of the surgeon, but also that of the radiologist, anaesthesiologist, 
ICU-physician and nurses contribute to the outcome of surgery.
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There is considerable evidence that the transhiatal approach leads to a reduced postoperative 
morbidity rate29-32. Presumed that the transthoracic approach with an extended 
lymphadenectomy is technically more challenging, one could propose that the performance 
of transthoracic esophagectomies in patients with a tumor located in the distal esophagus 
should be regarded as a quality indicator. No studies were found on other process indicators 
such as waiting times or psychological guidance during treatment.
Outcome measures
Outcome measures, like postoperative complication rates, tumor negative surgical margins, 
and number of retrieved lymph nodes are plausible measures of quality of care for physicians 
and their patients. Further investigation is warranted to look for additional valid outcome 
parameters of quality of care (e.g., hospital readmission rates, pain scores, number of 
anastomotic dilatations).
Limitations
A major limitation to this review is that there is no MESH term for “quality of care”. We 
have tried to give an overview of the available literature on evidence-based determinants 
for high-leverage quality of care, but our review may have been biased by the choice of 
our search terms. Secondly, case-mix plays an important role in evaluating differences in 
outcome after esophageal cancer surgery. Consequently, for many studies, with a lack 
of information on patients’ co-morbidity, tumor stage distribution, and patient selection 
criteria, the conclusions are debatable.
Future directions
The uniform use of well-defined quality-of-care indicators to measure and document practice 
performance holds the promise of improving outcomes in patients who undergo surgical 
treatment for esophageal cancer. Recently, another evidence-based review of esophageal 
cancer surgery was published33. In this review, non-surgical issues were not addressed. The 
present review places esophageal cancer surgery in a broader perspective. Improving the 
level of care for surgical esophageal cancer patients is a team effort from diagnosis, staging 
and risk assessment to follow-up and management of late sequelae of treatment. Ideally, 
each step is monitored by a set of measurable elements which reflect the quality of care.
Several projects have been started in which quality indicators are to be developed, not 
only based on evidence from the literature, but also on consensus of experts in the field. 
In Denmark, the Danish National Indicator Project has shown that continuous performance 
and outcome measurement, 
using clinical indicators is possible and fruitful in terms of quality improvement34. Recently, 
Bilimoria et al presented an extensive set of quality indicators for pancreatic cancer35. After 
reviewing the literature for potential quality indicators, a Delphi method was used to develop 
quality indicators consulting several expert panels. In our opinion, a similar procedure should 
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be pursued for esophageal cancer care. To benchmark the outcome of consensus-based 
quality indicators, multi-centred data-collection, data-analysis and feedback of individual 
data is essential to provide physicians with actionable information about their quality of 
care.
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There is on-going interest in measuring quality in clinical practice. Though quality of care is 
a multi-dimensional concept, it is often assessed using singular outcomes. The purpose of 
this study is to provide a multi-dimensional assessment of quality, using esophageal cancer 
surgery as an example.
Methods:
Two methods for multi-dimensional quality assessment were tested. A relevance-
weighted quality score (RWQS) and a cumulative quality profile, in which relevant quality 
parameters are ordered by their relevance for long-term outcome. Subsequent higher 
levels in the profile represent progressively more strict quality-standards; the proportion 
of patients meeting all standards is called the Exemplary Care and Outcome (ECO) 
measure. The two methods were used both unadjusted and adjusted for case-mix. 
Both methods were tested on outcome data from 12 hospitals that performed 1439 
esophagectomies between 1991 and 2004. 
Results:
No hospital scored best on more than one Observed/Expected quality score. O/E scores 
varied between hospitals from 0.65 to 1.05 for hospital survival, from 0.1 to 1.69 for 
profile-ECO, and from 0.88 to 1.03 for RWQS. Both multidimensional quality scores 
differed significantly between high and low volume hospitals, and between academic and 
non-academic hospitals, while O/E-scores for single-dimension of hospital survival did not 
differ significantly.
Conclusion:
Quality of care can be measured by more than one parameter only. We designed two 
methods of combining multiple quality parameters and a top-quality measure of ECO. Both 
methods seemed feasible, and results suggest that these methods may better discriminate 
between higher and lower quality of care.
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INTRODUCTION
Ever since the publication of the Harvard Medical Practice Study,1 and of the Institute of 
Medicine report “To Err is Human”,2 public attention has focused upon quality and safety 
in health care, or on the lack of it. The Institute of Medicine (IoM) has defined quality as a 
multi-dimensional concept, encompassing the dimensions effectiveness, safety, timeliness 
and patient centeredness. The Agency for Healthcare Research and Quality (AHRQ) 
described quality health care as “doing the right thing, at the right time, in the right way, 
for the right person, and having the best possible results”. In recent years, the IOM, AHRQ 
and other institutions such as the Institute of Health Care Improvement, the Leapfrog 
Group and the UK department of Health, have pioneered initiatives on quality assessment, 
improvement and transparency. However, although quality is conceptually clear, there 
is an on-going debate on how to measure quality in clinical practice. One approach has 
been to use simple and readily available outcomes, such as hospital mortality or duration 
of hospital admission, another approach to use procedural volume as a readily available 
quality-proxy3;4. However, neither of these simplifying approaches has adequate content 
validity, as it does no justice to the multi-dimensional concept of quality. High quality care is 
safe, effective, patient-centered and cost-effective, and its good outcomes are the result of 
high quality (infra)structure and process5. Thus, as quality is a multi-dimensional concept, it 
should be measured as such.
For esophageal cancer surgery, quality assessment has so far focused almost exclusively 
on in-hospital mortality. Although this mortality has declined in recent years,6 marked 
differences between institutions still exist, ranging from 2 to 10%.7;8 In a recently published 
study we were able to show that concentration of esophageal resections by outcome-based 
referral dramatically reduced hospital mortality9. However, high-quality esophageal cancer 
care encompasses more than in-hospital survival only. Anastomotic leakage (occurring in 
10-25% of the patients) and other adverse outcomes may severely affect esophageal cancer 
patients’ quality of life10. In addition, treatment effectiveness (radicality of cancer resection, 
long-term survival) is no less important than treatment safety.
There is a need for quality frameworks that encompasses and combines different 
dimensions or aspects of health care quality. If such frameworks are to be used to compare 
the quality of care between hospitals, they should take into account differences in patient, 
disease- and procedure-mix between hospitals. In the present study we designed and 
piloted multi-dimensional quality assessment that aims at providing a more valid insight 
into the quality of surgical oncological care than mortality alone. In general, such studies 
are hampered by the absence of a ‘golden standard’ for quality of care. In the absence 
of a clear reference standard, we used hospitals’ academic status as a proxy.  In addition, 
we investigated whether multidimensional quality assessment could have potential to 
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discriminate better between hospitals with different levels of care than mortality alone. 
Thus, in this study, we addressed the following three research questions: 
1. In cancer surgery, which parameters can be used to assess the quality of care provided to 
patients?
2. How can these parameters be combined into multidimensional assessment of quality, 
that could provide more insight than a singular quality measure (such as mortality) alone?
3. Is it plausible that multidimensional quality assessment, after correction for case-mix, 
better (or less good) discriminates between hospitals with higher and lower quality of 
care than a singular quality measure?
To test the framework’s feasibility, we used it to assess the (differences in) quality of care 
between hospitals that provided surgical treatment to patients with esophageal cancer 
between 1991 and 2004 in the Netherlands, and on which we reported one-dimensional 
outcome information in an earlier paper.11
METHODS
Patient data were derived from a database that was created to assess the quality of 
esophageal cancer surgery in 12 hospitals (2 academic hospitals, indicated by A1 and A2, 
and 10 general hospitals, G3 - G12) in the mid-western part of the Netherlands (1.7 million 
inhabitants). Through the ‘Cancer Registry’ of the Comprehensive Cancer Center Leiden 
we identified 1438 patients that were treated between 1990 and 2004.11;12 Patient and 
disease characteristics, and information on treatment and outcome were extracted and 
analyzed from patient records and hospital information systems. In our earlier study, we 
reported on a few separate outcomes only and thus could not provide a broader assessment 
on the quality of care that patients experienced. The quality framework we now propose 
aims at addressing these limitations.
Constructing and testing multidimensional quality assessment
Design and testing of multidimensional quality assessment was done in 3 phases; being 
a) the choice of relevant quality dimensions and parameters, b) design of two methods 
of combining different parameters into multidimensional assessment (a cumulative quality 
profile that provides insight, and a relevance-weighted quality score that supports choice), 
and c) testing these assessments on the dataset described above, both without and with 
case-mix adjustment.
In the first phase, we used the four main quality dimensions (safety, effectiveness, efficiency 
and patient-centeredness) to guide the selection of appropriate quality parameters (from 
those that were available in our retrospective database).13 To assess safety, 4 categories of 
adverse outcomes were selected from the Dutch surgical adverse outcome registry that is 
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carried by most Dutch hospitals.14 In decreasing order of severity these adverse outcomes 
were ‘in-hospital death’ (grade 4 adverse outcome), ‘major complications with permanent/
long term morbidity’ (grade 3 adverse outcome), ‘major complications requiring re-operation’ 
(grade 2 adverse outcome) and ‘minor complications leading to delayed discharge (> 14 
days) from hospital’ (grade 1 adverse events). To assess effectiveness, 2 treatment goals 
were chosen, one short-term and one longer term: ‘tumor free margins of cancer resection’ 
(R0-resection) and ‘1-year survival’. No information was available on the dimensions 
Table 1. Patient, tumor, treatment, outcome and hospital characteristics
Overall Academic General
Characteristics No. of patients % No. of patients % No. of patients % P value
Age
  median (yrs) 62.4 62.0 63.3 0.02
  range (yrs) 28-89 28-89 32-87
Gender
  Male 1099 76.4 775 77,9 324 72.9 0.04
  Female 340 23.6 220 22.1 120 27.1
Co-morbidity
  None 636 44.2 450 45,2 186 41.9 0.26
  1 organ system 467 32.5 317 31.9 150 33.7
  2 organ systems 202 14.0 141 14.2 61 13.7
  ≥ 3 organ systems 91 6.3 71 7.1 20 4.5
Stage (pTNM)
   I 228 15.8 155 15.6 73 16.4 0.001
   II 569 39.6 380 38.2 189 42.7
   III 463 32.2 313 31.4 150 33.6
   IV 179 12.4 147 14.8 32 7.3
Esophagectomy <0.001
  Transthoracic 304 21.1 178 17.9 126 28.4
  Transhiatal 1101 76.5 787 79.1 314 70.7
Adverse outcome
  None 509 35.4 400 40.2 109 24.5 <0.001
  Grade 1 587 40.8 407 40.9 180 40.5
  Grade 2 172 12.0 97 9.7 75 16.9
  Grade 3 62 4.3 38 3.8 24 5.4
  Grade 4 (mortality) 102 7.1 53 5.3 49 11.0
Length of stay
  mean (days) 22 20 28 <0.001
  range (days) 5-273 5-173 9-273
Radical resection 1054 73.2 729 73.3 325 73.2 0.98
1-year survival 1003 69.7 700 70.4 303 68.2 0.42
Hospital volume
  Low (<20/y) 566 39.3 122 12.3 444 100 <0.001
  High (>20/y) 873 60.7 873 87.7 0 0.0
Total no. of patients 1439 995 444
Academic = academic hospitals; general= general hospitals; yrs = years; adverse outcome: Grade 1 = minor 
complications without re-intervention or permanent damage leading to hospital stay > 14 days; Grade 2 
= complications needing re-intervention; Grade 3 = complications with permanent damage; Grade 4 = 
complications leading to in-hospital mortality
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efficiency and patient-centeredness. For each of these (4 + 2 =) 6 quality parameters, a 
favorable quality standard was defined, being the absence of adverse outcome for the first 
four, and achieving the treatment goal for the latter two.
In the second phase we combined the 6 quality parameters into two methods of 
multidimensional quality assessment. The first method is a cumulative quality profile (CQP) 
in which each subsequent profile-level indicates whether the quality standards of the 
present and all preceding levels are met (scored 1) or not (scored 0). Higher levels represent 
progressively more strict standards for health care quality, their order being determined by 
their relevance for long term outcome (using Cox regression for survival). The second method 
is a relevance-weighted quality score (RWQS), being the sum of products of relevance 
weights and parameter outcomes. Relevance weights represent the extent to which each 
of the 6 parameters is considered relevant for choosing a high quality hospital. For the 
present study, these weights were obtained by questionnaire (shown in appendix) from 
18 members of the Dutch Association of Surgical Oncologists who have special expertise 
in (the quality of) esophageal cancer care. At hospital level, the relevance weighted quality 
score is quantified as the average of scores for all patients.
For both multidimensional assessments (CQP and RWQS) 0 is the lowest score per patient 
and stands for (total) quality failure, while a score of 1 signifies that all predefined quality 
standards are met, i.e. that the patient has experienced exemplary care and outcome (ECO). 
Intermediate quality levels are represented on the quality profile by a score of 1 on lower 
profile only, and using the relevance weighted quality score by values between 0 and 1.
In the third phase we tested both these multidimensional quality assessment on the 
database of esophageal cancer patients, and compared them with the single-dimension 
quality measure of hospital survival. For all hospital comparisons, case-mix correction was 
applied by logistic regression for the covariates age, gender, co-morbidity and cancer 
stage to predict patient-specific outcomes for each parameter. For patient level-analysis, 
Table 2. The 6 quality parameters chosen and their correlation
avoiding adverse outcomes achieving goals
SurvHosp No long-term AO No Reop Hosp <14 days R0 Surv1YR
SurvHosp 1.000 -0.047 -.089* 0.045 0.031 .433*
No long-term AO 0.076 (ns) 1.000 -.078* .138* 0.013 -0.033
No Reop 0.001 0.003 1.000 .236* -.053* 0.005
Hosp<14 days 0.088 (ns) <0.001 <0.001 1.000 0.019 .086*
R0 0.244 (ns) 0.613 (ns) 0.045 0.475 (ns) 1.000 .242*
Surv1YR <0.001 0.205 (ns) 0.864 (ns) 0.001 <0.001
2-sided chi-square
SurvHosp = no complications leading to in-hospital mortality (grade IV adverse outcome); No Long-term AO = 
no complications with permanent damage (grade III adverse outcome) ;  No Reop = no complications needing 
re-intervention (grade II adverse outcome);  Hosp<14 days = no minor complications leading to hospital stay > 
14 days (Grade I adverse outcome);  R0 = microscopically radical resection;  Surv1YR = patient alive one year 
after resection; ns = not significant. For Pearson correlation coefficients (upper right table-half) stars (*) indicate 
statistical significance (at alpha 0.05). In the lower-left table-half, significance of correlations is quantified by 
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a case-mix corrected O/E-score is the quotient of the observed (0 or 1) and expected 
(between 0 and 1) patient-outcome. For hospital level-analysis, a case-mix corrected hospital 
score is the quotient of the observed and expected proportion of patients in whom the 
desirable outcome is achieved. The hospital ECO-score is the proportion of patients in whom 
all predefined quality standards are met.  Hospital performance was analyzed both per 
hospital, and for specific categories of hospitals (high versus low volume, and academic 
versus non-academic), using O/E-scores for survival, ECO and RWQS respectively.
Statistics
Differences in patient, tumor and treatment characteristics and outcome measurements 
were assessed using Kruskal-Wallis and Mann Whitney U test for continuous variables, 
and chi-square testing for categorical variables. Spearman rank and two-sided chi-square 
test were used to test correlations between outcomes. Survival was analyzed using Cox 
regression for the period between the date of first surgery to either death or the last patient 
contact, with follow up monitoring being continued until December 31st 2006. Prediction 
of events was calculated using multivariate logistic regression. All analyses were conducted 
using SPSS software (version 18.0; SPSS inc., Chicago.IL), using an alpha of 0.05 as the 
significance-threshold.
RESULTS
Results are reported per phase (parameters, multidimensional assessment, and hospital 
comparisons. Table 1 provides the characteristics of all patients. 
Correlations between patient-outcomes for the 6 quality parameters are shown in table 2. 
Interestingly, reoperation is not only associated with increased length of stay, but also with 
R0-resection, hospital survival and the absence of permanent or long term morbidity. 1 Year 
survival is not only (unsurprisingly) associated with hospital survival, but also with R0 resection 
and timely discharge. Table 3 shows the proportions and O/E-scores of patients meeting the 
6 separate quality standards (i.e. having a favorable outcome on a quality parameter) in each 
of the 12 hospitals. No hospital scored best on more than 1 case-mix corrected parameter. 
That quality parameters are not always positively associated is illustrated by hospital G8, 
that scored best on (both absolute and case-mix corrected) hospital survival (97%, 1.05) 
For the first multidimensional assessment, the cumulative quality profile, the order of 
the various parameters (on the basis of their relevance for long term outcome, by Cox 
regression) is shown in table 4. The most basic parameter is hospital survival, followed by 
1-year survival, R0-resection, no reoperation, timely discharge, and no permanent/long term 
morbidity respectively. Case-mix corrected hospital ECO-scores varied from 0.24 (G10) to 
1.63 (A2) and 1.69 (A1) for the two university hospitals. Figure 1 shows the quality profiles 
of the 12 hospital profiles graphically, both without (1a) and with (1b) case-mix correction. 
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Table 3. Hospital performance on each of the 6 separate quality parameters, both uncorrected (expressed 
as the proportion of patients meeting the quality standard), and with correction for case-mix (expressed as 
observed/expected ratio for each parameter)
Hospitals Outcome measures
Id Volume





% O/E % O/E % O/E % O/E % O/E % O/E
A-1 873* 94% 1.02 97% 1.01 91% 1.03 53% 1.16 72% 1.00 69% 1.01
A-2 122 93% 1.01 91% 0.95 85% 0.97 54%* 1.17* 80% 1.04 79%* 1.07
G-3 108 87% 0.94 96% 1.00 79% 0.90 48% 1.03 76% 1.01 76% 1.05
G-4 88 83% 0.90 94% 0.99 82% 0.93 27% 0.61 68% 0.94 56% 0.80
G-5 54 93% 1.01 94% 0.99 78% 0.88 15% 0.32 81% 1.03 70% 0.95
G-6 39 95% 1.02 100%* 1.04 92% 1.05 33% 0.72 67% 0.94 74% 1.08*
G-7 37 95% 1.03 92% 0.96 86% 0.98 3% 0.06 62% 0.86 70% 1.04
G-8 33 97%* 1.05* 94% 0.98 82% 0.93 36% 0.80 61% 0.83 73% 1.04
G-9 28 82% 0.89 100%* 1.05 100%* 1.11* 25% 0.52 75% 0.94 68% 0.91
G-10 25 92% 1.03 76% 0.80 80% 0.90 12% 0.30 84% 1.15 64% 0.98
G-11 21 90% 0.97 100%* 1.04 81% 0.91 19% 0.42 95%* 1.25* 71% 0.97
G-12 10 60% 0.65 100%* 1.05* 90% 1.01 40% 0.94 80% 1.05 50% 0.71
Id = hospital identification G = general hospital; A = academic hospital; SurvHosp = no complications leading 
to in-hospital mortality (grade IV adverse outcome); No Long-term AO = no complications with permanent 
damage (grade III adverse outcome) ;  No Reop = no complications needing  re-intervention (grade II adverse 
outcome); Hosp <14 days = no minor complications  leading to hospital stay > 14 days (Grade 1 adverse 
outcome);  R0 = microscopically radical resection; Surv1YR = patient alive one year after resection; * = highest 
score for separate measures
Table 4. Hospital performance on the cumulative quality profile, both uncorrected (expressed as the percentage 
of patients that meets each of the 6 progressively stricter cumulative quality levels), and with correction for 
case-mix (expressed as observed/expected ratio for each level).
Hospitals Cumulative standards satisfied (in O/E)
Id Volume
SurvHosp + Surv1YR + R0 + NoReop + No Long-
term AO
+ Hosp <14days 
(= ECO)
% O/E % O/E % O/E % O/E % O/E % O/E
A-1 873* 94% 1.02 69% 1.08 56% 1.21 51% 1.25 49% 1.25 31% 1.69*
A-2 122 93% 1.01 79%* 1.19* 65% 1.26 56% 1.23 50% 1.14 32%* 1.63
G-3 108 87% 0.94 76% 1.14 59% 1.21 44% 1.00 43% 1.03 27% 1.37
G-4 88 83% 0.90 56% 0.90 45% 0.97 33% 0.76 31% 0.75 10% 0.60
G-5 54 93% 1.01 70% 1.04 59% 1.12 43% 0.94 37% 0.82 9% 0.39
G-6 39 95% 1.02 74% 1.17 54% 1.18 51% 1.18 51% 1.23 21% 1.11
G-7 37 95% 1.03 70% 1.12 49% 1.09 41% 1.04 41% 1.09 3% 0.10
G-8 33 97%* 1.05* 73% 1.12 52% 0.96 39% 0.78 33% 0.70 12% 0.49
G-9 28 82% 0.89 68% 0.96 54% 0.88 54% 0.98 54% 1.03 4% 0.14
G-10 25 92% 1.02 64% 1.08 56% 1.26 44% 1.16 28% 0.80 4% 0.24
G-11 21 90% 0.96 71% 1.06 71%* 1.43* 62%* 1.37* 62%* 1.43* 14% 0.74
G-12 10 60% 0.66 50% 0.75 50% 0.96 40% 0.85 40% 0.90 10% 0.56
O/E = observed / expected ratio; Id = hospital identification G = general hospital; A = academic hospital; 
SurvHosp = no complications leading to in-hospital mortality (grade IV adverse outcome); No Long-term AO = 
no complications with permanent damage (grade III adverse outcome) ;  No Reop = no complications needing 
re-intervention  (grade II adverse outcome); Hosp <14 days = no minor complications  leading to hospital stay > 
14 days (Grade 1 adverse outcome);  R0 = microscopically radical resection;  Surv1YR = patient alive  one year 
after resection; * = highest score for separate measures without and with casemix correction.
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Figure 1. Cumulative outcome profile for 12 hospitals performing esophagectomy for cancer: A. shows the 
percentage of patients meeting the present and all preceding quality standards. B. shows the observed/
expected percentage, based on gender, age, cancer stage and number of co-morbidities. G = general hospital; 
A = academic hospital; SurvHosp = no in-hospital mortality; Surv1YR = 1 year survival;  R0 =  microscopically 
radical resection;NoGrade2 = no complications needing re-intervention; NoGrade3= no complications with 
permanent damage; NoGrade1= no minor complications leading to hospital stay > 14 days.
A B
For the second assessment, the multidimensional weighted quality score, we used relevance 
weights that were obtained from the 18 surgeons-experts, and that are shown in table 5. 
Hospital quality scores are shown in table 6, varying from 0.88 for G12 to 1.03 for G11.
Correlations between case-mix corrected hospital quality scores on single dimension hospital 
survival, and on multidimensional ECO-score and RWQS were compared, and yielded 
modest to low correlations, varying from 0.022 (Pearson correlation between hospital 
scores on O/E-survival and O/E-ECO), to 0.526 (for O/E-hospital survival and O/E-RWQS) and 
0.276 (for O/E-ECO and O/E-RWQS). This is not surprising, as these scores deal with failure 
(mortality/survival), perfection (ECO) and the whole quality range (RWQS) respectively. 
Table 5. Results of assessment of relevance for quality of care by 18 surgeon-experts.
Outcome SurvHosp R0 No Long-term AO Surv1YR No Reop Hosp <14days
parameter
Mean 26.7 24.8 19.2 14.7 11.5 3.2
Stdev 7.9 8.4 5.2 8.9 7.9 2.9
Max 45 45 30 35 25 5
Min 10 10 10 0 0 0
SurvHosp = no complications leading to in-hospital mortality (grade IV adverse outcome); No Long-term AO = 
no complications with  permanent damage (grade III adverse outcome) ;  No Reop = no complications needing 
re-intervention (grade II adverse outcome);  Hosp <14 days = no minor complications  leading to hospital stay 
> 14 days (Grade 1 adverse outcome);  R0 = microscopically radical resection; Surv1YR = patient alive one year 
















































Table 6. Hospital performance on the relevance-weighted quality score, both uncorrected (expressed as 
hospital averages for absolute quality scores), and with correction for case-mix (expressed as averages of 




26.7 24.8 19.2 14.7 11.5 3.2 100
Id Volume
SurvHosp R0 No Long-term 
AO




O O/E O O/E O O/E O O/E O O/E O O/E O O/E
A-1 873* 94% 1.02 72% 1.00 97% 1.01 69% 1.01 91% 1.03 53% 1.16 84% 1.02
A-2 122 93% 1.01 80% 1.04 91% 0.95 79%* 1.07 85% 0.97 54%* 1.17* 85% 1.01
G-3 108 87% 0.94 76% 1.01 96% 1.00 76% 1.05 79% 0.90 48% 1.03 82% 0.98
G-4 88 83% 0.90 68% 0.94 94% 0.99 56% 0.80 82% 0.93 27% 0.61 76% 0.91
G-5 54 93% 1.01 81% 1.03 94% 0.99 70% 0.95 78% 0.88 15% 0.32 83% 0.97
G-6 39 95% 1.02 67% 0.94 100%* 1.04 74% 1.08* 92% 1.05 33% 0.72 84% 1.01
G-7 37 95% 1.03 62% 0.86 92% 0.96 70% 1.04 86% 0.98 3% 0.06 79% 0.96
G-8 33 97%* 1.05* 61% 0.83 94% 0.98 73% 1.04 82% 0.93 36% 0.80 80% 0.97
G-9 28 82% 0.89 75% 0.94 100%* 1.05 68% 0.91 100%* 1.11* 25% 0.52 82% 0.96
G-10 25 92% 1.03 84% 1.15 76% 0.80 64% 0.98 80% 0.90 12% 0.30 79% 0.97
G-11 21 90% 0.97 95%* 1.25* 100%* 1.04 71% 0.97 81% 0.91 19% 0.42 87%* 1.03*
G-12 10 60% 0.65 80% 1.05 100%* 1.05* 50% 0.71 90% 1.01 40% 0.94 74% 0.88
Id = hospital identification G = general hospital; A = academic hospital; SurvHosp = no complications leading to 
in-hospital mortality (grade IV adverse outcome);No Long-term AO = no complications with permanent damage 
(grade III adverse outcome) ;  No Reop = no complications needing  re-intervention (grade II adverse outcome; 
Hosp <14 days = no minor complications  leading to hospital stay > 14 days (Grade 1 adverse outcome);  R0 
= microscopically radical resection; Surv1YR = patient alive one year after resection; * = highest score for 
separate measures without and with casemix correction; 
Table 7. Comparisons of different categories of hospitals (high versus low volume, academic versus 
non-academic) by single dimension patient O/E-scores for hospital survival, and by multidimensional patient 




average stdev average stdev average stdev
High volume 873 1.020 0.255 1.692 2.970 1.021 0.247
Low Volume 565 0.968 0.335 0.911 2.131 0.970 0.242
p (Mann Whitney U) 0.114 < 0.001* < 0.001*
Academic 995 1.019 0.257 0.168 2.928 1.021 0.243
Non-academic 443 0.957 0.350 0.713 1.933 0.956 0.248
p (Mann Whitney U) 0.095 < 0.001* < 0.001*
Comparison of the quality provided to patients treated in different categories of hospitals 
(high versus low volume, academic versus non-academic) is shown in table 7, and shows that 
O/E-hospital survival scores did not differ (p=0.114 for high vs. low volume, and p=0.085 for 
academic vs. non-academic by Mann Whitney U-test), while O/E-ECO and O/E-RWQS did, 
highly significantly (p<0.001).
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DISCUSSION
Our study addresses the fact that quality of care should be measured by more than one 
outcome only, and illustrates this point by introducing multidimensional assessment for the 
quality of esophageal cancer surgery. We introduce 6 quality parameters, including the 
traditional measure of hospital mortality, and combine these parameters into a cumulative 
quality profile and a relevance-weighted quality score. Both the finding that the separate 
quality parameters may be negatively correlated (table 2) and that no hospital scored best 
on all parameters, supports the relevance of such a multidimensional approach.
For both frameworks we introduce the concept of ECO, exemplary care and outcome. Per 
patient, this signifies the provision of care that meets all of the predefined quality standards, 
while at hospital level, the ECO score is the proportion of patients treated with ECO-quality. 
We tested the feasibility of multidimensional quality assessment on the performance of 
12 hospitals providing esophageal cancer surgery to patients treated in the west of the 
Netherlands between 1991 and 2004. Although no hospital performed best on more 
than 1 parameter, overall scores of the two university hospitals (A1 and A2) and one 
low-volume hospital (G11) tended to have higher scores in many assessments. Finally, we 
clustered hospitals in categories expected to provide different levels of esophageal cancer 
care (high versus low volume hospitals, and academic versus non-academic) and assessed 
quality between these categories. The results are shown in table 7, and demonstrate that 
differences in case-mix corrected O/E-ECO and O/E-RWQS between hospital categories 
are highly significant, whereas O/E-hospital survival does not differ significantly. This 
demonstrates that both multidimensional methods can provide a broader assessment of 
quality (suggesting better construct validity) but could also be more sensitive to differences 
in the quality of care provided (i.e. better criterion validity)
In recent years, a plethora of articles describing variation in outcome between different 
institutions has been published. Most studies are population-based and assess differences in 
outcome between large groups of hospitals, without evaluating quality of care on the level of 
individual institutions. Adopting Donabedian’s paradigm of structure, process and outcome, 
Birkmeyer et al. mentioned the relative merits of different approaches to measuring the 
quality of surgical care.3 More recently, Porter made a strong case for multidimensional 
outcome measurement, and for taking the point of view of the care-seeker, not the 
care-provider.
However, comparison of health outcomes between hospitals is not without its problems, 
the most obvious problems being data-quality and case-mix correction11.  In addition, for 
rare outcomes, there is ‘the problem of small sample size’. Dimick et al. investigated the 
minimum hospital caseloads necessary to detect a doubling of the mortality rate for different 
procedures, and found that an annual volume of 77 esophageal resections is necessary 
to detect significant mortality differences.15 He concluded that most operations are not 
performed frequently enough to use surgical mortality as an indicator of hospital quality.
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Multidimensional quality assessment aims at better construct validity (by taking a greater 
proportion of relevant quality aspects into account) and (hopefully) at better criterion 
validity (being better able to discriminate between hospitals with better and lower overall 
quality). However, it also adds a new challenge to existing ones; the question of how to 
combine different quality parameters. O’Brien, analyzing quality measurement of adult 
cardiac surgery on behalf of the Quality Measurement Task Force of the Society of Thoracic 
Surgeons, tested four methods of composite scoring (1 – an opportunity-based approach, 2 
- [weighted or un-weighted] averaging of item-specific estimates, 3 - all or none scoring, and 
4 - latent trait analysis), and concluded that none is without flaws or limitations.16 
In the present study, we use two ways of composite scoring. One, the relevance-weighted 
quality score, is a specific example of O’Brien’s second method. The parameters weights 
we used were obtained from 16 oncological surgeons-experts. They were asked to image 
that they were esophageal cancer patients choosing the most appropriate hospital, or that 
they were asked for such advice by a family member. Their relevance weights would thus 
represent both their professional insight, and their “as-if”-patient perspective.
The other way, the cumulative quality profile, is new and combines advantages of 
transparency and integration. In another study from our institution, we found that such a 
summary measure is very well received by patients.17 
Our study has several limitations. The first was mentioned in the introduction and is hampering 
quality assessment in general: the absence of a ‘golden standard’ for quality of care. We 
selected six parameters available in our database and gave them weights representing the 
extent to which each of the 6 parameters is considered relevant for choosing a high quality 
hospital. We used substitutes for patient preferences, obtained from surgeons-experts by an 
“as-if” questionnaire. However interesting and valid their stated preferences may be, they are 
no substitute for real patients’ preferences. The models presented in this study are therefore 
no more than a ‘proof of principle’, and the appropriateness of relative importance, either by 
sequence or by weights, requires more in-depth study in real patients. 
The second limitation is the low number of institutions evaluated and there is the obvious 
problem of low patient numbers per institution and the ensuing lack of statistical power 
for rare outcomes. The fact that the Dutch Health Care Inspectorate has recently banned 
esophageal surgery in low volume hospitals, will provide part of the solution to this 
problem.4 Another part of the solution may be our finding that multidimensional measures 
of quality may be more sensitive to quality differences, than single dimensional outcomes 
that rarely occur. In addition, following examples in our neighboring countries, nation-wide 
clinical audits for oncological and other care have recently been started in the Netherlands 
(www.clinicalaudit.nl).18 In 2011, the Dutch Upper Gastro-intestinal Cancer Audit has been 
initiated in which all patients in who an esophageal or gastric resection for cancer has been 
performed are registered. The results of the present study suggest that multidimensional 
quality assessment may be a valid tool to analyze differences in quality of care in these 
clinical audits.  It may provide broader and more relevant information on quality to patients, 
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doctors and society, but also may have better power to identify those hospitals that provide 
care of appropriate quality. The data from these much larger and detailed clinical databases 
may give us, or other researchers, the opportunity to refine and validate multi-dimensional 
frameworks for the assessment of quality of care, like the Exemplary Care and Outcome 
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APPENDIX
Evaluation of quality of care for esophageal resections for cancer: a survey (this survey is 
translated from the original Dutch version)
Publications regarding the inverse relationship between hospital volume and postoperative 
mortality have initiated an extensive debate on the quality of care for patients undergoing 
esophagectomy for cancer. However, in-hospital mortality is not the only factor that’s 
important in the evaluation of quality of care for this patient group. Preferably, a more 
extensive set of measures would be used for the assessment of quality of care in individual 
institutions.  Though, the data needed for this quality assessment are not always available 
and are usually limited to data regarding the outcome after surgery, like postoperative 
complications, re-operations, radicality of the resection and survival. In addition, it’s not 
always clear how these quality aspects have to be weighed. Through this survey we would 
like to investigate how medical specialists treating patients with esophageal cancer value 
different outcomes of esophageal cancer surgery, their selves.  
“Suppose that you, or a member of your family should be treated for esophageal 
cancer and you had to make a choice from a number of hospitals. From every hospital 
only a limited set of data regarding 6 quality aspects is available, collected by an 
independent authority. The differences in ‘case-mix’ of these hospitals do not have to 
be taken into consideration. The 6 quality aspects are: 
Quality aspect Definition
1 In-hospital mortality The percentage of patients that dies postoperatively during the same hospital 
admission.
2 Complications The percentage of  patients that has complications with permanent damage 
concerning functional loss or handicaps (for example: hoarseness, dysphagia, 
dependence on feeding tubes after failure of gastric tube reconstruction, 
cardiac failure after myocardial infarction)
3 Re-operations The percentage of patients in who one or more re-operations have been 
performed due to complications after esophagectomy.
4 Length of stay Percentage of patients with a length of stay longer than 2 weeks.
5 Radicality Percentage of patients with a radical resection (R0).
6 1-year survival Percentage of patients alive 1 year after the operation
 “If there was a hospital that scores perfect on every quality aspect, you would 
obviously choose for that hospital. Unfortunately, there’s no perfect hospital and 
hospitals score better or worse on different quality aspects. Therefore it’s necessary to 
make a choice based on a combination of different quality aspects.  Would you be so 











* divide 100 points between  6 quality aspects
Quality aspect Ranking*
- In-hospital mortality 4
- Complications 6
- Re-operations 2
- Length of stay 1
- Radicality 5
- 1-year survival 3





- Length of stay
- Radicality
- 1-year survival
* give ranking from “1” = most important to “6” = least important.
Question 1
Please select which quality aspect is most important for you, and which aspects gradually 
would be less important.
Question 2
You get 100 weight points. Can you divide these between the 6 quality aspects in such 
a way that the number of points represents the weight that you assign to the different 
aspects.
Examples
- Answers in the two examples beneath are intentionally chosen at random -
Answer 1
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Quality aspect Points*
- In-hospital mortality 8
- Complications 7
- Re-operations 20
- Length of stay 30
- Radicality 10
- 1-year survival 25
Total 100
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Care processes for patients with NSCLC can vary by provider, which may lead to unwanted 
variation in outcomes. Therefore, in modern health care an increased focus on guideline 
development and implementation is seen. It is expected that more guideline adherence 
leads to a higher number of patients receiving optimal treatment for their cancer which 
could improve overall survival. The aim of this study was to evaluate variations in treatment 
patterns and outcomes of patients with NSCLC treated in different (types of) hospitals and 
regions in the Netherlands. Especially, variation in the percentage of patients receiving the 
optimal treatment for the stage of their disease, according to the Dutch national guideline 
of 2004, was analyzed.
Methods:
 All patients with a histological confirmed primary NSCLC diagnosed in the period 2001-2006 
in all Dutch hospitals (N=97) were selected from the population-based Netherlands Cancer 
Registry. Hospitals were divided in groups based on their region (N=9), annual volume 
of NSCLC patients, teaching status and presence of radiotherapy facilities. Stage-specific 
differences in optimal treatment rates between (groups of) hospitals and regions were 
evaluated.
Results:
In the study period 43,544 patients were diagnosed with NSCLC. The resection rates for 
stage I / II NSCLC patients increased during the study period, but resection rates varied by 
region and were higher in teaching hospitals for thoracic/lung surgeons (OR 1.5; 95%CI 
1.2 - 1.9, p=0.001) and in hospitals with a diagnostic volume of more than 50/year (OR 1.3; 
95%CI 1.1 – 1.5, p=0.001). Also the use of chemoradiation in stage III patients increased, 
though marked differences between hospitals in the use of chemoradiation for stage III 
patients were revealed. Differences in optimal treatment rates between hospitals led to 
differences in survival. 
Conclusion: 
Treatment patterns and outcome of NSCLC patients in the Netherlands varied by region and 
the hospital their cancer was diagnosed in. Though resection rates were higher in hospitals 
training thoracic/lung surgeons, variation between individual hospitals was much more 
distinct. Hospital characteristics like a high diagnostic volume, teaching status or availability 
of radiotherapy facilities proved no guarantee for optimal treatment rates. 
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INTRODUCTION
In literature a plethora of studies describes hospital volume as an important predictor of 
surgical outcomes. Most of these studies evaluate the inverse relationship between volume 
and adverse surgical outcomes, like postoperative complications and mortality1. Only few 
authors address the mechanisms which lead to these differences. Intermediate outcomes, 
like the percentage of patients receiving potentially curative treatment for their cancer, 
could explain differences in survival. Moreover, other hospital characteristics reflecting the 
setting in which care is delivered to cancer patients, could be equally important predictors 
of outcome as hospital volume.
The variation of care processes by caregiver is widely recognized and can sometimes 
lead to unwanted variation in patients outcomes. Therefore, in modern health care an 
increased focus on guideline development and implementation is seen. It is expected that 
more guideline adherence leads to a higher number of patients receiving optimal treatment 
for their cancer which could improve overall survival. Moreover, evaluating differences in 
guideline adherence between hospitals can reveal the reasons behind the differences in 
outcome and can identify best practices with better outcomes. 
Differences in guideline adherence have been described for patients with Non small cell 
lung cancer (NSCLC) in several countries2-5. In the Netherlands, lung cancer is the second 
common tumor in men and the third in women, with an incidence of 71 and 31 per 
100,000 person years in 2007, respectively (European Standardized Rate)6. In 2007, 10,533 
patients were diagnosed with lung cancer and in eighty percent it concerned NSCLC. Only 
14% of patients diagnosed with NSCLC in the Netherlands survive 5 years. Unfortunately, 
these survival figures have not improved in the last decades6. While the incidence of 
NSCLC in men is decreasing since the early eighties, it has been rising in women until 
1999. Fortunately, recent reports predict the end of this lung cancer epidemic in women, 
meaning an overall decrease in lung cancer patients in the near future7. 
In 2004 the first Dutch National Guideline on NSCLC was introduced (www.oncoline.nl). 
The main reasons for development of this evidence-based guideline were the introduction 
of PET-scanning in staging NSCLC, induction chemotherapy in locally advanced NSCLC, and 
concurrent chemoradiation in stage III NSCLC. According to this guideline surgical resection 
is the preferred treatment in patients with stage I or II NSCLC, who are fit to undergo 
surgery. Under the guidelines valid in our study period, surgery is also the treatment of 
choice in patients with limited stage III disease (T1-3N1). Patients with more advanced stage 
III NSCLC (cT4 and/or cN2 or cN3) should be treated with a combination of radiation therapy 
and chemotherapy (chemoradiation), if their performance score is sufficient (WHO-score 
0-1). Chemoradiation is given in a concurrent regimen or sequentially. In general, stage 
III patients with malignant pleural effusions or tumor volumes too extensive for radiation 
treatment are no candidates for this combined modality therapy and are treated like stage 
IV patients with a platinum based chemotherapy regimen and / or best supportive care.
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The aim of this study was to evaluate variations in treatment patterns and outcomes of 
patients with NSCLC treated in different (types of) hospitals and regions in the Netherlands. 
Especially, variation in the percentage of patients receiving optimal treatment for the stage 
of their disease, according to the Dutch national guidelines, was analyzed.
METHODS
Netherlands Cancer Registry
In the Netherlands, all newly diagnosed malignancies are registered in the nationwide 
population-based Netherlands Cancer Registry (NCR). The automated pathological archive 
(PALGA) and the Hematology Departments are the main sources of notification. The National 
Registry of Hospital Discharge Diagnosis is an additional source, which accounts for up to 
8% of new cases.8 Data are collected from the medical records by specially trained registrars 
and are coded according to a national manual. Information on patient characteristics, tumor 
characteristics, treatment, hospital of diagnosis, hospital of treatment and follow-up is 
recorded. For coding tumor site and morphology the International Classification of Diseases 
for Oncology (ICD-O) is used.9 Cancers are staged according the TNM classification.10 
Quality of the data is high11 and completeness is estimated to be at least 95%.12 
Patients
All patients with a histological confirmed primary NSCLC diagnosed in the period 2001-2006 
were selected from the NCR. Excluded from analysis were clinical diagnosis (no pathology), 
autopsy findings, sarcomas, lymphomas, neuro-endocrine and carcinoid tumors. Moreover, 
patients living abroad and cases with an incomplete registration status in the NCR (<1%) 
were excluded from analyses. Stage grouping was done according to TNM classification, 
6th edition. 
Hospitals and regions
Patients treated in all 97 hospitals in the Netherlands were included in this analysis. Hospitals 
were divided in groups based on their teaching status, availability of radiotherapy facilities, 
annual amount of NSCLC diagnoses (hospital volume) and their region. For the analyses 
concerning treatment, type of hospital was based on the hospital where the tumor was 
diagnosed reasoning that referral of patients is good care as well. For the analyses on 
postoperative mortality and survival, type of hospital was based on the hospital where the 
resection was performed.
Hospitals were categorized in three groups: non-teaching, teaching and academic. A 
teaching hospital was defined as a hospital which provides medical training to residents. 
A distinction was made between a teaching hospital for chest physicians and thoracic/
lung surgeons. In the group of teaching hospitals for thoracic/lung surgeons all academic 
hospitals were included in the teaching hospital group. Academic hospitals are teaching 
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hospitals affiliated with a university. The one specialized oncology center in the Netherlands 
was also classified as an academic hospital as well.
Radiotherapy is an essential part of the treatment of patients with stage III NSCLC. In the 
Netherlands there are 24 hospitals with radiotherapy facilities and 73 hospitals without a 
radiotherapy department. These hospitals are affiliated with a radiotherapy department on 
a different location. All radiotherapy departments treat patients with NSCLC. Hospitals were 
categorized as having radiotherapy facilities in the same location or not. 
Hospital volume stands for the mean number of NSCLC diagnoses per year or for the mean 
number of lung resections per year. Hospital volume was categorized in 3 groups: less than 
50, 50-100 and more than 100 diagnoses per year. In the period 2005-2006, 88% of the 
patients were operated in the hospital were the tumor was diagnosed.
In addition, hospitals were categorized according to their Comprehensive Cancer 
Center region (9 groups). These Comprehensive Cancer Centers (CCCs) are non-hospital 
organizations that facilitate provision of consultancy services, implementation of national 
guidelines, coordinate organization of cancer care, palliative care and host the cancer 
registry. Each CCC serves a region that includes five to twenty hospitals. Hospitals are 
affiliated to one CCC.
Stage grouping
Since clinical stage determines treatment policies for NSCLC, the cTNM was used in the 
analysis concerning the treatment policies. For the analysis concerning the outcome after 
resection the pathological stage (pTNM) was applied. During the study period PET-scanning 
was introduced gradually as an addition to traditional clinical staging in NSCLC patients. 
Effectiveness and stage migration effects of PET-scanning were reported in a Dutch 
randomized study 13. A report on cost-effectiveness and availability of PET-scanning showed 
an unequal distribution across the Netherlands in 2005-06 of mobile units aimed especially 
for staging of localized lung cancer 14.
Treatment
Treatment was categorized by resection (pneumonectomy, lobectomy or segmentectomy), 
radiation therapy, chemotherapy or combined modality treatment (chemoradiation). 
Chemoradiation was defined as radiation therapy combined with chemotherapy given 
concurrent or sequentially. Treatment was described as percentages per clinical stage and 
age group (<75 years and ≥75 years). 
The optimal treatment ratio was defined as the percentage of patients receiving optimal 
treatment by stage of the disease according to the Dutch guideline of 2004 15: resection for 
stage I and II patients, chemoradiation (possibly followed by resection) for stage III patients 
and chemotherapy for stage IV patients. Resection ratios of stage IIIa patients, usually part 




Logistic regression analysis was performed to examine the influence of age at diagnosis (<60, 
60-74, 75+), gender, tumor size and invasion (cT), type of hospital of diagnosis (academic, 
teaching, general), radiotherapy facilities (same versus different location), hospital volume 
(<50, 50-100, >100), CCC-region and year of diagnosis on the odds of receiving optimal 
treatment per stage as described above.
Performance of the individual hospitals for these optimal treatment rates was exhibited 
in funnel plots using 95% control limits calculated around the mean.16 Each hospital 
was displayed as a scatter point presenting the rates of optimal treatment, i.e. resection 
for patients with stage I and II disease (adjusted for age, gender and tumor size) and 
chemoradiation for those with stage III disease (adjusted for age, gender, tumor size and 
nodal involvement). 
 
Furthermore, logistic regression analysis was used to investigate the influence of age at 
diagnosis (<60, 60-74, 75+), gender, tumor size and invasion (cT), type of hospital of surgery 
(academic, teaching, general), hospital volume of resections (<10, 10-19, 20-29 and ≥30/
year) and CCC-region on the odds of postoperative mortality, defined as death within 
30 days after resection. Patients with stage IV disease were excluded from this analysis. 
Postoperative mortality was determined for patients diagnosed in 2005 and 2006 only. 
Follow-up was calculated as the time from diagnosis to death or to 1st January 2008. Cox 
proportional hazard modeling was used to investigate the relation between resection 
and survival in patients with stage I and II disease, adjusted for age at diagnosis, gender, 
T-stage and year of diagnosis. Furthermore, this analysis was used to determine the relation 
between the resection rate of hospitals and overall survival. The hospitals were split into 3 
groups based on their resection rate in the funnel plot: higher than the 95% control limit, 
within the 95% control limits or below the 95% control limit. 
STATA (version 10.0) was used and a p-value of 0.05 was considered as being significant. 
RESULTS
In the period 2001-2006, 43,544 patients (69% male) were diagnosed with primary NSCLC 
(table 1) . During the study period the annual number of new NSCLC diagnoses increased 
from 6,774 patients in 2001 to 7,853 in 2006 (16%). The rise in incidence was much 
higher in women than in men, 45 and 5% respectively and occurred largely at middle age, 
contrasting the situation in males. Twenty-five percent of NSCLC patients were older than 
75 years at the time of diagnosis. During the study period there has been a minor shift from 
clinical stage I and II disease to the more advanced stages, especially stage IV (Figure 1a). 
Table 2 shows the distribution of patients between the different types of hospitals and their 
CCC region. The majority of the patients with NSCLC were diagnosed in general hospitals 
without training status for chest physicians (68%) or thoracic surgeons (84%). Only 18% of 
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Patients 43 544 100%
Age (years)
< 60 11 357 26%
60-74 21 403 49%
≥ 75 10 784 25%
Gender
Male 30 172 69%
Female 13 372 31%
Year of diagnosis
2001 6 774 16%
2002 6 954 16%
2003 7 108 16%
2004 7 395 17%
2005 7 460 17%
2006 7 853 18%
Histology
Adenocarcinoma 14 454 33%
Squamous cell carcinoma 14 310 33%
Large cell carcinoma 14 332 33%
Other histology 448 1%
Clinical stage
In situ 78 0%
Stage I 9 544 22%
Stage II 1 930 4%
Stage III 13 715 32%
Stage IV 17 231 40%
Unknown 1 046 2%
Pathological stage (in case of surgery)
In situ 13 0%
Stage I 5 681 13%
Stage II 2 002 5%
Stage III 1 749 4%























the patients were diagnosed in a center with radiotherapy facilities and 9% in an academic 
center. About 54% of the patients were diagnosed in 32 hospitals with an annual diagnostic 
volume of more than 100 cases with NSCLC. 
Table 2. Number of Non Small Cell Lung Cancer patients per hospital volume category, teaching status, 
radiotherapy facility and region 2001-2006.
N %
Total
Patients 43 544 100%
Hospital volume
<50 (23 hospitals) 3 910 9%
50-100 (44 hospitals) 16 209 37%
>100 (32 hospitals) 23 425 54%
Teaching status (chest physician)
Non-teaching hospital 29 582 68%
Teaching hospital 9 889 23%
Academic hospital 4 019 9%
Teaching status (lung- / thoracic surgery) physician)
Non-teaching hospital 36 622 84%
Teaching hospital (incl. academic hospitals) 6 922 16%
Radiotherapy facilities
No 35 538 82%
Yes 8 006 18%
Regions
I 5 888 13%
II 3 732 9%
III 3 172 7%
IV 7 868 18%
V 4 245 10%
VI 6 271 14%
VII 6 411 15%
VIII 2 908 7%
IX 3 049 7%
Hospital characteristics in this table are based on the hospital where the patient is diagnosed with NSCLC. 
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Treatment
Primary surgery i.c. resection of the tumor through pneumonectomy, lobectomy or 
segmentectomy, was performed in 23% of all NSCLC patients, being 60% for patients with 
clinical stage I or II (Figure 1b). The others received radiotherapy, either with or without 
chemotherapy. A substantial number of patients received no oncological therapy at all, 
being 25% in stage I and II patients older than 75 years. In only 43% of these elderly the 
tumor was resected. This percentage increased only slightly during the study period. In the 
younger patient group (<75 years), a resection was performed in 79% of the patients.  
Stage I and II
Logistic regression confirmed this role of age in the chance of a resection; in stage I and II 
patients older than 75 years the OR of a resection is 0.09 (95%CI 0.08 – 0.11, p=0.000). 
Also, the size of the tumor, expressed in T stage, was important. Nevertheless, the chance 
of resection did not only depend on patient- and tumor-characteristics. Patients with 
clinical stage I or II disease more often had a resection of their tumor in hospitals with a 
teaching status for thoracic surgeons (OR 1.5; 95%CI 1.2 - 1.9, p=0.001) and in hospitals 
with a diagnostic volume of more than 50 NSCLC patients a year (OR 1.3; 95%CI 1.1 – 1.5, 
p=0.001). Marked differences in resection rates appeared between groups of hospitals and 
regionally. The chance of a resection for stage I or II NSCLC ranged from an OR of 2.0 in 
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Figure 2. Percentage of stage I or II NSCLC patients in who a resection is performed for non-teaching and 
teaching hospitals (adjusted for differences in age, gender and T-stage). 
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Figure 2 shows differences in resection rates between individual hospitals from 75 to 93% 
for hospitals with accredited training of thoracic surgeons and from 54 to 97% for hospitals 
without training facilities.
Table 3. Multivariate analysis for the odds of resection for stage I and II NSCLC in the Netherlands during 
2001-2006
OR 95% CI p-value
Age (years)
< 60 ref
60-74 0.40 0.35-0.46 < 0.001
≥ 75 0.09 0.08-0.11 < 0.001
Gender
Male ref
Female 1.00 0.90-1.12 0.896
Year of diagnosis
2001 ref
2002 1.2 1.01-1.39 0.030
2003 1.53 1.31-1.78 < 0.001
2004 1.53 1.32-1.78 < 0.001
2005 2.04 1.75-2.37 < 0.001
2006 1.99 1.71-2.31 < 0.001
T-stage
T 1 ref
T 2 0.48 0.43-0.54 < 0.001
T 3 0.21 0.18-0.25 < 0.001
Hospital volume
<50 ref
50-100 1.40 1.17-1.68 < 0.001
>100 1.69 1.40-2.04 < 0.001
Teaching status (chest physician)
Non-teaching hospitals ref
Teaching hospitals 0.91 0.80-1.05 0.212
Academic hospitals 1.02 0.74-1.42 0.741
Teaching status (lung- / thoracic surgery)
Non-teaching hospitals ref
Teaching hospitals (incl. academic hospitals) 1.58 1.28-1.94 <0.001
Radiotherapy facilities
No ref
Yes 0.92 0.77-1.05 0.304
Region
I 0.94 0.82-1.12 0.452
II 1.52 1.23-1.76 < 0.001
III 0.82 0.69-1.01 0.045
IV ref
V 0.95 0.81-1.14 0.634
VI 0.97 0.85-1.17 0.729
VII 1.08 0.92-1.25 0.324
VIII 1.46 1.24-1.82 < 0.001
IX 1.02 0.83-1.23 0.794
Hospital characteristics based on hospital of diagnosis.
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The postoperative mortality rates after a resection for NSCLC were based on data from 
2005 and 2006. Within 30 days after the resection 111 of 3206 patients died (3.3%), being 
7.5% for patients older than 75 years. Tumor size (pT) and operative procedure also proved 
important factors. Patients operated in the 63 hospitals with less than 20 resections a year 
exhibited a similar postoperative mortality rate as in a higher volume hospital with 20 or 
more NSCLC resections annually (34 hospitals). Patients with stage I or II NSCLC operated 
in the academic centers had a significantly lower postoperative mortality (1.3%, p=0.012). 
Logistic regression showed that this reduced risk of dying postoperatively in academic 
centers is only borderline significant (OR 0.25; 95%CI 0.06 – 0.93, p=0.038).
Stage III 
During the study period 13,744 patients were diagnosed with stage III NSCLC, 4,938 stage 
IIIa and 8,806 stage IIIb patients. In the whole group of stage III patients 24% received 
combined modality treatment (figure 1b), 30% of the younger patients (<75 years, n=10,069) 
and 9% of the older patients (>75 years, n=3,675). The percentage of patients receiving 
chemoradiation went from 18% in 2001 to 29% in 2006 (p<0.001). Higher age and advanced 
tumor size were the most important factors to abandon chemoradiation (Table 4).The odds 
of receiving chemoradiation were lower when a patient was diagnosed in an academic 
center. Chemoradiation rates were not higher in high volume hospitals (>100 diagnoses a 
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Figure 3. Percentage of stage III patients who received chemoradiation according to mean number of lung 
cancer diagnoses per year. 
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Table 4. Multivariate analysis for the odds of receiving combined modality therapy for stage III NSCLC
OR 95% CI p-value
Age (years)
< 60 ref
60-74 0.63 0.58-0.70 < 0.001
≥ 75 0.16 0.14-0.18 < 0.001
Gender
Male ref
Female 0.92 0.84-1.02 0.101
Year of diagnosis
2001 ref
2002 1.21 1.03-1.42 0.019
2003 1.53 1.31-1.79 < 0.001
2004 1.54 1.32-1.79 < 0.001
2005 2.03 1.74-2.36 < 0.001
2006 1.99 1.71-2.31 < 0.001
T-stage
T 1 ref
T 2 1.03 0.87-1.22 0.732
T 3 1.00 0.81-1.22 0.967
T 4 0.87 0.74-1.03 0.107
N-stage
N 0 ref
N 1 0.56 0.42-0.75 <0.001
N 2 1.77 1.54-2.04 <0.001
N 3 1.64 1.40-1.93 <0.001
Hospital volume
<50 ref
50-100 0.77 0.66-0.91 0.002
>100 0.89 0.76-1.05 0.169
Teaching status (chest physician)
Non-teaching hospitals ref
Teaching hospitals 0.90 0.79-1.03 0.128
Academic hospitals 0.64 0.48-0.86 0.003
Teaching status (lung- / thoracic surgery)
Non-teaching hospitals ref
Teaching hospitals (incl. academic hospitals) 1.59 1.29-1.96 < 0.001
Radiotherapy facilities
No ref
Yes 0.93 0.79-1.09 0.345
Region
I 0.96 0.82-1.12 0.589
II 1.54 1.29-1.84 < 0.001
III 0.84 0.69-1.02 0.081
IV ref
V 0.97 0.82-1.16 0.755
VI 1.00 0.85-1.17 0.978
VII 1.12 0.96-1.31 0.145
VIII 1.49 1.23-1.81 < 0.001
IX 1.04 0.86-1.27 0.678
Hospital characteristics based on hospital of diagnosis.
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surgeons (OR 1.6, CI 1.3-1.9). Also, regional differences in the use of chemoradiation were 
revealed, but they seemed larger between individual hospitals, independent of their region, 
volume of NSCLC patients, teaching status or radiotherapy facilities (Figure 3).
Patients younger than 75 years diagnosed with stage IIIa in an academic hospital (26%), 
teaching hospital (26%) or in radiotherapy center (22%) had a resection of their tumor more 
often than patients in non teaching (15%) or hospitals without radiation facilities (16%). 
Resection rates in stage IIIa declined slightly during the study period (not significant), while 
combined treatment of stage IIIa disease with chemoradiation increased, from 24% in 2001 
to 43% in 2006 (p=0.001). A multivariate analysis revealed marked regional differences in the 
percentage of patients having surgery for their stage IIIa NSCLC, varying between 9 and 25%. 
Stage IV
The percentage of patients with stage IV NSCLC at primary diagnosis gradually increased 
during the study period from 38% in 2001 to 44% in 2006. The use of chemotherapy in the 
primary treatment of stage IV patients younger than 75 years also increased in this period, 
from 31% to 50% (p=0.001), but approximately 40% of stage IV patients received no active 
treatment. Hospital differences in the palliative use of chemotherapy in stage IV NSCLC 
were not a part of the current study. 
Survival
Patients who underwent a resection for stage I or II disease had a significantly higher survival 
than patients without a resection (Figure 4). Adjusted for age, gender, T-stage and year of 
diagnosis, overall survival of stage I and II patients was significantly higher in hospitals with 
a higher resection rate and significantly lower in hospitals whose resection rate was lower 
than the group of hospitals within the 95% control limits of the funnel plot of figure 2 (HR 
Figure 4. Survival of stage I and II NSCLC 
patients with or without surgical resection. 
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0.88, 95%CI 0.83-0.93 and HR 1.15, 95% CI 1.07-1.24, respectively). Though, no differences 
were found in overall survival for patients who underwent resection in the hospitals with 
high and with low resection ratios. 
DISCUSSION
The introduction of a national evidence-based guideline in 2002, appears to have had 
several effects on staging and patterns of care for NSCLC patients in our country. Especially 
the routine use of PET-scanning in the work-up of patients for curative therapy led to an 
increased number of patients with stage IV at diagnosis. In addition, recommendations 
on the use of chemoradiation for stage III patients led to an increased utilization of 
radiotherapy combined with chemotherapy, concurrent or sequentially. Nevertheless this 
study reveals marked variation in treatment patterns and outcome of patients with NSCLC 
in our country. Not only are these differences influenced by patient or tumor characteristics, 
also the hospital of diagnosis seems to affect the treatment given. On the level of the 
individual hospital resection rates in stage I / II patients varied between 54 and 97 percent. 
The administration of potentially curative chemoradiation in stage III patients varied from 
less than 10 to more than 40 percent. These differences were only sporadically explained 
by structural differences between hospitals, like their teaching status or the availability of 
radiotherapy facilities. Nevertheless, the variation in optimal treatment rates identified in 
this study could mean that there’s room for further improvement in the treatment of NSCLC 
patients in our country, possibly leading to actual survival benefits. 
Inequality in the treatment of NSCLC has been addressed in many publications. Several 
patient factors are associated with lower odds of undergoing a potentially curative treatment 
for lung cancer. Higher age is the most important factor, but in studies from the United 
States as well as Europe gender, comorbidity, race, socio-economic status, region or country 
of origin have also proven to be predictive 17-22. These inequalities are not only due to 
decreased access to care, but also differences in physicians’ treatment choices and differences 
in guideline implementation and adherence are believed to be of influence. Whereas active 
treatment of NSCLC patients appeared to be strongly associated with better survival, studies 
from Yorkshire and the Southeast of England 15,16 demonstrated wide regional variations 
in the use of active treatments like surgery and radiotherapy 23;24. In one of these studies 
the use of any active treatment in NSCLC patients, independent of stage, ranged from 15% 
in one area to 42% in another. Despite corrections for case-mix the reasons behind this 
variation stayed unclear, but if the first hospital visited was a radiotherapy center, patients 
were more likely to receive any active treatment. 
In the present study, we analyzed the treatment compliance according to the Dutch evidence-
based guidelines, not only at the regional level, but also on the level of the individual hospital. 
For early stage NSCLC (stage I and II) surgical resection by (bi)lobectomy or pneumonectomy 
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is treatment of choice and for advanced stage NSCLC (stage III) a combined treatment with 
radiotherapy and chemotherapy (sequentially or concurrent) is the advised treatment.
After adequate staging, the best chances for survival in early stage NSCLC are obtained by 
surgical resection. Despite, our study showed marked differences in resection rates between 
individual hospitals and regions. Patients who were diagnosed in a (specialized) center, with 
a training status for thoracic/lung surgery, seem to have higher chances for resection. These 
results confirm the findings of a regional study from the Netherlands showing that patients 
diagnosed with stage I or II disease at specialized centers or higher volume hospitals are 
more likely to receive surgical therapy. These differences were seen in all age groups 
and led to a better survival of patients diagnosed in specialized centers than those that 
initially went to a community hospital 25. Our study confirms these observations, but we 
cannot exclude that selective referral of patients with a good performance status has taken 
place before their NSCLC was diagnosed. Moreover, variation was most prominent on the 
individual hospital level, with resection rates for early stage NSCLC varying between 55 and 
100%. Also among teaching hospitals and specialized centers a wide range of variation 
was exhibited, between 64 and 89% and 75 and 93% respectively. Considering the results 
of our study, the choice for a teaching hospital or specialized hospital does not guarantee 
better care and guideline compliance. 
In literature many reports have shown that resection rates and surgical outcome of patients 
with early stage NSCLC can be improved by treatment in experienced and specialized 
multidisciplinary teams 2;3;26;27. The combination of heightened awareness, more adequate 
staging, improved surgical skill and postoperative care might lead to better outcome. In this 
context, the inverse relationship between procedural volume and mortality has been studied 
extensively 24;28. In our study half of the resections for early stage NSCLC were performed in 
low volume hospitals with an annual volume less than 20. Mortality hardly differed between 
low- and high volume hospitals, but ranged from 1% in the younger (< 60 years) to 8% in 
the oldest group (> 75 years). Opposite to our findings in high volume hospitals, a lower 
mortality rate was found in the specialized centers (1%). This is remarkable, considering the 
higher resection rates we found in elderly patients diagnosed with stage I and II NSCLC 
in the same centers. Patient selection for operative treatment as well as peri-operative 
management of the older patient could thus be better in specialized centers. Future ‘in 
depth’ studies could reveal the aspects of these care processes (best practices) that lead to 
these better outcomes and can be used to improve the care for older NSCLC patients in the 
whole field. 
In contrast with the plethora of studies investigating the differences in surgical outcome, 
only a few studies have investigated institutional differences for non-surgical treatments. 
In stage III patients with a favorable performance status, a potentially curative treatment 
by a combination of radio- and chemotherapy is recommended. In our study the use of 
this chemoradiation increased for stage IIIa as well as for stage IIIb patients. Nevertheless, 
our study showed a wide variation in the use of chemoradiation between regions and 
individual hospitals (figure 3), without a clear explanation based on their (infra)structural 
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characteristics. For example, the use of chemoradiation was not different between hospitals 
with or without radiotherapy facilities. With the data available in the NCR, we can only 
suggest that differences in experience with the complex radiotherapy techniques and the 
nontrivial toxicity encountered in patients undergoing these treatments, is causing hospital 
variation in the use of chemoradiation.
Our study has several limitations. First, only a limited set of (infra)structural characteristics of 
hospitals was available. For example, during the study period PET-scanning was introduced 
gradually for the staging of NSCLC in the Netherlands from 2000 on14. Improved clinical 
staging in hospitals using PET-scans could have influenced outcome for different stages of 
the disease. The addition of PET to conventional workup can improve staging and prevents 
unnecessary surgery in one out of five patients with suspected non-small-cell lung cancer13. 
Though, in our study only a minor shift from early to advanced stages NSCLC was detected 
(Figure 1a), the differential introduction of PET-scanning in the Netherlands can be a 
confounding factor for the survival analyses performed.
Furthermore, data on comorbidities and performance status of patients diagnosed with 
NSCLC were not available in the NCR. Lung cancer is predominantly a disease of the 
elderly. Physician treatment decisions can be guided by a patients’ age and general medical 
condition, in all stages of the disease29;30. On the other hand, in the Dutch setting there are 
no indications that patient groups of individual hospitals are truly different. Nevertheless, 
remarkable variation in resection rates (stage I-II) and the use of combined modality 
treatment (stage III) was shown. These differences are relevant, because they led to 
differences in survival, as was shown for stage I-II patients diagnosed in groups of hospitals 
with low- and high resection rates. 
In conclusion, treatment patterns and outcome of NSCLC patients vary by region and the 
hospital their cancer is diagnosed in. Though, resection rates are higher in hospitals training 
thoracic surgeons, variation between individual hospitals is much more distinct. Hospital 
characteristics like a high diagnostic volume, teaching status or availability of radiotherapy 
facilities proved no guarantee for optimal treatment compliance. Therefore, initiatives to 
improve quality of care for NSCLC patients should focus on actual differences in treatment 
patterns and outcome between hospitals, instead of using hospital characteristics as proxies 
for high quality of care. In addition, ‘in depth’ prospective documentation studies or clinical 
audits could reveal high leverage processes of care that lead to the better outcomes. This 
information creates the opportunity to optimize treatment of NSCLC patients and move the 
medical field forward.      
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Aim of this study was to describe treatment patterns and outcome according to region, 
and according to hospital types and volumes among patients with colon cancer in the 
Netherlands.
Methods:
All patients with invasive colon carcinoma diagnosed in the period 2001-2006 were selected 
from the Netherlands Cancer Registry. Logistic regression analyses were performed to 
examine the influence of relevant factors on the odds of having adequate lymph node 
evaluation, receiving adjuvant chemotherapy and postoperative mortality. Relative survival 
analysis was used to estimate relative excess risk of dying according to hospital type and 
volume.
Results:
In total, 39 907 patients were selected. Patients diagnosed in a university hospital had a 
higher odds (OR 2.47; 95% CI 2.19-2.78) and patients diagnosed in a hospital with >100 colon 
carcinoma diagnoses annually had a lower odds (OR 0.70; 95% CI 0.64-0.77) of having ≥10 
lymph nodes evaluated. The odds of receiving adjuvant chemotherapy was lower in patients 
diagnosed in teaching hospitals (OR 0.85; 95% CI 0.73-0.98) and university hospitals (OR 
0.56; 95% CI 0.45-0.70) compared to patients diagnosed in non-teaching hospitals. Funnel 
plots showed large variation in these two outcome measures between individual hospitals. 
No differences in postoperative mortality were found between hospital types or volumes. 
Patients diagnosed in university hospitals and patients diagnosed in hospitals with >50 
diagnoses of colon carcinoma per year had a better survival. 
Conclusions:
Variation in treatment and outcome of patients with colon cancer in the Netherlands was 
revealed, with differences between hospital types and volumes. However, variation seemed 
mainly based on the level of the individual hospital. 
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INTRODUCTION
Ever since the Institute of Medicine reviewed variations in the quality of cancer care in 
their 1999 report1, there is an ongoing debate on this issue, not only in the United States, 
but also in European countries. Especially, the differences in surgical outcome of patients 
treated in high and low volume hospitals and between specialized and non-specialized 
providers, have been studied extensively.2-4 Most of these studies focus on adverse 
outcomes like complications and postoperative mortality; few describe differences in the 
proportion of patients getting optimal treatment for their cancer. 
In the Netherlands, colon cancer is one of the most frequent cancers with more than 7 500 
new diagnoses in 2007.5 It is also one of the most frequent causes of cancer death with 
more than 3 800 deaths in 2007.6 According to the current Dutch guideline, the primary 
treatment for colon cancer is surgery, while adjuvant chemotherapy should be considered 
for patients with lymph node metastasis. Therefore, adequate lymph node evaluation is 
important in patients with colon cancer;7-9 10 or more lymph nodes should be evaluated 
for accepting N0 status.10 However, regional population-based studies in the Netherlands 
showed large variation on the level of lymph nodes evaluated by pathologists and in the 
proportion of patients receiving adjuvant chemotherapy.11;12
Currently, colon cancer patients are treated in every hospital in the Netherlands. These 
patients are treated in different settings: university, teaching and non-teaching hospitals; 
high- and low-volume hospitals, situated in urbanized or more rural regions. It is unknown, 
to what extent these structural differences between hospitals lead to differences in 
patterns of care and outcome. A number of studies demonstrated better patient outcomes 
in teaching versus nonteaching hospitals.13-15 Others found lower mortality with increasing 
hospital or surgeon volume.16;17 However, studies on mortality among patients with colon 
cancer showed conflicting results: some demonstrated an association between mortality 
and hospital volume or teaching status, while others did not.18-24
Aim of this study was to describe variation in staging, treatment patterns and outcome 
according to region and, according to type and volume of individual hospitals among 
patients with colon cancer in the Netherlands.  
METHODS
Netherlands Cancer Registry
In the Netherlands, all newly diagnosed malignancies are registered in the nationwide 
population-based Netherlands Cancer Registry (NCR). The automated pathological archive 
(PALGA) and the Haematology Departments are the main sources of notification. The 
National Registry of Hospital Discharge Diagnosis is an additional source, which accounts 
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for up to 8% of new cases.25 Data are collected from the medical records by specially 
trained registrars and are coded according to a nationally used manual. Information on 
patient characteristics, tumor characteristics, treatment, hospital of diagnosis, hospital of 
treatment and follow-up is recorded. For coding tumor site and morphology the International 
Classification of Diseases for Oncology (ICD-O) is used.26 Cancers are staged according the 
TNM classification.27 Quality of the data is high28 and completeness is estimated to be at 
least 95%.29 
Patients
All patients with an invasive colon carcinoma, diagnosed in the period 2001-2006 were 
selected from the NCR. Diagnoses without histological confirmation, diagnoses based only 
on autopsy findings, patients living abroad and incomplete records were excluded from 
analyses. Tumor site was classified as ascendens (C18.0-C18.2), transversum and descendens 
(C18.3-C18.6), sigmoid (C18.7) and overlapping/unknown (C18.8-C18.9). Pathological 
stage was used to classify the extent of the disease. In cases where pathological stage was 
unknown, clinical stage was used. 
CCC-regions and hospitals
The Netherlands are divided in 9 regions, each served by a Comprehensive Cancer 
Center (CCC). Activities of CCCs are facilitation of consultancy services, development and 
implementation of guidelines, improving organisation of cancer care, coordinating palliative 
care and the population-based cancer registry. Each CCC serves an area covering five to 
twenty hospitals. All hospitals are affiliated to one center. Within each CCC-region, treatment 
policies are discussed within multidisciplinary meetings which may lead to differences in 
oncologic care between the regions. Patients of all 97 hospitals in the Netherlands were 
included in the analyses. 
A teaching hospital was defined as a hospital which provides medical training to residents. 
A distinction was made between a teaching hospital for surgery and a teaching hospital for 
internal medicine. All teaching hospitals for surgery were also teaching hospitals for internal 
medicine. University hospitals were teaching hospitals affiliated to a medical university. The 
one specialized oncology center in the Netherlands was also classified as a university hospital. 
Hospital volume was based on the mean number of diagnoses of colon carcinoma per year or 
on the mean number of colon resections for cancer per year. In the Netherlands, resections 
for colon cancer are in general performed in the hospital of diagnosis. Hospital volume was 
categorized into <50 , 50-100 and >100 diagnoses/resections per year. 
For the analyses of treatment and relative survival, type of hospital was based on the hospital 
where the tumor was diagnosed reasoning that referral of patients for treatment in another 
hospital can also be considered as a good standard of care. For the analyses of postoperative 
mortality, type of hospital was based on the hospital where the surgery was performed.
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Statistical analyses
Treatment was described as percentages per stage and age group (<75 years and ≥75 years). 
Variation in lymph node evaluation and adjuvant chemotherapy
Logistic regression analysis was performed to examine the influence of age at diagnosis, 
gender, depth of invasion, nodal involvement, type of hospital of diagnosis, hospital volume, 
CCC-region and year of diagnosis on the odds of having an adequate lymph node evaluation 
(defined as ≥10 or more evaluated lymph nodes). Patients whose tumor was removed by 
polypectomy and patients with distant metastasis (M1) were excluded from this analysis. 
Moreover, the influence of age at diagnosis, gender, type of hospital of diagnosis, hospital 
volume, CCC-region and year of diagnosis on the odds of receiving adjuvant chemotherapy 
in patients with stage III disease colon cancer was analyzed using logistic regression analysis. 
To compare the performance of the individual hospitals for these two outcome measures, 
funnel plots were made using 95% control limits calculated around the mean of the 20% 
best performing hospitals.30;31 The proportion of resections involving 10 or more evaluated 
lymph nodes was adjusted for age, gender, depth of invasion (pT) and nodal involvement 
(pN). The proportion of resected patients receiving adjuvant chemotherapy was adjusted for 
age and gender. Each hospital was displayed as a scatter point presenting the adjusted rate 
for the outcome and the hospital volume.
Variation in postoperative mortality
Logistic regression analysis was used to investigate the odds of postoperative mortality by 
age at diagnosis, gender, depth of invasion, type of hospital of surgery, resection volume of 
hospital of surgery and CCC-region. Postoperative mortality was defined as death within 30 
days after surgery. Patients with distant metastasis (M1) and acute surgery (date of surgery 
= date of first pathological examination) were excluded from this analysis. Postoperative 
mortality was analysed for tumors diagnosed in 2005 and 2006, because date of surgery 
was not registered in the NCR until 2005.
Variation in survival
Relative excess risks (RER) of dying according to hospital type and volume were estimated 
by means of multivariate relative survival analyses. Relative survival, an estimation of disease-
specific survival, was calculated as the ratio of the observed rates in cancer patients to 
the expected rates in the general population using the Ederer method.32 Results of the 
multivariate relative survival analyses were stratified by pathological stage of the tumor, 
because interaction was found between stage and hospital type. Length of follow-up was 
calculated as the time from diagnosis to death or to 1st January 2008. Only first tumors 
were included in the multivariate relative survival analyses. 
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Table 1. Description of study population (N=39 907)
N %
Gender
  Male 19 882 49.8
  Female 20 025 50.2
Age at diagnosis
  < 60 7 269 18.2
  60-74 16 553 41.5
  75+ 16 085 40.3
Year of diagnosis
  2001 6 016 15.1
  2002 6 127 15.4
  2003 6 487 16.3
  2004 6 840 17.1
  2005 7 077 17.7
  2006 7 360 18.4
Tumor location
  Ascendens 14 434 36.2
  Transversum and descendens 9 318 23.4
  Sigmoid 15 091 37.8
  Overlapping/Unknown 1 064 2.7
Pathological stage
  I 6 209 15.6
  II 13 812 34.6
  III 10 024 25.1
  IV 8 662 21.7
  Unknown 1 200 3.0
Teaching hospital surgery
  No 16 808 42.1
  Yes 20 651 51.8
  University hospital 2 448 6.1
Teaching hospital internal medicine
  No 12 231 30.7
  Yes 25 228 63.2
  University hospital 2 448 6.1
Annual volume of hospital of diagnosis
  <50 diagnoses colon carcinoma 7 484 18.8
  50-100 diagnoses colon carcinoma 19 816 49.7
  >100 diagnoses colon carcinoma 12 607 31.6
Comprehensive Cancer Center region
  1 6 900 17.3
  2 5 496 13.8
  3 3 529 8.8
  4 2 930 7.3
  5 4 044 10.1
  6 5 632 14.1
  7 5 651 14.2
  8 2 485 6.2
  9 3 240 8.1
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STATA (version 10.0) was used for the analyses. A p-value below 0.05 was considered 
statistically significant. 
RESULTS
In the period 2001-2006 39 907 patients were newly diagnosed with colon carcinoma in 
the Netherlands, with an annual increase from 6 016 in 2001 to 7 360 in 2006. The male/
female ratio was 1:1 and 40% of the patients was aged 75 years or older. Most frequent 
were stage II tumors (35%). Stage was unknown for 3% of the patients. Six percent of the 
patients were diagnosed in a university hospital and half of the patients were diagnosed in 
a hospital with 50 to 100 diagnoses per year (Table 1). 
Treatment
Almost all patients with stages I-III disease underwent surgical resection. Around 10% of 
the stage I tumors were removed by endoscopic polypectomy. Of the patients younger than 
75 years with stage III disease 76% received adjuvant chemotherapy. Among patients 75 
years and older this proportion was 17%. Around 60% of patients with stage IV disease 
underwent surgical resection of the primary tumor. The surgery of the primary tumor was 
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Figure 1. Treatment according to stage and age at diagnosis
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of the patients 75 years and older. The proportion of patients with stage IV who did not 
receive any treatment was 15% among patients younger than 75 years and 37% among 
patients 75 years and older (Figure 1).   




  Male 1.00 Reference
  Female 1.14* 1.08-1.20
Age at diagnosis
  < 60 years 1.00 Reference
  60-74 years 0.74* 0.69-0.79
  ≥ 75 years 0.54* 0.50-0.58
Year of diagnosis
  2001 1.00 Reference
  2002 1.16* 1.06-1.28
  2003 1.30* 1.18-1.43
  2004 1.61* 1.47-1.77
  2005 2.57* 2.34-2.81
  2006 3.29* 3.00-3.60
Depth of invasion
  pT1 1.00 Reference
  pT2 3.06* 2.64-3.55
  pT3 5.02* 4.38-5.76
  pT4 4.62* 3.97-5.38
Nodal involvement
  pN0 1.00 Reference
  pN+ 1.27* 1.20-1.34
Hospital of diagnosis
  Non-teaching hospital 1.00 Reference
  Teaching hospital for surgery 1.04 0.97-1.11
  University hospital 2.47* 2.19-2.78
Annual volume of hospital of diagnosis
  <50 resections colon carcinoma 1.00 Reference
  50-100 resections colon carcinoma 0.97 0.91-1.04
  >100 resections colon carcinoma 0.70* 0.64-0.77
Comprehensive Cancer Center region
  1 1.00 Reference
  2 1.22* 1.11-1.34
  3 1.32* 1.19-1.47
  4 1.38* 1.24-1.55
  5 1.19* 1.08-1.32
  6 0.92 0.84-1.01
  7 0.70* 0.64-0.78
  8 0.85* 0.75-0.97
  9 1.28* 1.15-1.42
* p<0.05
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Lymph node evaluation
The proportion of patients with 10 or more evaluated lymph nodes after resection increased 
from 31% in 2001 to 58% in 2006, with an odds ratio of 3.29 (95% CI 3.00-3.60) in 2006 
compared to 2001. Female patients were more likely to have had 10 or more lymph nodes 
evaluated after resection. The odds ratio decreased with older age at diagnosis. The odds 
of having an adequate lymph node evaluation increased by year of diagnosis, up to 3.29 
(95% CI 3.00-3.60) in 2006 compared to 2001. Patients with a larger depth of invasion and 
with nodal involvement were more likely to have had 10 or more lymph nodes evaluated. 
Patients diagnosed in a university hospital were more likely to have an adequate lymph node 
evaluation (OR 2.47; 95% CI 2.19-2.78). Patients diagnosed in a hospital with more than 100 
resections per year were less likely to have an adequate lymph node evaluation (OR 0.70; 
95% CI 0.64-0.77). There was variation between CCC-regions in the odds of having 10 or 
more lymph nodes evaluated (Table 2). In the funnel plot, the adjusted proportion of patients 
with 10 or more evaluated lymph nodes is depicted for each hospital by mean number of 
colon resections per year, showing a large variation between the individual hospitals (Figure 
2). The proportion of patients with an adequate lymph node evaluation ranged from more 
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Figure 2. Funnel plot of proportion of patients of whom 10 or more lymph nodes were evaluated after 




In table 3 the odds of receiving adjuvant chemotherapy in patients with stage III tumors 
are shown. The use of adjuvant chemotherapy in patients with stage III tumors increased 
from 49% in 2001 to 58% in 2006, with an odds ratio of 1.66 (95% CI 1.40-1.97) in 2006 
compared to 2001. Female patients had a lower odds of receiving adjuvant chemotherapy 
(OR 0.88; 95% CI 0.80-0.98). The odds of receiving adjuvant chemotherapy decreased with 
increasing age, with an odds ratio of 0.03 (95% CI 0.03-0.04) in patients 75 years and 
older compared to those younger than 60 years. Patients diagnosed in a teaching hospital 
for internal medicine or in a university hospital had a lower odds of receiving adjuvant 
chemotherapy, compared to patients diagnosed in a non-teaching hospital. No significant 




  Male 1.00 Reference
  Female 0.88* 0.80-0.98
Age at diagnosis
  < 60 years 1.00 Reference
  60-74 years 0.40* 0.34-0.46
  ≥ 75 years 0.03* 0.03-0.04
Year of diagnosis
  2001 1.00 Reference
  2002 1.05 0.88-1.25
  2003 1.22* 1.02-1.46
  2004 1.34* 1.13-1.59
  2005 1.44* 1.21-1.71
  2006 1.66* 1.40-1.97
Hospital of diagnosis
  Non-teaching hospital 1.00 Reference
  Teaching hospital for internal medicine 0.85* 0.73-0.98
  University hospital 0.56* 0.45-0.70
Annual volume of hospital of diagnosis
  <50 diagnoses colon carcinoma 1.00 Reference
  50-100 diagnoses colon carcinoma 1.04 0.89-1.22
  >100 diagnoses colon carcinoma 0.91 0.74-1.11
Comprehensive Cancer Center region
  1 1.00 Reference
  2 0.84 0.70-1.02
  3 0.73* 0.59-0.90
  4 0.86 0.69-1.07
  5 0.76* 0.63-0.93
  6 0.98 0.82-1.18
  7 0.88 0.73-1.06
  8 1.66* 1.29-2.12
  9 0.84 0.68-1.05
* p<0.05
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difference in adjuvant chemotherapy administration between hospitals with different 
volumes was found. The administration of adjuvant chemotherapy differed between 
CCC-regions. However, there was also a wide variation between hospitals within the regions 
(data not shown). The funnel plot shows, for each hospital, the adjusted proportion of 
patients younger than 75 years with stage III disease receiving adjuvant chemotherapy by 
mean number of diagnoses per year, demonstrating some variation between the hospitals 
(Figure 3). The proportion of patients who received adjuvant chemotherapy varied from less 
than 50% to more than 90% for individual hospitals.
Postoperative mortality
Overall, 4.2% of the patients without distant metastasis at diagnosis undergoing an elective 
resection died within 30 days after surgery. Female patients had a lower odds of dying 
within 30 days after resection (OR 0.74; 95% CI 0.58-0.93). The odds of dying within 30 days 
increased with increasing age, up to 11.61 (95% CI 6.13-21.98) for patients aged 75 years 
and older compared to those younger than 60 years. The odds was higher for T4-tumors 
compared with T1-T3 tumors (OR 1.87; 95% CI 1.37-2.56). No differences in postoperative 
mortality were found between hospital types, hospital volumes and CCC-regions (Table 4). 
Figure 3. Funnel plot of proportion of patients receiving adjuvant chemotherapy in patients <75 years with 
stage III disease receiving adjuvant chemotherapy in the period 2001-2006 according hospital type and mean 
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Multivariate relative excess risks (RER) of dying
In the multivariate model for all patients with colon cancer, patients diagnosed in a university 
hospital had a lower risk of dying compared to patients diagnosed in a non-teaching hospital 
(RER 0.76; 95% CI 0.69-0.83). Patients diagnosed in hospitals with 50-100 diagnoses colon 
carcinoma per year and with more than 100 diagnoses colon carcinoma yearly had a lower 
risk of dying compared to patients diagnosed in a hospital with less than 50 diagnoses 
colon carcinoma yearly (RER 0.90; 95% CI 0.85-0.95 and RER 0.86; 95% CI 0.80-0.93, 
respectively). 
For stage I, survival was worse in patients diagnosed in a university hospital (RER 1.87; 
95% CI 1.02-3.42). No differences in survival of patients with stage II disease were found 
between hospital types or between hospital volumes. Both among patients with stage III 
disease and among patients with stage IV disease, patients diagnosed in a university hospital 




  Male 1.00 Reference
  Female 0.74* 0.58-0.93
Age at diagnosis
   < 60 years 1.00 Reference
  60-74 years 2.55* 1.30-5.00
  ≥ 75 years 11.61* 6.13-21.98
Depth of invasion
  T1-T2-T3 1.00 Reference
  T4 1.87* 1.37-2.56
  Unknown 1.58 0.37-6.81
Hospital of surgery
  Non-teaching hospital 1.00 Reference
  Teaching hospital for surgery 0.95 0.71-1.28
  University hospital 1.06 0.63-1.80
Annual volume of hospital of surgery
  <50 resections colon carcinoma 1.00 Reference
  50-100 resections colon carcinoma 1.33 0.93-1.88
  >100 resections colon carcinoma 1.23 0.77-1.98
Comprehensive Cancer Center region
  1 1.00 Reference
  2 0.69 0.44-1.08
  3 0.84 0.51-1.38
  4 0.95 0.58-1.57
  5 0.95 0.61-1.47
  6 0.83 0.54-1.27
  7 1.07 0.71-1.63
  8 0.61 0.32-1.16
  9 0.83 0.50-1.38
* p <0.05
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had a lower risk of dying compared to patients diagnosed in a non-teaching hospital (RER 
0.70; 95% CI 0.57-0.87 and RER 0.77; 95% CI 0.69-0.86, respectively). For stage IV, patients 
diagnosed in hospitals with 50-100 diagnoses colon carcinoma yearly and more than 100 
diagnoses colon carcinoma yearly had a better survival (RER 0.88; 95% CI 0.82-0.95 and RER 
0.85; 95% CI 0.77-0.94, respectively) (Table 5). 
DISCUSSION
In this nationwide population-based study, analyzing Netherlands Cancer Registry data of 
39 907 patients with colon carcinoma diagnosed in the period 2001-2006, considerable 
variation in treatment patterns and outcome was identified. The proportion of patients 
receiving optimal postoperative staging with adequate lymph node evaluation and accurate 
treatment for their cancer increased considerably over time, but differed widely between 
individual hospitals. 
Being diagnosed in a hospital with a large patient volume or in a university hospital was 
positively related with the odds of having an adequate lymph node evaluation, and being 
diagnosed in a teaching hospital or in a university hospital had a negative relation with 
the odds of receiving adjuvant chemotherapy. Differences in relative survival were found 
between the various types and volumes of hospitals. In total, patients diagnosed in a 
university hospital or patients diagnosed in a hospital with a large volume had a better 
survival. 
In literature, the number of studies evaluating differences in quality of care between various 
types of providers is overwhelming. Most studies show an inverse relationship between 
hospital volume and mortality, especially for high risk surgical procedures.2;16;17 However, 
few studies have focused on other dimensions of quality of care besides differences in 
morbidity and mortality after surgery. In our study two important aspects of high leverage 
colon cancer treatment were investigated, lymph node evaluation and the administration 
of adjuvant chemotherapy. The choice for these specific process measures is supported by 
evidence from literature.9;33
Lymph node evaluation 
Lymph node evaluation is crucial for staging and planning treatment in patients with colon 
cancer. Since adjuvant chemotherapy should be considered for patients with positive 
lymph nodes, inadequate lymph node examination might lead to understaging and 
undertreatment.7;8 On the other hand, according to Dutch treatment guidelines, adjuvant 
chemotherapy should be considered for patients with stage II disease who had less than 
10 evaluated lymph nodes, which could lead to overtreatment.10 In our study we found 
that patients diagnosed in a university hospital were more likely to have more lymph nodes 
examined. This confirms the results of earlier studies from Canada and France.34;35 The 
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available resources in university hospitals to provide high quality multidisciplinary cancer 
care could be an explanation for this result. Other studies found a positive correlation 
between hospital volume and number of evaluated lymph nodes.36;37 The current study, 
however, found an inverse relationship and showed that patients diagnosed in high-volume 
hospitals were less likely to have 10 or more lymph nodes examined. This suggests that an 
increased workload for pathology staff might lead to a less extensive lymph node evaluation, 
although a high-volume hospital not necessarily has to be served by a high-volume 
pathology laboratory. Furthermore, the workload per pathologist depends on the number 
of pathologists in a staff. Unfortunately, data on individual pathologists was not available 
in the NCR. However, the differences found between individual hospitals are remarkable. 
Adjuvant chemotherapy
Ever since a randomized trial in the early nineties showed that patients with stage III colon 
carcinoma treated with adjuvant chemotherapy had a significant survival benefit33], 
chemotherapy after surgery has been the standard of care for stage III patients with 
an adequate performance status.10 However, not all patients with stage III disease 
receive adjuvant chemotherapy.12 There are several explanations why elderly patients 
receive adjuvant chemotherapy less often than younger patients, such as the presence 
of comorbidities, unfavourable performance status or patient refusal.38-40 Our study is 
hampered by the lack of information about comorbidities and performance status of the 
patient at time of diagnosis. Nevertheless marked differences in performance status of 
patients between hospitals in the Netherlands have not been reported.
University hospitals and teaching hospitals proved more restraint in the use of adjuvant 
chemotherapy compared to general hospitals. A French regional study showed the opposite: 
a lower relative risk for receiving adjuvant chemotherapy in patients treated in non-teaching 
hospitals compared to a single university center.34 An American study demonstrated that 
Table 5. Relative excess risks (RER) of dying for patients with colon cancer diagnosed in the period 2001-2006, 
according to stage (multivariate relative survival analysis)
Total1 Stage I2 Stage II2 Stage III3 Stage IV4
RER 95 % CI RER 95 % CI RER 95 % CI RER 95 % CI RER 95 % CI
Type of hospital of diagnosis
  Non-teaching hospital 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  Teaching hospital surgery 1.03 0.98-1.09 1.11 0.70-1.76 1.14 0.99-1.31 0.96 0.86-1.07 1.05 0.98-1.12
  University hospital 0.76* 0.69-0.83 1.87* 1.02-3.42 0.74 0.54-1.00 0.70* 0.57-0.87 0.77* 0.69-0.86
Annual volume of hospital of diagnosis
  <50 diagnoses colon carcinoma 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  50-100 diagnoses colon carcinoma 0.90* 0.85-0.95 0.92 0.56-1.51 0.98 0.83-1.16 0.90 0.80-1.02 0.88* 0.82-0.95
  >100 diagnoses colon carcinoma 0.86* 0.80-0.93 0.84 0.44-1.61 0.87 0.70-1.07 0.88 0.75-1.03 0.85* 0.77-0.94
1 Adjusted for gender, age at diagnosis, grade, year of diagnosis, tumor location, stage, surgery, 
chemotherapy and CCC-region
2 Adjusted for gender, age at diagnosis, grade, year of diagnosis, tumor location, depth of invasion, surgery 
and CCC-region, * p<0.05
3 Adjusted for gender, age at diagnosis, grade, year of diagnosis, tumor location, depth of invasion, surgery, 
chemotherapy, number of positive nodes and CCC-region
4 Adjusted for gender, age at diagnosis, grade, year of diagnosis, tumor location, depth of invasion, surgery, 
chemotherapy and CCC-region
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patients treated by surgeons practicing in a teaching hospital were more likely to see a 
medical oncologist.41 Our contrasting findings suggest a more severe selection of patients 
for administering adjuvant chemotherapy in university hospitals. 
Postoperative mortality
In our study, age was an important predictor for postoperative mortality. According to a 
review of the Colorectal Cancer Collaborative Group, the increased proportion of elderly 
patients undergoing emergency surgery, together with multiple co morbidities, could 
contribute to this increased risk of postoperative mortality.42 However, in our study 
only elective procedures were included, with a very high risk of postoperative mortality 
in the elderly patient group compared to the younger patient group. Elderly patients 
undergoing major surgery can have similar outcomes as younger patients if carefully 
selected.42;43However, the risk of obstruction or even perforation in colon cancer patients 
forces surgeons to perform surgery in elderly patients with an unfavourable physical status. 
Apparently, colon resections in elderly people are high risk procedures, in which specific 
experience and expertise is needed. 
Nevertheless, no association between postoperative mortality and the volume or teaching 
status of hospitals was found in our study. This confirms the results of earlier Dutch and 
Canadian studies, in which no association between type or volume of hospitals and 
postoperative mortality was found.18;44 For other high-risk operations, like pancreatic or 
esophageal resections, clear differences between low- and high-volume hospitals were 
demonstrated, also in the Netherlands.2;3;45 Due to the high incidence of colon carcinoma, 
hospital volumes are substantially higher than the hospital volume of, for example, pancreas 
or esophageal cancer, which might explain our results. Nevertheless, despite the lack of 
an inverse relationship between hospital volume and postoperative mortality, our study 
Table 5. Relative excess risks (RER) of dying for patients with colon cancer diagnosed in the period 2001-2006, 
according to stage (multivariate relative survival analysis)
Total1 Stage I2 Stage II2 Stage III3 Stage IV4
RER 95 % CI RER 95 % CI RER 95 % CI RER 95 % CI RER 95 % CI
Type of hospital of diagnosis
  Non-teaching hospital 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  Teaching hospital surgery 1.03 0.98-1.09 1.11 0.70-1.76 1.14 0.99-1.31 0.96 0.86-1.07 1.05 0.98-1.12
  University hospital 0.76* 0.69-0.83 1.87* 1.02-3.42 0.74 0.54-1.00 0.70* 0.57-0.87 0.77* 0.69-0.86
Annual volume of hospital of diagnosis
  <50 diagnoses colon carcinoma 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
  50-100 diagnoses colon carcinoma 0.90* 0.85-0.95 0.92 0.56-1.51 0.98 0.83-1.16 0.90 0.80-1.02 0.88* 0.82-0.95
  >100 diagnoses colon carcinoma 0.86* 0.80-0.93 0.84 0.44-1.61 0.87 0.70-1.07 0.88 0.75-1.03 0.85* 0.77-0.94
1 Adjusted for gender, age at diagnosis, grade, year of diagnosis, tumor location, stage, surgery, 
chemotherapy and CCC-region
2 Adjusted for gender, age at diagnosis, grade, year of diagnosis, tumor location, depth of invasion, surgery 
and CCC-region, * p<0.05
3 Adjusted for gender, age at diagnosis, grade, year of diagnosis, tumor location, depth of invasion, surgery, 
chemotherapy, number of positive nodes and CCC-region




identified important differences in quality of care between hospitals in the Netherlands, as 
shown above. 
Survival
Some consider survival as the most important performance indicator for cancer treatments. 
Process measures, like the number of lymph nodes evaluated and the use of adjuvant 
chemotherapy investigated in the current study, are futile, when a relationship with direct 
outcome measures, like survival, is lacking. Survival was analyzed in the present study and 
significant differences between hospital types and volumes were found. Survival of patients 
diagnosed in university hospitals was better than in other hospitals, especially those with a 
high volume of colon cancer diagnoses. This finding does not parallel the restrained use of 
adjuvant chemotherapy in stage III patients diagnosed in these university hospitals, although 
it could be related to a better patient selection for adjuvant chemotherapy. Furthermore, 
one might speculate about a more aggressive and multidisciplinary approach in case of 
recurrence. Unfortunately, information on incidence and treatment of recurrences is lacking 
in the Netherlands Cancer Registry. The relatively low survival of patients diagnosed in low 
volume hospitals was reported before by a nested cohort study form the US.46 Another 
American population-based study found an association between both surgeon and hospital 
volume and outcome, but hospital volume had a stronger effect.47
Comparing quality of care between hospitals on the basis of structural characteristics 
like volume and teaching status might have important disadvantages. Investigating 
acknowledged measures of quality of care, our study shows that variation was largest on 
the level of the individual hospital. Characterisations of hospitals by, for instance, volume, do 
not necessarily correspond with quality of care and do not reveal the differences in patterns 
of care that lead to poor or better outcomes. The advantage of direct measurement of the 
care process and its outcome, is the possibility to feed this information back to individual 
hospitals. Several studies have stressed the beneficial effects of quality assurance and 
outcome analysis in the evaluation of the quality of cancer care. 
In conclusion, we found variation in treatment and outcome of patients diagnosed with 
colon cancer in the Netherlands, with differences based on hospital types and volumes. 
However, variation in quality of care seemed mainly determined on the level of the individual 
hospital. 
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High hospital volume is associated with better outcomes after esophagectomy and 
gastrectomy. In the Netherlands, a minimal volume standard of 10 esophagectomies per 
year was introduced in 2006.  For gastrectomy, no minimal volume standard was set. Aims 
of this study were to describe changes in hospital volumes, mortality and survival, and to 
explore if high hospital volume is associated with better outcomes after esophagectomy and 
gastrectomy in the Netherlands.
Methods:
From 1989-2009, 24,246 patients underwent esophagectomy (N=10,025) or gastrectomy 
(N=14,221) in the Netherlands. Annual hospital volumes were defined as very low (1-5), low 
(6-10), medium (11-20), and high (≥21). Volume-outcome analyses were performed using 
Cox regression, adjusting for year of diagnosis, case-mix, and the use of multi-modality 
treatment.
Results:
From 1989-2009, the percentage of patients treated in high-volume hospitals increased 
for esophagectomy (from 7% to 64%), but decreased for gastrectomy (from 8% to 5%). 
Six-month mortality (from 15% to 7%) and thee-year survival (from 41% to 52%) improved 
after esophagectomy, and to a lesser extent after gastrectomy (six-month mortality: 
15%-10%, three-year survival: 55-58%). High hospital volume was associated with lower 
6-month mortality (HR 0.48, P < 0.001) and longer 3-year survival (HR 0.77, P < 0.001) after 
esophagectomy, but not after gastrectomy. 
Conclusion:
Esophagectomy was effectively centralized in the Netherlands, improving mortality and 
survival. Gastrectomies were mainly performed in low volumes, and outcomes after 
gastrectomy improved to a lesser extent, indicating an urgent need for improvement in 
quality of surgery and perioperative care for gastric cancer in the Netherlands. 
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INTRODUCTION
Esophageal and gastric cancer are highly lethal malignancies.1 Despite surgery, which is the 
cornerstone of curative treatment for these diseases, survival is low, and compared to other 
surgical procedures, postoperative mortality is high. In the Western world, 5-year survival 
rates are below 25% for esophageal cancer,2,3 and do not exceed 40% for gastric cancer.2,4 
Reported postoperative mortality after esophagectomy varies from 2% for specialized 
centers5 to 10% for certain nationwide registries6. After gastrectomy, postoperative 
mortality varies between 3% to well above 10%.7,8 To reduce mortality and improve 
survival, it has been suggested that these high-risk operations should be performed in 
specialized centers with adequate annual volumes. Many studies have investigated volume-
outcome relations after esophagectomy and gastrectomy, but the relative importance of 
volume after gastrectomy in particular is disputed.9,10 
In the Netherlands, a relation between high hospital volume and low postoperative 
mortality was demonstrated for esophagectomy in 2000.11 Despite extensive discussions 
within the Association of Surgeons in the Netherlands, this study did not lead to significant 
changes in referral patterns for esophagectomies on a national level. Therefore, as of 2006 
a minimum volume of 10 esophagectomies per year was enforced by the Dutch Healthcare 
Inspectorate, and as of 2011 the Association of Surgeons in the Netherlands recommends 
a minimal volume of 20 esophagectomies per year. For gastrectomy, no minimum volume 
standard has been established in the Netherlands.
Aims of the present study were to describe changes in annual hospital volumes, postoperative 
mortality, survival, and lymph node yields for esophagectomy and gastrectomy in the 
Netherlands between 1989 and 2009, and to explore whether there is any association 
between annual hospital volume for esophagectomy and gastrectomy, and postoperative 
mortality, survival, and lymph node yield.
METHODS
The Netherlands Cancer Registry
Data were obtained from the Netherlands Cancer Registry (NCR), which covers all hospitals 
in the Netherlands, a country of 16.5 million inhabitants. Information on all newly 
diagnosed malignancies is routinely collected by trained registrars from the hospital records 
6-18 months after diagnosis. Quality and completeness of the data is high.12 
Topography and morphology were coded according to the International Classification of 
Diseases for Oncology (ICD-O).13 ICD-O morphology codes were used to classify tumors 
as adenocarcinoma (8140-8145, 8190, 8201-8211, 8243, 8255-8401, 8453-8520, 8572, 
8573, 8576), squamous cell carcinoma (SCC) (8032, 8033, 8051-8074, 8076-8123) and 
other or unknown histology (8000-8022, 8041-8046, 8075, 8147, 8153, 8200, 8230-8242, 
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8244-8249, 8430, 8530, 8560, 8570, 8574, 8575). Tumors were staged according to the 
International Union Against Cancer (UICC) TNM classification in use in the year of diagnosis. 
Vital status was initially obtained from municipal registries, and from 1994 onwards from 
the nationwide population registries network. These registries provide complete coverage 
of all deceased Dutch citizens. Follow-up was complete for all patients until December 31st, 
2009. The study was approved by the NCR Review Board.
Patients
Between January 1989 and December 2009, 71,090 patients with esophageal or gastric 
cancer were diagnosed in the Netherlands (Figure 1). Patients who did not undergo surgical 
treatment (N = 43,646) and patients without information on the hospital were the diagnosis 
was established, or where surgery was performed (N = 8), were excluded, leaving 27,436 
resections available to calculate annual hospital volumes. After establishing annual hospital 
volumes, patients with in-situ carcinoma (N = 288), and patients with distant metastases 
(N = 2902) were excluded, leaving 24,246 patients with non-metastatic invasive carcinoma 
available for volume-outcome analyses. 
Surgery
Since the NCR is a topography-based registry, and the type of surgery was not specified for 
every patient, the distinction between esophageal and gastric cancer surgery was based on 
tumor location. Esophagectomies were defined as resections for cancers of the esophagus 
Netherlands Cancer Registry 1989 - 2009  
Diagnosis of esophageal or gastric cancer   
N = 71,090  
 
Excluded (N = 8)  
No hospital in registry  
 
Resection for esophageal or gastric cancer  
N = 27,436  
Excluded (N = 3,190)  
In- situ/metastatic disease  
Resection for M0   
esophageal or gastric cancer  
N = 24,246 
Excluded (N = 43,646)  
No Resection  
Calculation of





Figure 1. Study profile.
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(C15.0-15.9) and gastric cardia (C16.0), whereas gastrectomies were defined as resections 
for non-cardia gastric cancer (C16.1-16.9). To ensure this distinction did not influence the 
results, volume-outcome analyses were repeated with cardia cancer coded as gastric cancer. 
Yearly resection rates were calculated as the number of resections relative to the number of 
cancers diagnosed in a year.
Hospital volumes
Annual hospital volumes were defined as the number of esophagectomies or gastrectomies 
per hospital per year. Clinically relevant volume categories were defined as very low (1-5/
year), low (6-10/year), medium (11-20/year), and high (≥21/year). From 2005-2009, the 
hospital where surgery was performed was registered for all patients. Before 2005, the 
hospital were surgery was performed was only registered in 53% of the cases, and showed 
an 80% overlap with the hospital of diagnosis. For the remaining 47%, with an unknown 
surgical hospital, the hospital of diagnosis was used to calculate hospital volume.
Statistical analysis
Esophagectomy and gastrectomy were analyzed separately. Resection rates and hospital 
volumes over time were analyzed with the Chi-square test. Changes in six-month mortality 
and three-year survival were analyzed with stratified Cox regression, adjusted for sex, age, 
socio-economic status,14 stage, morphology, preoperative therapy use, and postoperative 
therapy use (only for three-year survival). Overall survival (OS) was calculated from the day of 
diagnosis until death, because the date of surgery was not available before 2005. Six-month 
OS was calculated unconditionally, while 3-year OS was calculated conditionally on surviving 
the first six months after diagnosis. Lymph node yields over time were adjusted for sex, age, 
stage, and morphology.
For volume-outcome analyses, the patient was considered the unit of analysis, with hospital 
volume as the exposure factor. Differences in survival estimates were calculated with Cox 
regression, stratified for hospital volume and adjusted for the factors used to analyze 
changes over time, and for clustering of deaths within hospitals.15 Differences in lymph 
node yields were analyzed with generalized estimated equations, adjusted for the factors 
used to analyze changes over time, and for clustering within hospitals. 
Besides analyzing hospital volume in categories, annual volume was analyzed as a linear 
variable. Analyses were performed with SPSS (version 17.0.2) and R (version 2.12.2).
RESULTS
Patient characteristics
Between 1989 and 2009, 24,246 patients with resectable, non-metastatic esophageal 
(N = 10,025) or gastric cancer (N = 14,221) underwent a resection in the Netherlands. 
Patient characteristics (Table 1 and 2) varied between the different volume categories. 
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For esophageal cancer, high-volume hospitals treated more patients with squamous 
cell carcinoma and more advanced tumor stages. For gastric cancer, patients treated in 
high-volume hospitals were older and had more advanced tumors. 
Hospital volumes over time
From 1989 to 2009, the annual number of esophagectomies doubled (from 352 to 723), 
and the annual number of gastrectomies steadily decreased (from 1107 to 495) (Figure 2a 
and b). 
The percentage of esophagectomies performed in high-volume hospitals increased from 7% 
to 64%, while the number of gastrectomies performed in high-volume hospitals decreased 
from 8% to 5%. 
Table 1. Patient characteristics for all surgically treated patients with non-metastatic invasive esophageal 
cancer in the Netherlands between 1989 and 2009 (N = 10,025)
VLV (1-5) LV (6-10) MV (11-20) HV (≥21) P
N % N % N % N %












































































































































































































VLV: Very Low Volume (1-5 resections/year) LV: Low Volume (6-10 resections/year), MV: Medium Volume 
(11-20 resections/year), HV: High Volume (≥21 resections/year). SES: Socio Economic Status, SCC: Squamous 
Cell Carcinoma, Preoperative/postoperative therapy: chemotherapy with/without radiotherapy. * T4N1-3M0 
and T1-4N3M0 gastric cancers were assigned stage IV in the 6th edition TNM-classification
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In 2009, 44 of the 92 hospitals (48%) in the Netherlands performed esophagectomies, and 
91 of the 92 hospitals performed gastrectomies.
Resection rates, mortality, survival and lymph node yields over the years
Resection rates slightly decreased for esophageal cancer (from 1989-2009: 31% - 29%, P < 
0.01), and strongly decreased for gastric cancer (56%-37%, P < 0.01). Adjusted six-month 
mortality after esophagectomy decreased from 14.8% in 1989 to 7.1% in 2009 (P < 0.001), 
while adjusted six-month mortality after gastrectomy decreased to a lesser extent: from 
15.2% in 1989 to 9.9% in 2009 (P < 0.001) (Figure 3a). Adjusted three-year conditional 
survival significantly increased after esophagectomy: from 41.0% in 1989 to 52.2% in 2009 
(P < 0.001). Adjusted three-year conditional survival after gastrectomy increased to a lesser 
Table 2. Patient characteristics for all surgically treated patients with non-metastatic invasive gastric cancer in 
the Netherlands between 1989 and 2009 (N = 14,221)
VLV (1-5) LV (6-10) MV (11-20) HV (≥21) P
N % N % N % N %



































































































































































































VLV: Very Low Volume (1-5 resections/year) LV: Low Volume (6-10 resections/year), MV: Medium Volume 
(11-20 resections/year), HV: High Volume (≥21 resections/year). SES: Socio Economic Status, Preoperative/
postoperative therapy: chemotherapy with/without radiotherapy. * T4N1-3M0 and T1-4N3M0 gastric cancers 















































Figure 2a. Number of esophagectomies per hospital volume category.
Figure 2b. Number of gastrectomies per hospital volume category.
extent: from 55.0% in 1989 to 58.4% in 2009 (P < 0.01) (Figure 3b). The improvement 
in six-month mortality and three-year survival over time was significantly stronger after 
esophagectomy, when compared to gastrectomy (both P < 0.01).
Mean lymph node yield after esophagectomy increased from 10.1 in 1999 to 16.2 in 2009 
(P < 0.001), and mean lymph node yield after gastrectomy increased from 8.1 in 1999 to 
12.4 in 2009 (P < 0.001).
Volume-outcome relations
Results from the multivariable analyses on volume-outcome relations are shown in Table 
3. After esophagectomy, medium and high volume hospitals were associated with lower 
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Figure 3a. 6-Month mortality 
for esophagectomy and 
gastrectomy, adjusted for sex, 
age, socio-economic status, 
stage, morphology, and use of 
preoperative therapy (1989-2009). 
Esophagectomy, HR 0.96 for each 
year, P < 0.001. Gastrectomy, HR 
0.98 for each year, P < 0.001. 
Difference between esophagectomy 
and gastrectomy: P = 0.003
Figure 3b. 3-Year survival rate 
conditional on surviving the first 
6 months for esophagectomy and 
gastrectomy, adjusted for sex, 
age, socio-economic status, stage, 
morphology, and use of preoperative 
and postoperative therapy 
(1989-2006). Esophagectomy, 
HR 0.97 for each year, P < 0.001. 
Gastrectomy, HR 0.99 for each 
year, P < 0.001. Difference between 
esophagectomy and gastrectomy: P 
< 0.001
Figure 3c. Median lymph node 
yield for esophagectomy and 
gastrectomy, adjusted for sex, age, 
stage and morphology (1999-2009). 
Esophagectomy: P < 0.001. 


































































Table 3. Volume-outcome relations for esophagectomy and gastrectomy (1989-2009). Mortality and survival 
were calculated with multivariable Cox regression, nodal yield was calculated with generalized estimated 
equations.
Esophagectomy Gastrectomy
6-month mortality 3-year survival* LN yield** 6-month mortality 3-year survival* LN yield**
HR 95% CI HR 95% CI OR 95% CI HR 95% CI HR 95% CI OR 95% CI
Hospital Volume
  Very Low (1-5/yr)
  Low (6-10/yr)
  Medium (11-20/yr)






















































































































































































































































































*conditional on surviving the first six months. **1999-2009. HR: Hazard Ratio, OR: Odds Ratio, SES: Socio 
Economic Status, SCC: Squamous Cell Carcinoma, CI: Confidence Interval, Bold: significant (P < 0.05)
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Table 3. Volume-outcome relations for esophagectomy and gastrectomy (1989-2009). Mortality and survival 
were calculated with multivariable Cox regression, nodal yield was calculated with generalized estimated 
equations.
Esophagectomy Gastrectomy
6-month mortality 3-year survival* LN yield** 6-month mortality 3-year survival* LN yield**
HR 95% CI HR 95% CI OR 95% CI HR 95% CI HR 95% CI OR 95% CI
Hospital Volume
  Very Low (1-5/yr)
  Low (6-10/yr)
  Medium (11-20/yr)






















































































































































































































































































*conditional on surviving the first six months. **1999-2009. HR: Hazard Ratio, OR: Odds Ratio, SES: Socio 
Economic Status, SCC: Squamous Cell Carcinoma, CI: Confidence Interval, Bold: significant (P < 0.05)
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six-month mortality and longer three-year conditional survival when compared to very-low 
volume hospitals (Figure 4). After gastrectomy, neither six-month mortality, or three-year 
conditional survival were associated with hospital volume category (Figure 5). High 
hospital volume was associated with high lymph node yield both after esophagectomy and 
gastrectomy.
When analyzing hospital volume as a linear covariate, volume-survival results remained the 
same. No changes in the results were found when volume-outcome relations were analyzed 
with surgery for cardia cancer coded as gastrectomy (data not shown).
Figure 4.  Volume-outcome relations for esophagectomy. a. Relation between volume and 6-month survival, 
adjusted for year of diagnosis, sex,  age, socio-economic status, stage, morphology, and preoperative therapy 
use. * P < 0.05 compared to Very Low Volume. b. Relation between volume and 3-year survival, conditional on 
surviving the first 6 months, adjusted for year of diagnosis, sex, age, socio-economic status, stage, morphology, 














20 High Volume* (≥21/yr)
Medium Volume* (11−20/yr)
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DISCUSSION
Over the study period, the number of esophagectomies performed in high volume hospitals 
considerably increased, while in 2009 most gastrectomies were performed in low volume 
hospitals. Both six-month mortality and three-year survival improved after esophagectomy, 
but to a lesser extent after gastrectomy. In the current dataset, a volume-survival relation 
was revealed for esophagectomy, but not for gastrectomy.
Since Luft et al. published the first study on volume-outcome relations for surgery,16 many 
studies have emerged investigating the effect of hospital and surgeons volume on short term 
and long term outcomes for a variety of diseases, including resections for esophageal and 














20 High Volume (≥21/yr)
Medium Volume (11−20/yr)
Low Volume (6−10/yr)























Very Low Volume (0−5/yr)
a
b
Figure 5. Volume-outcome relations for gastrectomy. a. Relation between volume and 6-month survival, 
adjusted for year of diagnosis, sex, age, socio-economic status, stage, morphology and preoperative therapy 
use. * P < 0.05 compared to Very Low Volume. b. Relation between volume and 3-year survival, conditional 
on surviving the first 6 months, adjusted for year of diagnosis, sex, age, socio-economic status, stage, 
morphology, and preoperative and postoperative therapy use. * P < 0.05 compared to Very Low Volume.
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and low postoperative mortality both for esophagectomy,17-20 and gastrectomy17,20-22, but 
other studies did not find an association23-25. In a meta-analysis exploring volume-outcome 
relations, high volume surgery was associated with lower postoperative mortality after both 
esophagectomy and gastrectomy.9 A limited number of studies investigate the relation 
between hospital volume and long-term survival after esophagectomy and gastrectomy, 
with conflicting results.7,24,26,27
Over the past two decades, the number of esophagectomies in the Netherlands has 
increased, corresponding with an increasing incidence of esophageal cancer.28 The 
decreasing incidence of gastric cancer explains the low number of gastrectomies currently 
performed in the Netherlands.29 Furthermore, the resection rate for gastric cancer dropped 
significantly, most likely the result of improved preoperative staging. Combined with the 
almost complete disappearance of surgery for reflux disease and ulcers, surgeons are 
decreasingly exposed to gastrectomies. This might partly be compensated by increasing 
volumes of bariatric surgery for obesity, but the surgical techniques used differ significantly.
In the current study, increasing hospital volume was associated with lower mortality 
and increased long-term survival after esophagectomy, but not after gastrectomy. This 
observation for gastrectomies might be explained by the low number of high-volume 
gastrectomies (2.5% of all gastrectomies in the current dataset), and the low threshold 
for what was considered high volume surgery. In other studies that did find an association 
between gastrectomy in high volumes and good outcomes, the lower limit of high-volume 
surgery varied from 20/year up to 264/year.17,27
The current study covers an extensive period of two decades of esophago-gastric cancer 
surgery in the Netherlands, and analyzes a significant population of about 25,000 patients. 
Unlike many of the large volume-outcome studies, the current study uses a clinical database 
with highly reliable data, providing complete coverage of all diagnosed cancers in the 
Netherlands. Furthermore, outcomes are case-mix adjusted, increasing reliability of the 
results.30 The absence of comorbidity in the current dataset was partly compensated by the 
use of SES, which can be considered a proxy for comorbidity.31
A potential bias when analyzing outcomes over a long period is that preoperative staging 
and (perioperative) care generally improve over time. For example, endoscopic ultrasound, 
multislice high resolution computed tomography, and PET computed tomography were 
introduced resulting in improvement of staging. Hospital volumes for esophagectomy 
significantly changed during the study period, with most high-volume resections performed 
in the more recent years. Therefore, high volume resections are intrinsically associated 
with better outcomes. However, adjusting for year of diagnosis offsets this effect. Another 
potential weakness is the unavailability of the surgery hospital for part of the patients treated 
before 2005. Instead, the hospital of diagnosis was used. However, this only happened 
in the first years of the study, when hospitals less frequently referred patients to another 
hospital for surgery. 
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A point of discussion might be that volumes are analyzed on hospital level, rather than 
surgeon level.27,32,33 Quality of care, however, consists of more than an individual surgeon’s 
performance. Perioperative care, anesthesia, ICU staffing, experience of the nursery staff, 
and collaboration between different disciplines all contribute to outcomes associated with 
the performed procedure.34 The role of the surgeon is only one, yet important, factor 
contributing to outcome.
Initiatives to improve medical and especially surgical care are legion. Randomized trials 
improve care by selecting appropriate treatments for certain indications,3,35 and by educating 
surgeons participating in the trial.36,37 However, the majority of cancer patients are treated 
outside trials, and especially improvements in the process and structure of care on a nation-
wide level will bring benefit to this group of patients. Many studies have advocated the 
centralization of low-volume, high-risk operations, thereby improving nationwide quality of 
care.11,27 Centralization of esophageal and gastric cancer is currently performed in several 
European countries, whereas referral to high-volume centers is also advocated in the United 
States by the Leapfrog group.38 In Denmark, centralization of gastric cancer surgery from 
37 to 5 hospitals leaded to a drop in postoperative mortality from 8.4% to 2.1% over a 
period of 5 years.39 
Unlike the Netherlands, which is a relatively small country with good infrastructure, 
centralization of care in countries with large rural areas might lead to unreasonable 
travel burdens and problems with continuity of care after surgery. Therefore, others have 
advocated implementing processes that are related to excellent outcomes in low volume 
hospitals, but identification of these processes remains challenging.40
Meanwhile, using hospital volume as the sole basis for referral to improve outcomes is 
criticized.17 Although hospital volume can reliably identify groups of hospitals with better 
results on average, individual low volume hospitals can have excellent outcomes and vice 
versa. In contrast to volume-based referral, outcome based-referral avoids this problem, 
and has proven its value for esophagectomy in the Western part of the Netherlands. In this 
area, a prospective audit was conducted to identify hospitals with excellent performance in 
esophagectomy. During the five-year audit, a gradual concentration towards centers with 
excellent performance occurred, leading to a drop in postoperative mortality (12% to 4%) 
and an improvement in survival.41
Combining centralization with auditing substantially adds to improvement of care.42 With 
auditing, providers of care are monitored and their performance is benchmarked against 
their peers. Auditing is performed on a national level for esophagogastric cancer in 
Denmark,39 Sweden and the United Kingdom. A nationwide audit for both esophageal 
and gastric cancer surgery has started in the Netherlands as of 2011 aiming for complete 
coverage of all esophagectomies and gastrectomies.
In conclusion, enforcing centralization for esophagectomy in the Netherlands has resulted in 
a shift in annual hospital volumes: most resections are currently performed in high volume 
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centers. For gastrectomy, no minimum number of resections was required, and the majority 
of gastric cancer resections were performed in low volume hospitals. However, as of 2012 
gastrectomies in the Netherlands will be centralized to a minimum of 10/year, and as of 
2013 to a minimum of 20/year. Esophagectomy in high volume hospitals is associated with 
improved outcomes. No such relation for gastric cancer could be established in the current 
dataset, but only a minority of patients was treated in high volume hospitals. Over the past 
two decades, short-term mortality and long-term survival after esophagectomy decreased 
significantly, while outcomes after gastrectomy improved to a lesser extent, indicating an 
urgent need for improvement in quality of surgery and perioperative care for gastric cancer 
in the Netherlands. 
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“the systematic critical analysis of the quality of medical care, including the procedures
used for diagnosis, treatment and resulting outcome for the patient, carried out by those 
personally engaged in the activity concerned”.
Ernest Amory Codman, Surgeon, 1869 - 1940
Discussion and future perspectives
In most modern health care systems the quality as well as the costs of health care are 
high priority. This is especially so in cancer care where recent developments force us to 
constantly re-evaluate the way we provide care to our patients. The number of cancer 
patients is rising and will continue to do so with, concurrently, a rise in the number of 
elderly patients leading to a greater risk of treatment-related morbidity and mortality. 
Moreover, the processes of care, including diagnostic procedures, multidisciplinary decision 
making, combined modality and targeted treatments, are becoming more and more 
complex, demanding specific knowledge, expertise and infrastructure in the institutions 
that provide such care.  
Volume and outcome
Simultaneously, there is a growing concern about the quality and safety of health care. 
Much has been said about the harmful effects of care that fails to deliver the desired 
benefits1. A plethora of articles have reported on variation in patient safety and quality 
of care delivered by different types of hospitals2-4. The differences in operative mortality 
between high and low volume providers can be striking, especially for high-risk low-volume 
cancer procedures, like pancreaticoduodenectomy and esophagectomy. The first reports 
on this issue were published at the end of the 20th century. Initially there was solid criticism 
on the methodological quality of these volume-outcome studies: the majority was based 
on administrative instead of clinical data, lacking important information on differences 
in hospitals’ casemix and limited to postoperative mortality as the sole determinant of 
outcome. Our study from the region of the Comprehensive Cancer Centre Leiden [this 
thesis] emphasized the role of casemix-adjustments in comparing outcomes between 
hospitals, though showed substantial differences in outcome between high- and 
low-volume providers5. During the last decade more than 40 studies on the volume-
outcome relationship for esophageal cancer surgery have been added to the literature, 
including extensive casemix-adjustments and using several outcome parameters, like 
morbidity, mortality, long-term survival and quality of life. Our meta-analysis of these 
studies shows that hospital volume is an important determinant of outcome in esophageal 
cancer surgery [this thesis]6. Other reports show the same for other low-volume high-risk 
procedures and other attributes of hospitals, like their teaching status or specialized setting 
(e.g. cancer centers)2,7,8. 
This suggests substantial opportunities for improving outcome through the selective referral 
of patients to centers with high procedural volumes of these high-risk operations9. On 
the other hand, doubts remain about actual improvement in outcome after concentrating 
high risk cancer operations in centers selected exclusively on their procedural volume [this 
thesis]10,11. The differences found in volume studies between high- and low-volume 
providers might only be true for groups of hospitals on average, without adequate 
discrimination in quality of care between individual hospitals c.q. future referral centers for 
complex surgical procedures like esophagectomies. 
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Variation in quality of care
In 2010, the ‘Quality of Cancer Care taskforce’ of the Dutch Cancer Society published its 
report on variation in quality of care between hospitals in the Netherlands12. Considering 
the reports on variation in quality for high-risk cancer procedures, the question was raised 
how extensive or wide-spread hospital-based quality differences could be? An initial review 
and meta-analysis of the volume-outcome literature, performed by the taskforce, showed 
substantial provider variation in the whole field of cancer procedures (Figure 1) 13-17. 
Despite these results, the taskforce found several impediments translating these results 
into policy. No evidence-based cut-offs between low- and high volume could be identified 
and most studies originated from essentially different health care systems, hampering the 
extrapolation of their results to the Dutch setting. 
Figure 1. Meta-analyses: odds ratio (OR) plots for postoperative mortality (fig 1a) and survival (fig 1b) after 
pancreatic, breast, bladder, lung, and colorectal resections for cancer, in high volume versus low volume 
hospitals The center of the square represents the pooled OR and its extremities represent its 95% confidence 
interval.
Figure 1b. Hospital volume versus long-term survival
Figure 1a. Hospital volume versus postoperative mortality
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Therefore, the taskforce selected four tumor types based on their varying risk profiles 
(Table 1), to investigate actual differences in quality of cancer care between hospitals in the 
Netherlands. For this study the best available data at that moment, those of the Netherlands 
Cancer Registry, were used. Investigations were not limited to the quality of surgical 
treatment; instead different quality parameters in the whole treatment process of cancer 
patients were analyzed. In these studies, substantial differences in quality of care were 
revealed for the treatment of bladder-, colorectal-, non-small cell lung (NSCLC) and breast 
cancer18-23. For NSCLC patient’s treatment patterns and outcome varied by region and 
the hospital their cancer was diagnosed in. Though resection rates were on average higher 
in hospitals training thoracic surgeons, variation between individual hospitals was much 
more distinct. Hospital characteristics like volume, teaching status or on-site availability of 
radiotherapy facilities proved no guarantee for optimal treatment rates [this thesis]23. For 
colon cancer, patients treated in high-volume hospitals had lower odds to have more than 
10 lymph nodes examined – an important quality indicator for colon cancer treatment - 
than patients in low-volume hospitals [this thesis]19. Similar results from the other studies 
performed by the taskforce, emphasized that quality varies widely between individual 
hospitals and that hospital attributes alone are inadequate predictors for high quality care.
Table 1. Profile of tumors investigated by the ‘Quality of Cancer Care’ taskforce
Tumor Number / year Morbidity 5- year survival
Invasive bladder cancer 1 300 / year High 33%
Non-small cell lung cancer 6 400 / year High 15%
Colorectal cancer 10 000 / year High 59%
Breast cancer 13 000 / year Low 86%
Data-source: Netherlands Cancer Registry 2009
Also in literature, despite multiple efforts to investigate the root causes of variation in 
outcomes, the underlying mechanisms remain largely unknown24. Analyzing variation, 
it’s important to understand that variation in outcome is not synonymous with variation 
in quality. There are legitimate causes of variation. According to Iezzoni’s ‘algebra of 
effectiveness’ there are three contributing factors: patient characteristics, quality of the 
care process and chance25. Consequently, only after adequate corrections for differences in 
characteristics of patients treated by hospitals (casemix adjustments) and chance variations 
(reliability adjustments), real differences in quality of care can be revealed5,26. 
Quality of the care process 
In surgical oncology eight different phases of the clinical process can be distinguished: 
diagnosis and staging, pre-operative work-up (including neo-adjuvant treatment), surgical 
procedure, pathology, postoperative care and adjuvant treatment and follow-up (Figure 2). 
Variation in quality of care can originate from every phase of the care process and interact 
with the outcome of the other phases. For example, in rectal cancer surgery inadequate 
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pre-operative imaging of the pelvis can lead to inadequate neo-adjuvant treatment and 
irradical circumferential resection margins as an outcome of the surgical procedure. On 
the other hand, complications occurring after surgical cancer procedures, like colorectal 
resections, are associated with omission of or a delay in the administration of adjuvant 
chemotherapy, possibly affecting the long term outcomes of these patients27. These 
downstream effects of quality issues in preceding phases of the care process underline the 
importance to evaluate the whole process of diagnosis and treatment in quality improvement 
Figure 2. Different phases of the care process for patients in who rectal cancer surgery is performed, with 
quality indicators for each phase according to the Dutch Surgical Colorectal Audit (www.clinicalaudit.nl).
Patients - 3000 patient/year
- 85% resection
- 15% irresectable
Quality indicators DSCA Indicator results DSCA
Diagnosis - coloscopy, colography on indication
- tumor biopsy
- tumor marker CEA
- MRI/CT pelvis
- endoscopic ultrasound on indi 
indication
- CT thorax or X thorax
- CT abdomen or ultrasound liver
- multidisciplinary meeting (MDT)
% full visualization of colon
% fully staged
% preoperative MRI






- short-course pre-operative 
radiotherapy
- long-course pre-operative 
radiotherapy
- pre-operative chemoradiation 
% neo-adjuvant treatment 
(cT3-T4)




- short course RTx 47%
- long course RTx 7%
- chemoradiation 28%
Surgery - intake/informed consent surgeon
- consultation anaesthesiologist
- consultation stoma-nurse
- other consultations (e.g. cardiologist)
- open or laparoscopic resection
- Low Anterior Resection, APER or 
Hartmann 











 - end 44%
 - deviating 35% 
Pathology - histology, grade
- radicality (R0)
- Circumferential Resection Margin








11% CRM tumor positive
61% >10 lymph nodes
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recovery
- fast track recovery program









% failure to rescue






 2 % mortality
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initiatives and not focus on surgical treatment alone. Hence, it’s remarkable that few 
volume-outcome studies have evaluated non-surgical issues, like differences between 
providers in the quality of diagnostic procedures. In esophageal cancer treatment van Vliet 
et al. compared the diagnostic sensitivity of pre-operative metastasis detection in a high 
volume referral center and regional referring centers. The better CT scanning equipment 
and more experienced radiologists in the referral center prevented futile esophagectomy in 
1 in 20 patients28. Patient selection, the ability to give a patient the optimal treatment in 
his or her situation is the essence of surgical oncology. This process has benefitted largely 
from pre-operative multidisciplinary decision making that was introduced in practically all 
hospitals in the Netherlands. Still, the limited experience of a multidisciplinary team with 
low-volume tumor types can hamper the quality of such decisions. 
Measuring quality of care
According to the definition of the Institute of Medicine, quality of care is a multidimensional 
concept, encompassing safety, effectiveness, timeliness, efficiency and patient centeredness. 
In this thesis only two domains of quality have been addressed, the safety and effectiveness 
of cancer surgery, not meaning that the other determinants of quality are less important. 
The way quality is measured depends largely on the availability of reliable data. Only 
recently, large and detailed multicenter clinical databases have become available, mainly 
from north-western Europe and the United States29-31. In general, simple and readily 
available clinical outcomes have been used to evaluate the quality of surgical care. This 
does not do justice to the multidimensional construct of quality and the complexity of care 
processes described above. The framework in which quality is measured is evaluated by 
research groups around the world seeking for better ways to measure quality.
As mentioned, to reveal real differences in quality of care, measurements of variation 







Figure 3. Donabedian paradigm for health care 
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understand variation, it is important to consider relationships between structure, process of 
care and clinical outcomes as was described by Donabedian32. Though, quality should be 
viewed from different perspectives, not only that of the health care provider, but preferably 
also from a patients’ and social perspective. Therefore, the integration of patient reported 
experiences (PREMs) and outcomes (PROMS) in quality measurement models is of utmost 
importance (Figure 3). 
Structure
Structural variables describe the setting in which care is provided, which can be attributes 
of the hospital (infrastructure, volume), multidisciplinary teams or individual physicians. 
These structural variables, for instance procedural volume, availability of a plastic surgeon, 
high-level ICU or on-site radiotherapy department, can be related to patient outcomes, 
especially by the influence they have on the process of care. Hospital volume is a structural 
measure that has been related to outcome of surgical procedures in an overwhelming 
number of studies 33. Though, the extent of this relationship varies widely by type of 
procedure2. In their landmark publication in the New England Journal of Medicine in 2002, 
Birkmeyer et al. reported on the inverse relationship between hospital volume and surgical 
mortality for different types of cancer procedures. For low-volume high-risk procedures 
like esophagectomy and pancreatectomy a 3- to 4-fold higher mortality was seen in very 
low-volume hospitals compared to high-volume hospitals. Though, for cancer procedures 
that are more frequently performed and/or have a lower risk profile, like colectomies or 
lung resections, mortality was only 1.2 to 1.4 times higher. Moreover, as argumented above, 
the relationship between hospital volume and outcome has proven to be true on average, 
however as a quality measure it may fall short in identifying highleverage processes of care 
in hospitals with excellent outcomes. Focusing on ‘procedural volume’ has few ability to 
move the medical field forward in better understanding the complex clinical processes that 
lead to success or failure [this thesis]34.   
Process of care
Process components of care refer to the interactions between the provider (i.e. physician) 
and the patient, for example the delivery of adequate staging investigations to detect distant 
metastases in patients considered for curative surgery. To use process measures to evaluate 
quality levels in different institutions, it has to be determined which care processes lead to 
the better outcomes. The development of evidence-based guidelines has provided standards 
for diagnostic and treatment policies used by clinicians35. Measuring the implementation 
of these standards in routine patient care, could give insight in the quality provided by an 
institution. Regretfully, the empirical evidence of relationships between measurable process 
variables and outcome is limited [this thesis]33. Many components of the clinical process 
are not evidence-based and guidelines often provide evidence only for a selected group of 
patients. Especially in elderly, current guidelines can fall short in guiding clinicians in their 
decision process. The absence of a clear clinical guideline for a certain group of patients 
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(e.g. elderly) can be an important cause of variation in patterns of care. Moreover, there 
are no studies available that provide evidence for process indicators really discriminating 
between high- and low quality of care (construct validity). Therefore, comparing quality by 
oversimplifying the clinical process using a few measurable aspects of care might not be 
feasible. On the other hand, process characteristics can have an intrinsic value for patients, 
without a direct relationship with clinical outcome, e.g. limited waiting times, assistance 
by case managers, shared decision making. As mentioned above, a multi-dimensional 
approach of quality, in which patient preferences and experiences are combined with clinical 
outcomes, might give a more sound view on health care quality (Figure 3).  
Clinical outcome
The ultimate outcome in (surgical) oncology is survival, in which also the ‘quality of survival’ 
has to be taken into account. In cancer surgery irradical resections can reduce survival and 
adverse events do affect patients’ quality of life. Unfortunately, patient reported outcomes 
after cancer surgery are not yet available on such a scale that they can be used in routine 
outcome monitoring. Nevertheless, direct outcome measurements are preferable in the 
evaluation of quality, not in the least because they are face-valid for physicians as well 
as patients. Though, there are several limitations to direct outcome measurement. First, 
relevant casemix-factors should be available to make reliable outcome comparisons between 
institutions [this thesis]5. Recently, we published data from the Dutch Surgical Colorectal 
Audit in which an extensive set of casemix-factors is collected to be able to adjust hospital-
specific complication and mortality rates for colorectal cancer surgery36. The expected 
mortality, based on patient- and tumorcharacteristics of groups of patients treated in Dutch 
hospitals ranged from 1.5 to 14 percent36. Surprisingly, in the Netherlands the majority of 
high-risk coloncancer patients, with an unfavorable expected mortality, are not treated in 
high-volume, but in low-volume hospitals. And high-risk rectal cancer patients are treated 
in non-teaching instead of academic hospitals. These findings underline the need for proper 
casemix-adjustments in the evaluation of quality of care. Second, when evaluating differences 
in outcome between institutions, the reliability of these comparisons is largely dependent 
on sample sizes. For low-volume cancer procedures the number of cases per hospital 
(denominator) and the number of complications (nominator) can be too small to evaluate 
quality of care within a reasonable period of time37. Moreover, in quality assessment various 
outcome parameters can interact. For example, complication rates after colorectal surgery 
can be reduced substantially by omitting a primary anastomosis and performing a colostomy 
in the majority of patients. Likewise, local recurrence rates of patients with advanced rectal 
cancer can be improved with neo-adjuvant chemoradiation, though radiation may lead to 
more perineal wound complications. Such improvements in outcome on one parameter 
(anastomotic leakage and local recurrence rates) at the expense of another (colostomy and 
wound complication rate) asks for a more comprehensive approach in outcome assessment. 
The combination of different case-mix adjusted outcomes in quality measurement can 
provide a better construct validity, by taking a greater proportion of relevant quality 
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measures into account and possibly also a better criterion validity, being better able to 
discriminate between hospitals with better and worse overall quality [this thesis]. 
Improving quality
Acknowledging the differences in the quality of (infra)structure, care processes and outcome 
for cancer patients, efforts to reduce undesired variation could lead to real benefits for the 
whole patient group. Traditionally, improvement of quality of surgical care on a national 
level is the domain of professional organizations like the Association of Surgeons in the 
Netherlands. Until recently, quality improvement efforts were based on the transfer of 
knowledge and skills through surgical education and training, the development of evidence-
based guidelines and the organization of scientific meetings. In addition, periodical 
consultation of teaching hospitals was performed to guarantee the quality of surgical 
training.    
Guideline adherence
Despite these initiatives, actual information on variation in quality of care in routine practice 
is generally lacking. The implementation process following development of evidence-based 
guidelines is seldom monitored and reasons for non-adherence are largely unknown. The 
gradual introduction of studies comparing outcomes between providers has changed this 
situation and gave rise to more and more research groups evaluating hospital-variation 
in quality of care, also in the Netherlands38,39. Despite important variation in outcomes 
identified for high-risk cancer procedures performed in high- and low-volume hospitals, for 
a long time no changes in referral patterns were seen in our country40. The regionalization 
project for esophageal cancer surgery described in this thesis proved to be an exception, 
showing actual changes in referral patterns and marked improvements in outcome in 
comparison to the national average [this thesis]11. The major difference of this successful 
regional intervention with other centralization initiatives was that it was accompanied 
by a routine data collection system, to monitor guideline adherence and outcomes of 
participating hospitals in the region (clinical audit). Risk-adjusted outcome data were fed 
back to the participating surgeons and hospitals. Important differences in quality of care 
were revealed which led to actual changes in referral patterns and marked improvements in 
outcome [this thesis]41. 
Selective referral
The potential benefits of selective referral of patients to hospitals with better outcomes has 
been speculated upon by many authors10. In response to an Institute of Medicine report on 
building a safer healthcare system1, in 2000, several large employers in the United States 
formed the Leapfrog group. The objective of Leapfrog is to improve the quality and safety 
of medical care and steering surgical patients to hospitals likely to have the best results, is 
one of their instruments. Since 2003 Leapfrog has a volume standard for esophagectomy 
(>13/year), which was recently evaluated in Washington state. This investigation showed 
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that on average Leapfrog hospitals had lower risk-adjusted mortality rates, though between 
hospitals meeting the Leapfrog standard there was still important variation in outcomes, 
including a 5-fold variation in mortality42. Apparently, procedural volume as a proxy 
for quality of care falls short in identifying hospitals providing ‘excellent’ care. Recently, 
Simunovic et al. published the results of centralization of pancreatic surgery in two provinces 
in Canada, Ontario and Quebec43. In a 10 years period, pancreatic surgery was concentrated 
in high-volume hospitals in both provinces to the same extent. However, only in Ontario this 
resulted in actual improvement in outcomes of pancreatic surgery patients. The difference 
was that in Ontario centralization was accompanied by an audit of results, which were fed 
back to participating surgeons. The parallel with the outcome-based centralization project 
for esophagectomies described in this thesis is striking and was noticed by Birkmeyer et al. 
who concluded that adequate hospital caseloads are important for achieving safe surgery, 
but not necessarily sufficient: ‘to ensure acceptable mortality rates, high volume surgeons 
and hospitals should actively monitor their outcomes and benchmark their performance 
against their peers’ 44.  
Quality assurance
An alternative approach to selective referral, are strategies that aim to improve quality 
of care in all hospitals treating a certain patient group. Such an approach seems most 
appropriate for high-volume cancer surgery performed in significant volumes by almost all 
hospitals, like breast and colorectal cancer surgery. Though, given the remarks of Birkmeyer 
et al. mentioned above, also low-volume cancer surgery might benefit from a strategy that 
sets quality standards that are continuously monitored. 
Quality assurance is such a strategy and focuses on the implementation and monitoring of 
a complete set of systematic actions that is required to achieve a certain standard of care. 
Since variability in skills and techniques performed by surgeons can lead to irreproducible 
results, quality assurance is used in clinical trials, in which the quality of surgery is essential 
for the outcome45. Therefore, to reduce variation, participating surgeons are trained to 
perform the procedure in an identical way. Yet, quality assurance is not necessarily limited 
to the surgical aspects of treatment; it is a complete set of measures required to achieve 
a treatment result that meets a certain standard46. For example, quality assurance was 
integrated in the Dutch TME trial, in which a new surgical technique was used in rectal 
cancer resections by all participating surgeons47. It was considered crucial that the study 
was quality controlled. To train the surgeons, workshops, videotapes and instructors 
supervising the first 5 operations were used. Also, for radiotherapy exact descriptions 
of dose, volume, fields and simulation techniques were used and for pathology a strict 
protocol was dictated, which gave the surgeons immediate feedback on their performance. 
The quality assurance in this trial proved to be very successful: local recurrence rates were 
reduced by 50% compared to historical data48. The association between circumferential 
resection margin (CRM) involvement and outcome (local recurrence, survival) demonstrated 
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the importance of this parameter in evaluating surgical performance, not only in trials, but 
also in daily practice49.
The question is: shouldn’t adequate quality control on how diagnostic procedures and 
treatments are performed be an integrated part of daily medical practice?
Clinical audit 
An instrument that combines the relative merits of monitoring guideline adherence, quality 
assurance, outcome measurement and selective referral is clinical audit. Clinical audit as 
a quality improvement tool was first defined by Ernest Amory Codman, a surgeon at the 
Harvard university hospital in 1912: ‘the systematic critical analysis of the quality of medical 
care, including the procedures used for diagnosis, treatment and resulting outcome for the 
patient, carried out by those personally engaged in the activity concerned’. In Healthcare, 
clinical audits can be carried out on different levels, on the level of a clinical department, on a 
hospital, regional or national level. There are different types of audits. First, those that focus 
on individual cases, with an unexpected or adverse outcome, which are peer-reviewed by 
a multidisciplinary team to reflect on the way the team functioned and to learn from in the 
future. An example of such a ‘significant event audit’, though on a national level, is the Dutch 
Surgical Adverse Outcomes Registry (Landelijke Heelkundige Complicatie Registratie)50. 
Another type, is the ‘standards-based audit’, using an audit-cycle that involves the definition 
of quality standards, collecting data to measure current practice, setting benchmarks and 
implementing improvements (Figure 4). This concept of auditing is closely related to quality 
assurance and provides continuous feedback on a set of quality standards and outcomes to 
the participating clinicians. 
Recently, we performed a systematic review on the outcome of clinical audits reported in the 
literature, that showed that audit and feedback of quality information has a positive effect 
on the quality of surgical care 51. This conclusion is supported by the results of nationwide 
clinical audit programs that have been developed in the United States and Western Europe 
in the last two decades52,53. In Norway local recurrence rates dropped from 28 to 7% as 
a result of a national audit program for rectal cancer surgery 54. In the United States the 
National Surgical Quality Improvement Program (NSQIP) that began more than 20 years 
ago in the Veterans Affairs hospitals, reported marked reductions in morbidity (45%) and 
mortality (27%) after surgery in the participating hospitals52. This is accomplished by a 
peer-controlled program of continuous and timely feedback of case mix adjusted outcomes 
of surgical care. Recently, similar results have been shown after adoption of the NSQIP 
program by the private sector55.
The reason for clinical auditing being a powerful instrument for quality improvement is 
found in the combination and integration of several quality improvement tools. First, the 
peer-controlled development of datasets covering a set of quality standards based on 
evidence-based guidelines, explicates which aspects of the care process are believed to 
be essential for optimization of clinical outcome. Through the data-collection as well as 
the -reporting process these sets of standards are spread within the surgical community 
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(knowledge transfer). The continuous data-collection, often executed or supervised by the 
clinicians themselves, gives constant attention to these quality aspects. In addition, clinicians 
are provided with rigorous feedback of their outcomes relative to those of their peers 
(benchmarking). That feedback itself can be very effective in improving outcome was shown 
in New England, United States, were mortality after CABG fell with 25%, almost immediately 
after feedback was given to thoracic surgeons56. This surgical “Hawthorn effect” has been 
observed by many of the starting clinical audits, though can be strengthened if feedback is 
accompanied with benchmark information and meaningful suggestions for improvement51. 
The remarkable success of the centralization process, linked to a regional audit for 
esophagectomy, as was described in this thesis, can be considered as additional proof for 
this concept41.
Understanding variation
Next to its direct influence on quality of care, one of the most important side-effects of the 
development of nationwide data-collection systems, is the detailed clinical information that 
is retrieved by these clinical audits. Apart from quality assurance and the initiation of local 
improvement initiatives, reliable databases with essential information on (differences in) care 
processes and outcome may move the whole medical field forward. Recognizing groups of 
patients at risk for adverse outcome, revealing the underlying mechanisms and identifying 
processes of care with better outcomes, are the central issues in outcomes research (Figure 
5). The ultimate goal is to transfer best practices found in centers with excellent results to 
all hospitals treating these patients. For example, Ghaferi et al. reported recently on hospital 
differences in mortality after esophagectomy, gastrectomy and pancreatectomy57. They 
found that complication rates did not differ largely between hospitals. Instead, differences 
seemed to be associated with the ability of a hospital to effectively rescue patients once 




complications occur (failure to rescue). The adequate way clinical teams in hospitals with 
low mortality rates react on symptoms or signs of complications, may be of benefit for all 
patients having this kind of surgery. 
Transparency
It is generally believed that transparency in hospital-specific quality information, catalysts 
quality improvement. Additional to the benefits of clinical auditing, public reporting of 
a hospitals’ outcomes could stimulate improvement initiatives in under- as well as good 
performing hospitals. Moreover, transparency could steer patients to the hospitals with 
better outcomes for certain kinds of procedures, given these the opportunity to specialize in 
treating such a group of patients. 
A recent report of the Boston Consulting Group has compared the availability and 
transparency of reliable quality information between Sweden and the Netherlands58. In 
Sweden, there are 82 national registries collecting detailed data on quality of care for a 
broad spectrum of diseases, on average covering 70% of patients diagnosed. With these 
registries, developed and controlled by medical specialists, Sweden is the worlds’ front 
runner in the transparency of hospital-specific outcome-information. 
The transparency paradigm
Transparency has different levels, first hospital-specific outcome information can not be 
available at all, also for the clinicians involved. Second, clinicians know their own results, 
though do not share it with their environment. Third, clinicians share this information with 
patients in their daily practice to inform them on the morbidity and mortality of medical 
procedures. Fourth, clinicians have outcome-information and share that with their peers, 
within or outside the hospital, for example in regional networks like that of the comprehensive 
cancer Leiden [this thesis], though also sharing information with referring centers or family 
physicians is possible. Fifth, clinicians share their outcome information with the management 
Figure 5. The merits of clinical 
auditing: identifying high risk 
patients for postoperative 
mortality after colorectal cancer 
resection (source: Dutch Surgical 
Colorectal Audit)
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of their institution . And sixth, with (external) stakeholders like their professional organization 
or payers; for example in the negotiations with insurance companies. Finally, hospital-specific 
(or clinician-specific) outcome information is publicly available.
These 7 levels of transparency are meaningless if they are not accompanied with an 
appreciation of the quality of information. Good outcome information is meaningful, reliable 
and comparable. It’s generally believed that the relevance of outcome-indicators is best 
appreciated by those directly involved in the clinical process: patients and their doctors. 
Therefore, most successful outcome-registries are developed by clinicians and their professional 
organizations, though often lack direct patient involvement. Consequently, patient reported 
outcomes (PROMS) are seldom collected. Reliable outcome information is best retrieved 
using uniform definitions and preferably data is quality controlled. As stated before, in the 
comparison of providers, adjustments for differences in casemix [this thesis] and chance 
variation are essential. Moreover, to be meaningful, outcome-information has to be compared 
(benchmarked) with information of other providers treating the same patient group. 
These criteria for good outcome information can be combined with the levels of transparency 
identified above, into a transparency-paradigm (Figure 6). According to the Boston 
Consulting Group report, Swedish healthcare is at the highest transparency level for several 
diseases, though a clear insight in the quality of quality information is not provided by the 
authors58. The alleged benefits of open reporting are closely associated with the quality 
of the outcome information presented to the public. Since, transparency can very easily 
turn into a risk for quality of care, when inaccurate data wrongly stigmatize and demoralize 
hospital staffs and unnecessarily decrease patients’ confidence in a particular hospital or 
healthcare in general59. 
Transparency in the Netherlands
In the Netherlands, the Healthcare Inspectorate introduced performance indicators for 
hospitals in 2003, which are publicly reported. In addition, a nation-wide quality indicator 
program, Zichtbare Zorg Ziekenhuizen, has been launched by the Dutch government, to 
reveal hospital-specific quality information for patients and payers. Only a minority, 16 %, of 
Figure 6. Transparency 
paradigm for hospital-specific 
outcome-information: degree 




these indicators is outcome-based, the quality of self-reported hospital-data is not controlled 
and the lack of information on differences in casemix undermines the reliability of indicator 
results58. Nevertheless, these government-initiated efforts to enhance transparency in 
quality of care in the Netherlands, has raised awareness of clinicians and their professional 
organizations which led to a number of bottom-up initiatives. For example, a Dutch Surgical 
Colorectal Audit was initiated by the Dutch College of Surgeons to collect reliable data 
on all patients in who a resection of a primary colorectal cancer was performed in our 
country60. This nation-wide peer-reviewed quality-controlled outcome-based and casemix-
adjusted clinical audit program, feeds back benchmarked information on the quality of 
colorectal cancer treatment to the participating surgeons. All hospitals participate and data 
are validated by the Netherlands Cancer Registry, suggesting a 95% completeness on a 
population-level in 201136. An extensive set of outcome indicators is reported, including 
radicality of resections, complications and mortality after colorectal surgery. However, in 
addition care processes are monitored by process indicators to identify shortcomings as 
well as best practices. At this moment, three other clinical audits, for breast-, lung- and 
upper-gastrointestinal cancers, have been initiated in the Netherlands, consistent with 
the formula of this colorectal audit51. A number of quality indicators from these reliable 
data-sources are reported publicly through the Zichtbare Zorg Ziekenhuizen program, 
improving transparency of Dutch healthcare. 
Measuring improvement
Through the improvement-cycle and transparency of hospital-specific quality information, 
clinical auditing can reduce variation and lead to an overall improvement in quality of care. 
In its first 3 years, feeding back benchmarked information on guideline adherence lead 
to remarkable reduction of variation between hospitals in the Dutch Surgical Colorectal 
Audit (Figure 7). The quality improvement curve did not only shift right, but also narrowed, 
meaning that high quality care – based on evidence-based guidelines - was optimized for the 
whole group of colorectal cancer patients (Figure 8). In addition, significant improvements 
in outcome after colon cancer surgery were shown, with a more than 20 percent drop in the 
risk for postoperative mortality and 14 percent reduction in the risk for severe postoperative 
morbidity. 
Health care costs
In many western countries the costs of healthcare are rising exponentially, as a consequence 
of demographic developments, technological advancements and increased healthcare 
consumption. Consequently, finding more efficient ways to provide high-quality care is high 
on the political agenda. Although, clinicians tend to avoid discussions about the costs of 
their medical actions, quality and costs of care are closely related. Improvement of patient 
care, by reducing complication rates proves to reduce costs61. Pay-for-performance initiatives 
in the United States are aimed at process compliance to achieve rapid and significant 
quality improvement. For example, in Michigan, a financial incentive to promote that every 
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colorectal surgery patient received an appropriate antibiotic within 60 minutes before 
incision, increased from 70 to more than 95%, virtually over night24. Despite, empirical 
proof that paying for quality leads to actual improvement in outcome, is lacking62. 
To discover how a limited health care budget is spent best, we need information on the 
value of health services for patients. Porter et al. defined value in health care as outcomes 
relative to costs. The proper unit for measuring value should encompass the whole process 
of care, completed with short-term as well as long-term outcome information. According to 
Porter, outcome measurements should include risk-adjustments and in the complexity of the 
clinical process competing outcomes should be weighed against each other. This calls for 
an integrated approach, in which quality information for the whole care process – from a 
Figure 7. Improvement in guideline 
adherence: reduction of hospital 
variation and  improvement of 
average hospital performance on 
the quality indicator ‘ percentage 
of rectal cancer patients discussed 
in a pre-operative multidisciplinary 
meeting ‘ in the Dutch Surgical 
Colorectal Audit in 2009 (Figure 7a), 







physicians as well as a patients’ perspective - becomes available and can be weighed against 
costs. Combining cost-information with the risk-adjusted outcomes acquired in clinical audits 
can provide a transparent view on the value of health services in the Netherlands. 
Conclusion
This thesis shows that quality of care in surgical oncology varies by provider and is partly 
based on differences in procedural volume and other attributes of hospitals. Especially for 
low-volume high-risk surgical procedures concentration of services in hospitals with better 
outcomes (outcome-based referral) can lead to dramatic improvement in short- as well as 
long-term outcomes. Casemix- and reliability adjustments are essential in the evaluation 
of quality of care. In addition, an integrated approach, in which several determinants of 
outcome are combined, might provide a more valid instrument to assess the quality of 
complex clinical processes. 
Clinical audit combines several ways to improve quality of care. It stimulates guideline 
adherence and provides clinicians with continuous and timely feedback on their performance, 
in relation to a national benchmark. Feedback itself has proven to be very effective, 
though the most important benefits of clinical audit can be found in the identification 
and appreciation of clinical processes that lead to better outcomes. This knowledge can 
be transferred to all practices treating such patient groups, improving outcome on a 
population-level. In addition, transparency of reliable, meaningful, hospital-specific outcome 
information, can catalyst the continuous process of quality improvement, steer patients to 
the right hospitals and reduce the costs of healthcare.    
Figure 8. Quality improvement curve: reduction in hospital variation and improvement o f average hospital 
performance
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Meten en verbeteren van kwaliteit van zorg in de Chirurgische 
Oncologie
De Nederlandse gezondheidszorg staat voor grote uitdagingen. In de afgelopen twintig jaar 
zijn de medische wetenschap en technologie met sprongen vooruit gegaan, maar is de zorg 
ook in toenemende mate multidisciplinair en complex geworden. Dit geldt bij uitstek in de 
kankergeneeskunde, waar de snelheid van de ontwikkelingen een voortdurende evaluatie 
van de zorg nodig maakt. Het aantal kankerpatiënten neemt snel toe met tegelijkertijd een 
toename van het percentage ouderen met kanker. Doordat zij naast hun ziekte, vaak ook 
meerdere chronische aandoeningen hebben, nemen de risico’s van kankerbehandelingen 
fors toe. Daarnaast worden de zorgprocessen steeds ingewikkelder, bijvoorbeeld door 
toegenomen diagnostische mogelijkheden, multidisciplinaire samenwerking, multimodaliteits 
behandelingen, en zogenoemde ‘targeted drugs’. Deze toegenomen complexiteit vraagt 
om specifieke kennis, ervaring en infrastructuur in de ziekenhuizen die deze moderne 
kankerzorg verlenen. Bovendien is er meer en meer aandacht voor de veiligheid, effectiviteit 
en patientvriendelijkheid waarmee de zorg geleverd wordt, waarbij ook de beheersing van 
de stijgende zorgkosten hoog op de politieke agenda staat.
Volume en uitkomst
Aan het eind van de vorige eeuw verschenen er in de medische literatuur een aantal artikelen 
die verschillen in postoperatieve sterfte rapporteerden tussen ziekenhuizen waarin bepaalde 
kankeroperaties vaak (hoogvolume ziekenhuizen) en minder vaak, of zelfs zelden uitgevoerd 
werden (laagvolume ziekenhuizen). Aanvankelijk was er veel kritiek op deze volume-
uitkomst studies omdat zij gebaseerd waren op administratieve in plaats van klinische 
gegevens en niet corrigeerden voor verschillen in zorgzwaarte tussen de onderzochte 
ziekenhuizen (casemix-correcties). Bovendien werden alleen verschillen in postoperatieve 
sterfte onderzocht, terwijl ook lange-termijn overleving en kwaliteit van leven belangrijke 
uitkomsten van kankerzorg zijn.
Onze studie naar de kwaliteit van slokdarmkanker operaties in de regio van het Integraal 
Kankercentrum West, welke destijds 11 ziekenhuizen in de regio Leiden, Den Haag, Delft 
en Gouda omvatte, toonde aan dat er inderdaad aanzienlijke verschillen in zorgzwaarte zijn 
tussen ziekenhuizen die slokdarm kankerpatiënten behandelen (Hoofdstuk 3). Omdat voor 
dit onderzoek gebruik werd gemaakt van klinische gegevens, verkregen uit de statussen 
van patiënten die tussen 1990 en 1999 behandeld werden in deze 11 ziekenhuizen, was 
het mogelijk om voor deze zorgzwaarte verschillen te corrigeren. Bovendien konden naast 
postoperatieve sterfte, ook andere zorguitkomsten worden onderzocht, zoals complicaties, 
heroperaties, opnameduur, radicaliteit van de resectie en lange termijn overleving van 
patiënten. 
Er bleken aanzienlijke verschillen in zorguitkomsten tussen de 11 ziekenhuizen in de regio. 
Een vergelijking met het dichtstbijzijnde hoogvolume centrum voor slokdarmchirurgie 
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toonde bovendien aan dat er ook in zuid-west Nederland sprake was van een relatie tussen 
hoog volume en betere zorguitkomsten.
Literatuurstudie
Ook in de wetenschappelijke literatuur nam het aantal studies dat een volume-uitkomst 
relatie onderzocht snel toe. Vooral complexe hoog-risico operaties, zoals slokdarm- en 
alvleesklieroperaties, waren het onderwerp van deze onderzoeken. Onze literatuurreview 
en meta-analyse van studies naar ziekenhuis- en chirurg-volume voor slokdarmoperaties 
enerzijds en uitkomsten zoals postoperatieve sterfte en overleving anderzijds, was de 
eerste die alleen onderzoeken van hoge kwaliteit includeerde (Hoofdstuk 2). Alleen 
als er gecorrigeerd werd voor verstorende factoren, zoals verschillen in casemix tussen 
ziekenhuizen, werden studies in de meta-analyse meegenomen. De meta-analyse leverde 
het bewijs dat ziekenhuisvolume een belangrijke determinant is van goede uitkomsten van 
operaties voor slokdarmkanker. 
Centralisatie
De gegevens uit de regio van het Integraal Kankercentrum West (IKW) suggereerden dat 
het verwijzen van patiënten naar een hoogvolume ziekenhuis voor slokdarmoperaties zou 
kunnen leiden tot betere zorguitkomsten. In de regio waren er echter geen ziekenhuizen 
die meer dan 7 slokdarmoperaties per jaar verrichtten. Het professioneel netwerk van 
kankerchirurgen besloot daarom een ‘clinical audit’ uit te voeren, waarbij gedurende 5 jaar 
de patiënten-, tumor-, behandelingsgegevens en uitkomsten van zorg van alle slokdarm 
kankerpatiënten in de regio verzameld, geanalyseerd en teruggekoppeld zouden worden 
binnen het netwerk. Deelname aan deze audit was vrijwillig, maar niet vrijblijvend: wanneer 
er verschillen in zorguitkomsten zouden worden geconstateerd, zouden patiënten voortaan 
verwezen worden naar de ziekenhuizen met de betere uitkomsten (uitkomst-gestuurde 
centralisatie). 
De uitkomst van deze interventie in de IKW regio was uitermate onzeker. In de literatuur 
waren er verschillen tussen groepen hoogvolume en laagvolume ziekenhuizen aangetoond, 
maar het was destijds onvoldoende duidelijk of het verwijzen van de patiënten uit 
laagvolume naar hoogvolume ziekenhuizen ook daadwerkelijk betere uitkomsten voor 
de gehele groep op zou leveren. In de periode 2000 tot 2004, werden de resultaten van 
de slokdarmchirurgie halfjaarlijks teruggekoppeld aan de slokdarmchirurgen in de regio, 
waarbij men inzicht had in elkaars resultaten. Er waren aanzienlijke verschillen in percentages 
complicaties, heroperaties, opnameduur, radicaliteit en sterfte. Dit leidde binnen 5 jaar tot 
het centraliseren van slokdarmoperaties in 4 en later 3 van de 11 ziekenhuizen in de regio. 
De uitkomsten verbeterden in deze periode aanzienlijk, waarbij de postoperatieve sterfte 
werd verlaagd van 12 naar 4 procent, maar ook de lange-termijn overleving van patiënten 
significant verbeterde (Hoofdstuk 4).
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Volume of uitkomst-sturing 
Het succes van deze ‘clinical audit’ voor slokdarmoperaties in de IKW regio riep de vraag 
op of concentratie van zorg op basis van volume-criteria zou moeten gebeuren, of dat 
patiënten verwezen zouden moeten worden naar de ziekenhuizen met de beste uitkomsten. 
De bekende volume-uitkomst studies lieten zien dat ook binnen de groep ziekenhuizen in de 
hoogvolume categorie, er veel variatie in uitkomsten was tussen individuele ziekenhuizen. 
Volume is dus geen garantie voor kwaliteit! Om er zeker van te zijn dat centralisatie leidt 
tot betere uitkomsten zou men dus niet alleen op volume, maar ook op aantoonbaar goede 
uitkomsten van zorg moeten sturen.
Op basis van de volume-uitkomst studies in de literatuur, waarvan er ook enkele uit 
Nederland afkomstig waren, besloot de Inspectie voor de Gezondheidszorg in 2006 als 
prestatie-indicator een volumenorm voor slokdarmresecties in te stellen. Ziekenhuizen met 
minder dan 10 resecties per jaar moesten stoppen met slokdarmchirurgie en hun patiënten 
verwijzen naar ziekenhuizen die meer dan 10 resecties per jaar deden. Om een uitspraak 
te kunnen doen of deze specifieke volumenorm effectief zou kunnen zijn in het verbeteren 
van de uitkomsten van zorg voor slokdarmkanker patiënten in Nederland, deden wij een 
validatiestudie op basis van de literatuur en de gegevens van de Landelijke Medische 
Registratie. De resultaten in de verschillende volume categorieën onderzocht in de literatuur 
lieten zien dat vooral boven de 20 resecties per jaar een verlaging van postoperatieve sterfte 
verwacht mocht worden. Bovendien konden wij aantonen dat slokdarmresecties verricht 
in Nederlandse ziekenhuizen met 10 tot 20 van deze operaties per jaar, significant slechter 
waren dan de gemiddelde uitkomst in ons land (Hoofdstuk 5). 
Hier tegenover werden de resultaten in de IKW regio gezet in drie tijdsperiodes van 5 jaar. 
De eerste twee periodes, 1991-1994 en 1995-1999, gingen vooraf aan de ‘clinical audit’ in 
de regio. In de periode 2000-2004 vond de audit plaats. De IKW regio bleek in de eerste 
twee periodes aanzienlijk slechtere resultaten te hebben dan de andere regio’s in ons land. 
Na 2000, ten tijde van de audit, verbeterden de resultaten echter zodanig dat de regio 
juist betere resultaten had dan het landelijk gemiddelde. Samenvattend legde deze studie 
bloot, dat ‘volume’ als afgeleide van kwaliteit, het risico met zich meebrengt dat patiënten 
worden verwezen naar ziekenhuizen met suboptimale uitkomsten. Het combineren van 
een minimale volumenorm met uitkomstnormen op basis van gegevens verzameld in een 
‘clinical audit’, lijkt veel effectiever in het verbeteren van de zorg, dan het hanteren van een 
op zich staand volumecriterium. 
Variatie in kwaliteit van kankerzorg
De eerste studies die variatie in kwaliteit van zorg tussen ziekenhuizen aantoonden, 
onderzochten de verschillen bij weinig voorkomende hoog-risico operaties, zoals slokdarm- 
en alvleesklierresecties. De logische vragen die vervolgens opkwamen zijn:
l	 Is variatie in kwaliteit van zorg ook aantoonbaar voor hoog-risico hoogvolume operaties, 
of zelfs laag-risico hoogvolume operaties?
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l	 Is de variatie in kwaliteit van zorg alleen aantoonbaar voor het chirurgische deel van 
kankerbehandelingen of geldt het ook voor andere onderdelen van de behandeling 
zoals radio- en chemotherapie?
l	 Is de variatie beperkt tot ongewenste uitkomsten zoals complicaties en operatiesterfte, 
of betreft het ook andere aspecten zoals het percentage patiënten dat de optimale 
behandeling voor zijn/haar stadium van de ziekte krijgt? 
Deze vragen werden onderzocht door de werkgroep Kwaliteit van Kankerzorg van de 
Signaleringscommissie van het Koningin Wilhelmina Fonds (KWF). De werkgroep voerde een 
uitgebreide literatuurstudie uit naar de relatie tussen volume en kwaliteit, maar onderzocht 
ook voor het eerst op landelijk niveau de variatie in kwaliteit van kankerzorg geleverd 
door Nederlandse ziekenhuizen. Hiervoor werden de op dat moment best beschikbare 
gegevens gebruikt, die van de Nederlandse Kanker Registratie (NKR). Variatie in kwaliteit 
werd onderzocht voor vijf tumorsoorten: borst-, darm-, endeldarm-, long- en blaaskanker. 
In dit proefschrift zijn twee van deze studies opgenomen, die voor long- en darmkanker, 
respectievelijk Hoofdstuk 9 en 10. 
Voor patiënten met een laagstadium longkanker is een chirurgische resectie de 
optimale behandeling, met de grootste kans op lange-termijn overleving. Toch bleek er 
aanzienlijke variatie tussen Nederlandse ziekenhuizen, in het percentage laagstadium 
longkankerpatiënten dat een resectie onderging. Wanneer de diagnose werd gesteld in 
een ziekenhuis dat longchirurgen opleidt, of dat meer dan 50 longkankerpatiënten per jaar 
diagnosticeert, bleek de kans op een resectie groter dan in niet-opleidings of laagvolume 
ziekenhuizen. 
Ook voor patiënten met een gevorderd stadium van de ziekte, bij wie een combinatie 
van chemo- en radiotherapie de grootste kans op overleving geeft, bestaan er 
ziekenhuisverschillen in het percentage patiënten dat de optimale behandeling krijgt. 
Voor patiënten met darmkanker werden vergelijkbare kwaliteitsverschillen tussen 
Nederlandse ziekenhuizen gevonden. Bijvoorbeeld varieerde het aantal patiënten waarbij 
na de darmkankerresectie meer dan 10 lymfeklieren werd onderzocht en het percentage 
patiënten dat aanvullende chemotherapie kreeg. Patiënten die werden gediagnosticeerd in 
een academisch ziekenhuis of een ziekenhuis met meer dan 50 darmkankerdiagnoses per 
jaar, hadden een betere overleving. 
Op basis van vergelijkbare resultaten gevonden bij de andere tumorsoorten die de 
KWF-werkgroep bestudeerde, concludeerde men dat er aanzienlijke variatie is in de 
kwaliteit van kankerzorg in Nederlandse ziekenhuizen. Die variatie was echter niet goed 
te duiden, omdat in de NKR onvoldoende gegevens aanwezig zijn ten aanzien van 
patiënt- en tumorkarakteristieken, zoals comorbiditeit, tumorcomplicaties en de urgentie 
waarmee de patiënt zich presenteert. Het rapport van de KWF-werkgroep ‘Kwaliteit van 
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Kankerzorg’ werd gepubliceerd in de zomer van 2010. Het advies van de werkgroep was 
dat concentratie van kankerzorg plaats zou moeten vinden op basis van kwaliteitsnormen, 
betreffende de infrastructuur, het minimale volume en de specialismen die nodig zijn om 
in een ziekenhuis optimale kankerzorg te verlenen. Daarnaast zouden kankerspecialisten 
voortdurend op de hoogte moeten zijn van de resultaten van de kankerzorg die zij leveren, 
gecombineerd met landelijke spiegelinformatie, zodat verbeterpunten aangepakt kunnen 
worden (‘clinical audit’).   
Kwaliteitsindicatoren
Om (verschillen in) kwaliteit van zorg zichtbaar te maken, zijn parameters nodig die iets zeggen 
over de kwaliteit van de geleverde zorg. In hoofdstuk 7 wordt een systematische review 
van de literatuur beschreven, waarin wij zochten naar ‘evidence-based’ kwaliteitsindicatoren 
voor de behandeling van slokdarmkanker. De indicatoren werden onverdeeld in indicatoren 
betreffende de (infra)structuur van het ziekenhuis, de kwaliteit van het zorgproces en 
de zorguitkomsten. Het meeste bewijs werd gevonden voor structuurparameters, maar 
ook voor het optimale zorgproces waren een aantal indicatoren te definiëren, zoals het 
multidisciplinair bespreken van de behandelingsstrategie, voorafgaand aan de operatie. 
Voor uitkomstindicatoren was er sterk bewijs voor de uitkomsten die vastgesteld worden 
met pathologisch onderzoek, zoals de radicaliteit van een tumorresectie. Veel andere 
kwaliteitsaspecten zijn echter nauwelijks onderbouwd, en vooral gebaseerd op consensus 
binnen de beroepsgroep. 
Afgezien van het feit dat het bewijs voor specifieke kwaliteitsindicatoren zeer beperkt is, 
kan er getwijfeld worden aan het concept van een enkele kwaliteitsindicator die de kwaliteit 
van een complex zorgproces weerspiegelt. Bovendien heeft het begrip kwaliteit meerdere 
dimensies: het gaat niet alleen om effectieve zorg, maar ook om zorg die veilig is, op tijd 
verleend wordt, op een patiëntvriendelijke manier, maar ook kosten-efficiënt. Vervolgens 
kan de kwaliteit van de zorg ook nog bekeken worden vanuit verschillende perspectieven, 
niet alleen vanuit die van de dokter, maar vooral ook vanuit het perspectief van de patiënt 
en zijn/haar omgeving. 
Kwaliteit meten
De manier waarop kwaliteit van zorg gemeten wordt, wordt van oudsher bepaald door 
de gegevens die daar min of meer toevallig voor beschikbaar zijn. Door de introductie van 
klinische registraties (‘clinical audits’) in de Verenigde Staten en de landen in Noord-west 
Europa, is daar echter verandering in gekomen. In deze registraties worden gegevens 
verzameld met het specifieke doel om kwaliteit te meten en kwaliteitsverschillen tussen 
ziekenhuizen aan te tonen. Het gaat hierbij over het gehele zorgproces, waarbij een set van 
kwaliteitsaspecten wordt gedefinieerd die het gehele proces van diagnostiek en behandeling 
beslaat (quality assurance). Daarnaast worden zorguitkomsten geregistreerd, zowel voor 
wat betreft de gewenste (radicale resectie, overleving) als voor wat betreft de ongewenste 
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uitkomsten (complicaties, sterfte), van het zorgproces. Daarbij wordt er gecorrigeerd voor 
casemixverschillen tussen ziekenhuizen en de toevalsvariatie die vooral optreedt als het gaat 
om kleine aantallen patiënten per ziekenhuis of weinig voorkomende uitkomsten.
De gemeten uitkomsten worden vaak opzichzelfstaand gepresenteerd, wat geen recht doet 
aan het multidimensionele karakter van kwaliteit, zoals hier boven beschreven. Idealiter zijn 
verschillende aspecten van kwaliteit te combineren in een samengestelde uitkomstmaat, 
gecorrigeerd voor casemix en gewogen voor datgene wat patiënten belangrijk vinden, 
patientenpreferenties.
In hoofdstuk 8 worden twee van deze samengestelde uitkomstmaten gepresenteerd. We 
laten enerzijds zien dat het mogelijk is om verschillende uitkomsten van zorg zodanig te 
rangschikken dat per ziekenhuis bepaald kan worden hoe vaak de gewenste uitkomsten 
gehaald en ongewenste uitkomsten vermeden worden. Het percentage patiënten bij wie 
alle uitkomsten positief zijn, wordt de ‘Exemplary Care and Outcome’ score genoemd. 
Daarnaast, wordt er een samengestelde maat geïntroduceerd waarin de uitkomsten gewogen 
kunnen worden op basis van patiënten- of dokterspreferenties. In beide gevallen is er een 
kwaliteitsmaat ontwikkeld die meerdere kwaliteitsaspecten combineert, en tegelijkertijd 
beter onderscheid maakt tussen de kwaliteit geleverd in individuele ziekenhuizen, dan op 
basis van een enkele uitkomstmaat mogelijk is. 
Kwaliteit verbeteren
In Nederland spelen Wetenschappelijke Verenigingen van Medisch Specialisten een 
belangrijke rol bij het verminderen van variatie en verbeteren van kwaliteit van zorg, onder 
andere in de Oncologie. Er staan hen verschillende kwaliteitsinstrumenten ter beschikking. 
Voorheen beperkten die zich tot scholing, richtlijnontwikkeling en periodieke (kwaliteits)
visitaties van klinieken. Na het verschijnen van het Kwaliteit van Kankerzorg rapport, heeft 
een aantal Wetenschappelijke Verenigingen, waar onder de Nederlandse Vereniging voor 
Heelkunde, het voortouw genomen om kwaliteitsnormen te formuleren, onder andere 
voor de Chirurgische Oncologie. Recent zijn die kwaliteitsnormen door de Samenwerkende 
Oncologische Specialismen (SONCOS) aangevuld tot multidisciplinaire normen. Bovendien 
hebben de ‘clinical audits’, die inmiddels opgezet zijn voor borstkanker-, darmkanker-, 
slokdarm-maag- en longkanker, de kwaliteitscirkel gesloten. Waar voorheen met opleiding, 
nascholing en richtlijnen, ‘evidence based’ kennis werd overgedragen, maar nauwelijks 
bekend was wat er in de dagelijkse praktijk gebeurde, is dit nu veranderd. Er is sprake 
van een geïntegreerd kwaliteitsbeleid (zie figuur 1), waarin van de ‘evidence-based’ richtlijn 
kwaliteitsnormen en –indicatoren worden afgeleid, die vervolgens op ziekenhuisniveau 
worden gemeten om de kwaliteit van het zorgproces te waarborgen (‘quality assurance’). 
Bovendien worden ook verschillen in uitkomsten van zorg zichtbaar, en voor casemix 
gecorrigeerd teruggekoppeld aan de behandelaars, vergezeld van een landelijke benchmark 
(‘clinical audit’). Dit leidt tot een continue verbetercyclus, die bovendien versterkt wordt 
door het ‘surgical Hawthorne effect’: een snelle verbeterimpuls geobserveerd in veel van 
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de startende audits. Dit effect wordt veroorzaakt door de aandacht die er ontstaat voor de 
kwaliteit van het zorgproces, en ‘awareness’ van groepen patiënten met een hoog risico op 
ongewenste uitkomsten. 
Transparantie
Naast een interne verbetercyclus, is er ook een externe -cyclus gedreven door transparantie 
van ziekenhuisspecifieke kwaliteitsinformatie. Het publiek rapporteren van indicatorresultaten 
op ziekenhuisniveau is een krachtige stimulans voor ziekenhuizen om zichzelf te verbeteren. 
Bovendien kan deze informatie patiëntenstromen buigen naar de ziekenhuizen met de betere 
uitkomsten, wat hen weer de kans geeft zich verder te specialiseren in de desbetreffende 
behandeling. 
In Nederland staan we echter nog maar aan het begin van echte transparantie. De mate 
waarin er sprake is van kwaliteitstransparantie is namelijk niet alleen afhankelijk van de 
bereidheid van medisch specialisten om hun resultaten te delen met collega’s, patiënten, 
de ziekenhuisdirectie, zorgverzekeraars of patiëntenverenigingen, maar ook van de 
betrouwbaarheid van de verzamelde kwaliteitsinformatie. Het gaat dan om eenduidig 
verzamelde gegevens, met uniforme definities en inclusiecriteria, geverifieerd en 
gecorrigeerd voor casemix en toevalsvariatie, en gespiegeld aan de resultaten van anderen 
met een overeenkomstige patiëntengroep. Dat dit kan leiden tot snelle verbeteringen 
in de kwaliteit van de geleverde zorg, wordt bewezen door het audit-project voor 
slokdarmchirurgie beschreven in dit proefschrift (Hoofdstuk 4, 5 en 6), maar ook de 
resultaten van de Dutch Surgical Colorectal Audit, die sinds 2009 aanzienlijke verbeteringen 
in de uitkomsten van darmkankerchirurgie in Nederland laat zien. Niet alleen zijn de 
gemiddelde scores op een aantal kwaliteitsindicatoren landelijk aanzienlijk verbeterd, ook 
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de variatie in indicatorresultaten tussen ziekenhuizen is fors afgenomen. Dit is een voorbeeld 
van het klassieke kwaliteitsverbetermodel, waarbij de Gausse kromme niet alleen naar rechts 
verschuift, maar ook smaller wordt (figuur 2).
Conclusie
Dit proefschrift laat zien dat kwaliteit van zorg in de Chirurgische Oncologie varieert 
tussen ziekenhuizen, en deels gebaseerd is op volumina en andere structurele kenmerken 
van die ziekenhuizen. Vooral voor laagvolume hoog-risico ingrepen kan concentratie in 
ziekenhuizen met aantoonbaar goede resultaten een sterk kwaliteitsverbeterend effect 
hebben (outcome-based referral). Correcties voor verschillen in casemix en toevalsvariatie 
zijn essentieel voor het vergelijken van kwaliteit van zorg tussen ziekenhuizen. Bovendien 
zou een geïntegreerde benadering, waarin verschillende kwaliteitsaspecten gecombineerd 
worden tot een samengestelde uitkomstmaat, een meer valide instrument op kunnen 
leveren en kwaliteitsverschillen beter aan kunnen tonen.  
Clinical audit combineert verschillende instrumenten om kwaliteit van zorg te verbeteren. 
Het stimuleert richtlijncompliance en voorziet clinici van continue en snelle feedback op hun 
prestaties, gespiegeld aan een landelijke benchmark. Daarnaast zorgt het voor transparantie 
van betrouwbare en betekenisvolle kwaliteitsinformatie op ziekenhuisniveau waarmee  een 
continu proces van kwaliteitsverbetering tot stand wordt gebracht.
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Veel plezier haal ik uit het enthousiasme dat  ontvlamt bij de jonge onderzoekers waar ik 
dagelijks mee samen mag werken en de steeds grotere groep mensen die zich inzet voor 
de ‘clinical audits’ die we in de afgelopen jaren hebben opgebouwd. 
Ook mijn collega’s in het NKI-AvL, mijn familie, gezin en vrienden dank ik voor de ruimte en 
steun die zij mij gaven bij de totstandkoming van dit proefschrift.
229

